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ABSTRACT 
Background: Despite increased awareness and efforts to improve prevention, foot 
problems account for the most serious and costly complication of diabetes. Amputations 
a major adverse outcome of diabetic foot can be mostly prevented as 85% of amputations 
are preceded by foot ulceration. Yet, it has been estimated that the lifetime risk of a patient 
with diabetes to develop foot ulcer is 15-25%. High pressure and endothelial dysfunction 
are two major contributing elements in the development of diabetic foot ulceration. 
Higher prevalence of non-plantar ulcers with the majority of ulcers located on the foot 
dorsum, in addition to lower healing rates compared with plantar ulcers have been 
reported in diabetic foot. However, earlier studies and guidelines have so far focused on 
plantar ulceration, plantar pressure measurements and different interventions for plantar 
pressure relief for ulcer prevention and treatment with no assessment of the dorsal surface. 
Aim of the study: To investigate foot pressures experienced on both dorsal and plantar 
surfaces of the foot, and the impact of pressure application on endothelial function of the 
superficial skin blood vessels on both aspects of the foot in subjects with Type 2 diabetes 
mellitus in comparison to a group of control without diabetes. 
Methods: In-shoe pressure experienced on dorsal and plantar surfaces of the foot were 
assessed using Pedar insole system in subjects’ own shoes and orthopaedic shoes known 
to be prescribed for diabetic patients. In-shoe peak pressures (PP) were applied by a 
device designed to deliver a known pressure along with housing a laser Doppler 
flowmetery probe to assess blood flow changes. The effect of pressure on the skin blood 
flow response to iontophoresis of acetylcholine (ACh), an endothelium-dependent 
vasodilator and sodium nitroprusside (SNP), an endothelium-independent vasodilator, 
were assessed in a group of subjects with Type 2 diabetes and an age-matched control 
group of subjects with no diabetes. 
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Results: No significant differences were found between the two study groups in dorsal 
PP within the orthopaedic shoes (p=0.409) as well as in participants’ own shoes 
(p=0.389). However, both study groups had a significantly higher dorsal PP (p<0.001) in 
their own shoes when compared with the orthopaedic shoes. No significant differences in 
planter PP were detected between groups in participants’ own shoes (p=0.384), though, 
midfoot areas were significantly higher in diabetes groups and lateral areas under toes 
and metatarsal heads were significantly reduced. The orthopaedic shoes showed a 
significantly higher plantar PP (p=0.013) in the diabetes group compared to control. A 
significantly higher in-shoe plantar PP within participants’ own shoes than orthopaedic 
shoes (p<0.05) was noted in both study groups. However, this significant difference was 
apparent in one foot area in the diabetes group. No significant correlations were detected 
between PP and changes in blood flow in response to the iontophoresis of ACh or SNP 
on dorsal and plantar surfaces in both study groups. Both study groups have shown a 
significant reduction (p<0.001) in blood flow response to the iontophoresis of ACh and 
SNP under own shoes PP as well as orthopaedic shoes PP than resting /no pressure 
condition on the dorsal and plantar surfaces of the foot. A significantly higher change in 
response (p<0.05) was recorded in the control group than diabetes in blood flow changes 
in response to iontophoresis of ACh under no pressure. The control group showed a 
significantly higher change in response (p<0.001) under the orthopaedic shoes dorsal PP 
than own shoes with ACh and SNP while diabetes group only recorded a significant 
change in response with SNP. The diabetes group had a significantly higher blood flux 
values on the plantar surface in response to ACh iontophoresis in resting /no pressure, 
under orthopaedic PP and own shoes PPs. However, no significant differences from the 
control group were detected in changes in response from baseline flux with the 
iontophoresis of ACh or SNP on the plantar surface under any of the pressure conditions. 
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Conclusion: Although orthopaedic footwear had significantly reduced total in-shoe PP, 
pressure assessment is essential to adjust shoe design in-order to better distribute dorsal 
as well as plantar pressures and achieve effective offloading required for ulcers 
prevention. Diabetes group showed an increased blood flow values on the plantar surface, 
which could have been caused by an early sympathetic neuropathy. Additionally, diabetes 
group had an impaired endothelium-dependent response which may predispose to foot 
ulceration and the development of vascular complications in this group. Though low PPs 
were recorded on the foot dorsum, a significant reduction in blood flux response was still 
present on applying dorsal PP. Also, the dorsal foot surface was more sensitive to changes 
related to endothelial dysfunction in patients with diabetes. Therefore, dorsal pressure 
measurement and pressure’s impact investigation can provide valuable input in the 
assessment of diabetic foot and should be considered in the design and prescription of 
therapeutic footwear to reduce the risk of diabetic foot ulceration. 
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CHAPTER 1 INTRODUCTION 
1.1 BACKGROUND 
Diabetes mellitus is recognised as a syndrome; a collection of disorders that have 
hyperglycaemia and glucose intolerance as their hallmark, as a result of insulin 
deficiency, impaired effectiveness of the insulin’s action, or a combination of both 
(Magliano et al., 2015). The chronic hyperglycaemia of diabetes is associated with long-
term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels that significantly impair those patients’ quality of life 
(American Diabetes Association, 2014). 
No country, whether wealthy or poor, is immune from this global epidemic. In 2017 the 
worldwide prevalence of diabetes mellitus reached over 425 million people; that is 1 in 
11 adults has diabetes. Two-thirds (327 million) are of working age (20-64 years). A 
further 352 million people have impaired glucose tolerance and are at a high risk of 
developing diabetes. International Diabetes Federation (IDF) estimates that 212 million 
people worldwide, close to half of the people with diabetes, are unaware of their disease 
with most of these cases being Type 2 diabetes. As many as one-third to one-half of Type 
2 diabetes cases can go undiagnosed because sufferers may remain without symptoms for 
years until presenting with complications of hyperglycaemia (IDF Diabetes Atlas, 2017). 
In the UK, Type 2 diabetes accounts for 90.4% of all diabetes with approximately one in 
22 being diagnosed with Type 2 diabetes (approximately 4.5% of the UK population) 
(Holman et al., 2015). Despite being largely preventable, the number of people with Type 
2 diabetes is growing rapidly worldwide (Kakkar, 2016). This is likely due to economic 
development, ageing populations, increasing urbanisation, dietary changes, reduced 
physical activity, and changes in other lifestyle patterns (Cho et al., 2018). This rise in 
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prevalence is accompanied by a proportional increase in numbers of people with diabetes-
related complications, including foot problems. 
Foot complications occur in both Type 1 and Type 2 diabetes (Jeffcoate and Harding, 
2003). The term ‘diabetic foot’ includes any foot pathology that results directly from 
diabetes or its long-term complications (Boulton, 2010). According to the World Health 
Organization (WHO), it is possible to encompass all foot complications in the term 
diabetic foot syndrome (DFS), that has been defined as ulceration of the foot (distally 
from the ankle and including the ankle) associated with neurological abnormalities, 
various degrees of peripheral vascular disease and infection (Katsilambros N et al., 2007, 
Tuttolomondo et al., 2015).  
The major adverse outcomes of diabetic foot are foot ulcers and amputations. Studies 
suggest the global prevalence of diabetic foot ulceration is approximately 6.3% 
worldwide which is higher in males than females and more common in Type 2 Diabetic 
patients (Zhang et al., 2017). It has been estimated that 15-25% of diabetics are at risk of 
developing a foot ulcer at some point during their lifetime with 9.1-26.1 million people 
developing diabetic foot ulcers annually (American Diabetes Association, 1999, 
Armstrong et al., 2017). Moreover, 70% of foot ulcer patients will have recurrent lesions 
within five years after treatment (Ferreira et al., 2004, Hoogeveen et al., 2015). 
It has been claimed that a lower limb is amputated every thirty seconds due to diabetes 
(Apelqvist, 2012). Studies show the rate of lower extremity amputation is 10-20 times 
higher in diabetic patients compared with non-diabetics (Moxey et al., 2011). And it is 
estimated that up to 50-70% of all non-traumatic amputations throughout the world occur 
in diabetic patients (Abbott et al., 1998, Hoogeveen et al., 2015). An alarming proportion 
(50%) of those who have had a major amputation have died within two years following 
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their procedure (MacRury et al., 2018). The majority of these amputations are considered 
preventable as 85% are preceded by foot ulceration (Forlee, 2010, Al Sayah et al., 2015).  
Therefore, several countries and organisations, such as WHO and the International 
Diabetes Federation, have worked toward setting a strategy with goals to reduce the rate 
of amputations by up to 50%. By identifying patients at risk of developing foot disease, 
taking the appropriate preventive measures, patient and staff education, multidisciplinary 
treatment of foot ulcers and close monitoring, it has been claimed that amputation rates 
can be reduced by 49–85% (Bakker et al., 2012). 
Despite increased awareness and efforts to improve prevention, diabetic foot accounts for 
the first cause for hospitalisation of diabetic patients with 4.7% of inpatients worldwide 
reported with diabetes-related foot disease (Lazzarini et al., 2015). Thus, diabetic foot 
poses a heavy financial burden to healthcare systems all over the world. The UK National 
Health Service (NHS) expenditure on diabetic foot disease is equivalent to approximately 
£1 in every £175 spent by the NHS in England (Kerr et al., 2014) and it is estimated that 
£60 million is spent on foot ulcers and amputations in Scotland alone (MacRury et al., 
2018). In addition to, the significant psychosocial effects it may have on patients’ quality 
of life because of impaired mobility and substantial loss of productivity (Boulton et al., 
2005, Bakker et al., 2012). 
Many factors have been investigated as having a role in diabetic foot ulcer formation such 
as neuropathy, increased biomechanical stress, external trauma, impairment of the local 
vascular supply and endothelial dysfunction. Furthermore, the slower healing rate, which 
is often complicated by infection, leads to amputation as the final outcome. It is generally 
thought that a combination of several mechanisms has been involved in ulcer formation 
(Figure 1.1) (Schaper et al., 2003, Pendsey, 2010, Korzon-Burakowska and Dziemidok, 
2011, Bakker et al., 2012). 
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Figure 1.1 Mechanisms of Diabetic Foot ulceration  
Adapted from Boulton 2010 
Affecting up to 50% of diabetic patients, peripheral neuropathy is among the most 
common of all long-term complications of diabetes. Diabetic peripheral neuropathy plays 
a central role in ulcer pathogenesis and has been reported in >80% of ulcer affected 
patients (Abbott et al., 1998, Korzon-Burakowska and Dziemidok, 2011). While 
impairment of local vasculature and endothelial dysfunction are other known 
complications of diabetes, regular trauma usually unperceived, may further damage the 
skin microcirculation including the endothelium, thus increasing the risk of ulceration 
(Newton et al., 2005). 
It was noted that 66% of patients with diabetic peripheral neuropathy wear shoes that are 
too narrow and yet ill-fitting footwear is well recognised as a cause of foot injury and 
ulceration (Veves et al., 1992). Ninety-four percent of diabetic ulcers are known to occur 
under areas of increased pressure (Pataky et al., 2000). Consequently, the reduction of 
plantar pressure has been suggested to play a key role in the treatment of plantar ulcers 
and thus, the prevention of amputations. This could be achieved by correctly fitting 
footwear, full contact insoles, orthopaedic footwear and foot orthoses which can be 
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effective in redistributing plantar pressure and as a result promote ulcer healing (Fiedler 
et al., 2011). 
Foot ulcers have previously been reported on both plantar and dorsal surfaces of diabetic 
foot, yet no research has been conducted to investigate the effect of pressure and 
endothelial dysfunction on the dorsum of the foot. Prompers et al. 2007, studied the 
prevalence of foot ulcers in diabetic patients and found that more than half of ulcers (52%) 
were non-plantar ulcers and the majority of all foot ulcers were located on the dorsal 
surface or in the interdigital spaces of toes (32%). Moreover, their results have indicated 
that ulcers in patients with peripheral arterial disease and infection are mainly non-plantar 
(65%) and are associated with more extensive tissue loss as they were also deeper and 
larger. 
Despite the fact of relatively high rates of non-plantar ulcers and healing rates, which may 
be lower in dorsal ulcers compared with plantar ulcers (Eneroth et al., 2004, Prompers et 
al., 2007, Roth-Albin et al., 2017), most earlier studies and guidelines have focused on 
plantar foot ulceration including plantar pressure measurements and different 
interventions for pressure relief as an ulcer treatment modality. 
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1.2 RATIONALE FOR THE STUDY 
The current study proposes to investigate the effect of pressure application on endothelial 
function on both dorsal and plantar surfaces of the foot when comparing findings in 
subjects with Type 2 diabetes with an age-matched control group of subjects without 
diabetes. 
Peak pressures exerted on both dorsal and plantar surfaces of the foot have been measured 
within participants’ own comfortable shoes which they have chosen to bring on the 
assessment session as well as a therapeutic footwear that is commonly prescribed for at-
risk patients with Diabetes Mellitus that will be referred to as “orthopaedic shoes”. 
Endothelial function under the loading pressure has been non-invasively assessed using 
laser Doppler flowmetry (LDF). Blood perfusion changes under the loading pressure have 
been studied in response to the iontophoresis of two vasoactive agents, acetylcholine 
(ACh) an endothelium-dependent vasodilator and sodium nitroprusside (SNP) an 
endothelium-independent vasodilator. The premeasured loading pressures will be 
simulated using a pressure delivery equipment that was specifically developed to apply a 
given pressure to a local area whilst not damaging or interfering with the iontophoresis 
equipment or the laser Doppler probe which have been utilised as the endpoint for 
pressure delivery and monitoring of the skin blood flow changes. 
This experimental work hypothesised that dorsal pressure measurement and its effect 
investigation will provide a more easily accessible tool for assessment of the diabetic foot 
(Newton et al., 2005). Additionally, this work will add to the understanding of the 
mechanisms underlying the development of diabetic foot ulcer and help the future 
production and design of better therapeutic interventions to prevent diabetic foot 
ulceration and its subsequent burden. 
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1.3 AIM 
The aim of the present study has been to investigate the foot pressure experienced on both 
dorsal and plantar surfaces of the foot, and the effect of pressure application on 
endothelial function of the superficial skin blood vessels on both aspects of the foot in 
subjects with Type 2 diabetes mellitus in comparison to the response in a group of control 
without diabetes. 
1.4 OBJECTIVES 
• Review relevant literature 
• Determine peak walking in-shoe pressure on the dorsal as well as the plantar 
surface of the foot and examine differences in areas that experience high pressure 
between a group of Type 2 diabetic patients and a control group of subjects 
without diabetes 
• Investigate the endothelial function of the superficial blood vessels of the foot by 
assessing blood flow changes in response to the iontophoresis of an endothelium-
dependent vasodilator, acetylcholine (ACh) and endothelium-independent 
vasodilator, sodium nitroprusside (SNP) under peak walking pressures 
experienced in participants’ own shoes and within a standard therapeutic footwear 
on the dorsal and plantar surfaces of the foot in both study groups 
• Compare results of diabetic subjects with an age-matched control group of 
subjects with no diabetes 
 
  
8 
CHAPTER 2 LITERATURE REVIEW 
2.1 FOOT PRESSURE  
2.1.1 Introduction 
Pressure1, a form of mechanical stress, is equal to the magnitude of the force applied to a 
specific surface area. Foot pressure represents the pressure field that acts between the foot 
and the external, supporting surface during everyday locomotor activities (Abdul Razak 
et al., 2012). As the standard to reflect the balance of the human body, foot pressure is 
the one measurement which is of great interest in the clinical and research fields of 
kinematics (Park et al., 2009, Huang et al., 2013, Giacomozzi et al., 2016). Foot pressure 
distribution is made by the anatomical and functional status or state of the foot/shoes and 
the ground surface while walking (Park et al., 2009). Hence, foot pressure is a known 
critical variable in orthotic, prosthetic, and footwear design, especially with the known 
evidence linking high pressures to skin breakdown in patients with impaired sensation 
(Mueller, 1999, Pataky et al., 2000, Patry et al., 2013).  
Foot pressure is affected by several factors including; the anatomical structure of the foot, 
body mass, gender, age, joints range of motion and different disease dependent 
modifications which alter foot function and gait, such as those in conditions like diabetes 
(Rosenbaum and Becker, 1997, Bosch et al., 2009, Putti et al., 2010, Charalambos et al., 
2015, McKay et al., 2017, Sole et al., 2017).  
Foot pressure provides valuable information about the mechanical behaviour and function 
of the human foot as well as the ankle, knee, hip and back in both static and dynamic load 
conditions. It also could illustrate an indication of potential musculoskeletal, neurological 
 
 
1 Pressure = Force/Area. Pascal is the International System (SI) unit of pressure.  
Conversions: 1 psi = 6.9 KPa = 0.69 N/cm2 
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or other disorders that are reflected on the footprint (Ramirez-Bautista et al., 2018). 
Therefore, foot pressure measurement, analysis have been used in various research 
studies to detect foot pathologies and evaluate many medical conditions and different 
therapeutic interventions (Alexander et al., 1990, Abboud et al., 2000, Lyons et al., 2006, 
Ramanathan et al., 2008, Park et al., 2009).  
In the currently available literature, several studies have identified and extensively 
examined plantar foot pressure characteristics during gait, the contact area of the plantar 
aspect of the foot and the forces produced (Alexander et al., 1990, Natali et al., 2010, 
Putti et al., 2010, Charalambos et al., 2015). However, very few studies have investigated 
the measurement of the pressure on the dorsal side of the foot (Jordan and Bartlett, 1995a, 
Olaso et al., 2007, Hagen et al., 2008, Rupérez et al., 2009). This is likely because most 
foot pressure measurement systems are designed to evaluate the interaction between the 
foot plantar surface and the ground during static positions or different activities but not 
for measuring the pressure on the dorsal side of the foot (Herbaut et al., 2016). 
2.1.2 Methods of Foot Pressure Measurement 
During functional activities such as walking, the human foot exerts a force, produced by 
body weight, upon the underlying surface, and in turn, an equal and opposite force is 
created that is known as ground reaction force (GRF) (Zammit et al., 2010). This GRF is 
proportional to infinite discrete areas on the plantar surface of the foot when in contact 
with the ground and is described as plantar foot pressure (Abboud and Rowley, 1996). 
Due to the repetitive nature of that loading, any alterations of the biomechanical 
behaviour of the foot structure and/or soft tissue elements will have a greater impact on 
other body structures with multiple repetitions (Flynn, 2014).  
To assess foot pressure, a discrete sensor or a matrix of multiple sensors is used to 
measure the force acting on each sensor while the foot is in contact with the supporting 
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surface. The magnitude of pressure is then determined by dividing the measured force by 
the known area of the sensor or sensors evoked while the foot was in contact with the 
supporting surface (Orlin and McPoil, 2000). Foot pressure can be measured under static 
and/or dynamic conditions, however, dynamic pressure measurement appears to be the 
more sensitive and reliable method for identifying “at-risk feet” (Abdul Razak et al., 
2012, Patry et al., 2013, Zulkifli and Loh, 2020). 
There are two main components of the loading experienced by the plantar surface of the 
foot: vertical and horizontal (shear). It has been confirmed that the shear component is 
vital in the determination of skin stresses and has an important role in the development of 
foot ulcers (Lord, 1981). Thus, it was thought, shear pressure may explain the variation 
noted between vertical peak pressure location and the location of foot ulceration (Yavuz 
et al., 2007, Yavuz, 2014). Unfortunately, commercially available plantar pressure 
measurement devices only provide an indication of the vertical force acting on the foot 
ground interface, or with in-shoe systems the foot insole interface, but they do not 
measure the shear pressure that also impacts upon the function of the foot during activity 
(Flynn, 2014). The quantification of this lower magnitude horizontal components of 
pressure has proved to be technically challenging as shear is also dependent on frictional 
properties of the sensor surface (Fernando et al., 2018). 
Over the past century, many attempts have been made to develop a suitable technique to 
determine the distribution of pressure underneath the plantar surface of the foot. Early 
techniques were simple, innovative methods that provided investigators with semi-
quantitative data (Lord, 1981). This was seen in detecting barefoot pressure distribution 
with the use of ink impressions produced using products such as Morton’s kinetograph 
then Harris & Beath™ mat (Abboud and Rowley, 1996). These initial investigations were 
only able to capture the shape of the foot and the impressions on its surface, in an attempt 
at the recognition of different foot pressure patterns (Rosenbaum and Becker, 1997). The 
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introduction of computer technologies has allowed quantitatively accurate and 
reproducible high-resolution measurements with high sampling rates and easily 
interpreted graphic displays. This has allowed pressure assessment systems to be 
commonly employed in research as well as clinical settings, providing data that helps in 
optimising patient assessments and treatment outcomes (Alexander et al., 1990, Lyons et 
al., 2006, Chevalier et al., 2010). Currently, a range of systems are available to measure 
both static and dynamic foot pressure characteristics. These systems vary in their sensor 
technology, spatial resolution, pressure range, sampling rate, calibration and processing 
procedures (Giacomozzi, 2010).  
Sensor technologies that are utilized within different foot pressure measurement devices 
include; capacitive sensors, resistive sensors, piezoelectric sensors, and piezoresistive 
sensors (Abdul Razak et al., 2012, Fernando et al., 2018, Zulkifli and Loh, 2020). In 
general, these pressure transducers have the ability to convert a mechanical event into an 
electrical signal that can be recorded and stored for further data analysis (Rosenbaum and 
Becker, 1997). The type of sensors used would be a great determinant of the measurement 
accuracy and precision (Giacomozzi, 2010, Fernando et al., 2018). Each pressure 
measurement system can have a different number of sensors to provide an electrical signal 
output proportional to the measured foot pressure (Zulkifli and Loh, 2020). 
Foot pressure measurement systems are commonly found in two formats: an in-shoe 
based or a platform-based system. Both barefoot (platform) and in-shoe measurements 
are of value and have been used by clinicians to assess foot pressure. For instance, the 
study of barefoot patterns is more applicable for the orthopaedic surgeon who wishes to 
evaluate foot surgery outcomes, whereas in-shoe prints would be appropriate to illustrate 
the redistribution of loading caused by wearing a particular design of shoe or insole (Lord, 
1981). However, on comparison of both systems, it was noted that the system used has 
its effect on the measurement outcomes. It is therefore essential, in conjunction with the 
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standardisation of data collection conditions, the data obtained from these systems is not 
to be used interchangeably (Chevalier et al., 2010). 
Both systems, platform and the in-shoe have their own advantages and disadvantages and 
can provide different types of biomechanical information owing to the different interface 
studied, though the information contained can overlap. The decision of what type of 
system to use should not be based on the 'best' system but what the most appropriate 
system for the clinical or research prerequisites, the loading characteristics, and the 
outcomes of interest (Rosenbaum and Becker, 1997, Fernando et al., 2018). 
2.1.2.1 Platform Systems 
Platform systems are constructed from a flat, rigid, floor embedded array of pressure 
sensing elements. These pressure sensors are arranged in a matrix configuration on a flat 
surface platform, that should set flush into a walkway, allowing the capture of foot 
pressure applied to its top surface in static posture or a single step of the gait cycle during 
simple dynamic activities such as walking, running, and jumping (Abdul Razak et al., 
2012, Zulkifli and Loh, 2020).  Platform systems are manufacturer-specific, and comprise 
of different; sensor types, number of sensors per area (different resolutions), sampling 
rates, and ranges of detectable pressure (Giacomozzi, 2010, Hafer et al., 2013, Telfer and 
Bigham, 2019). The installation of the platform requires a rigid flat surface area to avoid 
sensors breaking or bending due to an uneven surface. Since it is embedded into the floor, 
the platform is commonly installed in laboratories. The shorter platform (0.5 m) is usually 
used for the static position (postural analysis) while the longer platform (2 m) is mostly 
used for more dynamic movement (motion analysis). However, platform installation will 
always abide by the length constraints of indoor laboratories (Zulkifli and Loh, 2020). 
Platforms classically measure plantar foot pressure in the barefoot state (Figures 2.1, 2.2). 
The barefoot assessment has the advantage of investigating the whole foot/ground contact 
13 
area and the inherent foot pressures experienced in healthy or impaired foot conditions, 
as in neuropathy or deformity, without the influence of footwear that can mask some 
crucial information regarding the loading of different anatomical structures of the foot 
(Fernando et al., 2018). 
 
Figure 2.1 Barefoot plantar pressure measurement using Emed® platform  
(Abdul Razak et al., 2012) 
 
Figure 2.2 Pressure measurement using Emed® platform 
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Platforms include a greater number of sensors, thus a higher resolution. The pressure 
sensors are always positioned parallel to the supporting surface, which would provide a 
“true” vertical force measurement. Although subjects are able to walk naturally without 
wires or data boxes attached to them, the platform recording does not present the pressure 
changes under a continuous support surface. A larger number of steps are required for 
data collection and targeting of the force plate can be an issue that may result in alteration 
of the patient’s typical pressure pattern. This necessitates having a walkway with 
sufficient length to allow enough steps before reaching the platform and enough space 
behind it to prevent any intended slowing down during measurement. Furthermore, a 
'warm-up' /practice period is required to familiarise the subject with the testing 
environment and determine the best starting position to reproducibly generate a normal 
walking pattern where contacting the platform does not generate any adjustment in stride 
length (Rosenbaum and Becker, 1997). 
The midgait method is considered the 'gold standard’ for the collection of plantar pressure 
using platform systems, where barefoot pressure from multiple repeated trials are 
collected during a steady state halfway along a relatively long walkway. Diabetic patients 
with poor vision and possibly neurological impairment may have difficulty striking the 
platform without a large number of attempts because of proprioception and coordination 
problems. This could lead to patient fatigue causing an abnormal pattern of pressure or 
increase the incidence of the platform targeting to ensure that the foot contacts the sensor 
surface. Moreover, patients with diabetes and neurological impairment could be placed 
at risk of plantar ulceration when collecting pressure data using this method, because of 
the increased repetitive stresses with a large number of attempts and numerous steps 
required for adequate data collection (Lord, 1981, Cavanagh and Ulbrecht, 1994, McPoil 
et al., 1999, Orlin and McPoil, 2000, Flynn, 2014). This led to the development of 
different step-protocols involving fewer steps before contact is made with the pressure 
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platform. This includes the one-step, two-step, and three-step methods, relating to the 
number of steps a person must take before stepping onto a platform to capture their foot 
pressure. When compared, all are valid methods for obtaining barefoot plantar pressure 
in the diabetic neuropathic foot with the two-step method producing pressure values that 
are closer to those of the mid-gait technique (McPoil et al., 1999, Bus and Lange, 2005). 
Irrespective of the protocol used, at least three to five gait trials are required to minimise 
variability in measurement to reliably assess foot pressure (Fernando et al., 2018). 
2.1.2.2 In-Shoe Systems 
In-shoe pressure measurement systems offer great advantages over platform systems in 
the ability of data collection in the foot’s normal functioning environment, experienced 
during daily activities. In-shoe pressure measurement devices have been used to 
investigate the interaction between the foot and the shoe, during static and dynamic 
activities where the influence of footwear and orthotics can be determined. The in-shoe 
system offers the key benefits of flexibility, mobility, simplicity, and lower cost, as 
opposed to platform systems, which are less portable and generally more expensive. One 
significant advantage of in-shoe measurement systems is that multiple steps can be easily 
collected. This feature allows robust relevant parameters to be obtained for the study of a 
wider variety of activities, with different gait tasks such as stair climbing or various sports 
activities, compared to the limited level locomotion study possible using platform systems 
(Urry, 1999, Abdul Razak et al., 2012). Additionally, subjects can use their natural gait 
during testing which prevents the issues of platform targeting (Urry, 1999, Shu et al., 
2010, Melvin, 2014, Zulkifli and Loh, 2020). 
The ability to collect multiple steps is very beneficial, due to the natural variability in 
human gait where no two steps are alike (Putti et al., 2007). The ideal number of steps 
needed for reproducible and valid foot pressure data has been investigated in the 
16 
published literature (Owings and Grabiner, 2003, Najafi et al., 2010). An average of 12 
steps per foot has been found necessary to obtain valid and reliable in-shoe pressure data 
in neuropathic diabetic patients when wearing custom-made therapeutic footwear (Arts 
and Bus, 2011). 
Many techniques have been utilised in measuring the pressure inside footwear. Both 
discrete transducers and matrix systems have been developed, with matrix systems 
(insoles) being preferable (Cavanagh et al., 1992, Shu et al., 2010). Using discrete sensors 
at anatomically pre-defined sites offer an inexpensive, simpler manufacture measurement 
technique since fewer sensors are required. However, it requires accurate locating of the 
sensors which has been an issue with this method due to imprecise positioning under the 
areas of interest or by sensors migrating during the investigation. Also, the sensors will 
act as a 'foreign body' within the shoe, changing the mechanical conditions at the foot-
shoe interface. Matrix (Insole) in-shoe measurement systems consist of numerous 
pressure sensing elements arranged in rows and columns, aiming at covering the entire 
plantar surface of the foot. Unlike discrete systems this array pattern permits a larger area 
to be monitored at any given time, thereby limiting the amount of “dead space” between 
sensors, where loads applied remain unmeasured, with no need for precise localisation of 
sensors (Cavanagh et al., 1992, Melvin, 2014). 
In-shoe pressure measurement provides real-time information regarding foot pressures 
while wearing footwear. However, they can be technically challenging with sensors more 
susceptible to damage, cables may experience bending as they emerge from the shoe and 
the positioning of the wires/data box can alter the subject’s natural gait. The material of 
the insole itself (e.g. a stiff insole) and the depth of the insole can alter the pressure and 
make it uncomfortable for the subject. Sensors should be suitably secured/inserted to 
avoid bending, slippage and ensure reliable results. Furthermore, the inside of the shoe 
can be described as a ‘hostile environment’ for sensors, with the trapped heat and sweat 
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of the foot inside the shoes. All of these factors have the potential to increase 
measurement error and device failure (Cavanagh et al., 1992, Abdul Razak et al., 2012, 
Flynn, 2014, Fernando et al., 2018, Zulkifli and Loh, 2020). 
2.1.3 Foot Pressure Outcomes 
Using matrix systems, platforms or in-shoe, yield a considerable volume of information 
which needs to be reduced into useful subsets (masks) to facilitate data processing and 
specific variables extraction. Production of masks is considered a common approach, 
where pressure measurement data of the studied area is divided into discrete anatomical 
regions of interest by identifying the corresponding sensors. Defined masks are then 
analysed separately, and desired outcomes are extracted. Masks can be useful if the 
research is looking for identifying pressure behaviour/changes at specific sites. On the 
other hand, “masking” introduces artificial boundaries into the collected data. As the 
anatomical distinction between adjacent regions does not indicate functional distinction, 
though segmented data may be anatomically relevant, it may not be in functional terms 
(Pataky et al., 2008a). Anatomical mapping also assumes that changes in location are pre-
known which leads to potential loss of useful information. Studies have shown, some 
differences may exist at the pixel level but not at a foot region level (Pataky et al., 2008b, 
Pataky and Maiwald, 2011). The use of statistical parametric mapping was proposed to 
solve the issue of the potential loss of data with the spatial mapping presumptions (Pataky 
and Goulermas, 2008, Pataky, 2010). This approach can produce continuous statistical 
maps based on individual sensor data rather than predetermined groups of sensors, with 
no prior assumptions regarding where the differences in pressures may occur (Melvin, 
2014). However, the statistical parametric mapping should be implemented with caution, 
as different processing approaches within this method can lead to a variety of statistical 
results (Booth et al., 2018). 
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Regardless of the analysis approach, a wide range of variables can be extracted from the 
foot pressure measurements data. One of the most commonly reported variables is 
Maximum Peak Pressure (MPP), which corresponds to the highest pressure at a specific 
sensor, or in a specific mask (anatomical region), at any point during the gait cycle, while 
mean pressure is calculated as the average pressure at a specific sensor, or in a specific 
mask, over the entire gait cycle. Another important variable is Pressure Time Integral 
(PTI) which is defined as the time integral of the peak pressure measured in any sensor 
within the specified region during one-foot step. This is calculated as the area under the 
peak pressure versus time curve of a particular region (Waaijman and Bus, 2012). Other 
variables include force, contact area, force-time integral, mean area, and contact time 
(Melvin, 2014). 
Peak pressure and the pressure-time integral are the most commonly used outcomes in 
studies investigating foot pressure behaviour. Yet, it is still not well understood which is 
superior as a predictor for ulceration or ulcer healing as in individuals with diabetes and 
diabetic peripheral neuropathy (Bus and Waaijman, 2013, Fernando et al., 2018). MPP 
has historically been more popular as a representative of the magnitude of pressure with 
the assumption that high loads are the cause for tissue damage leading to ulceration 
(Ledoux et al., 2013). As PTI incorporates the magnitude as well as the time of exposure 
of pressure, it may be a more accurate indicator of mechanical loading than either 
parameter, pressure or time, individually. PTI, signifying the cumulative effect of 
pressure over time, explains the application of lower pressures over a longer time period 
may also cause tissue damage (Sauseng et al., 1999, Hsi et al., 2002, Melvin, 2014). 
These could be of significance in evaluating lower pressure values as those of dorsal 
pressure. Hence, the two measurements provide different types of information, it may be 
appropriate to measure both outcomes to fully comprehend the influence of pressure 
(Fernando et al., 2018). 
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2.1.4 Foot Pressure Abnormalities in Diabetes Mellitus 
Foot pressure measurements in patients with diabetes have been widely investigated in 
the literature, where high loads have been reported at the sites of ulceration (Stokes et al., 
1975, Veves et al., 1992, Frykberg et al., 1998, Pham et al., 2000, Fernando et al., 2014). 
An abnormal redistribution of loading was generally noted in patients with diabetes 
compared to nondiabetic control. This included a reduction in the load carried by toes, 
especially in case of ulceration, and shift of loading either, to the lateral side of the foot 
(Stokes et al., 1975), medial side to be transmitted through the metatarsal heads 
(Ctercteko et al., 1981, Plank et al., 2000) or neither both, though a transfer of peak 
pressures from the great toe to the first metatarsal head was seen in diabetic patients with 
neuropathy (Veves et al., 1991). Another observation was the lower frequency of 
existence of peak pressures under the heel in diabetic patients with and without 
neuropathy compared to a control group. This finding, in diabetic patients without 
neuropathy, may suggest early changes where the pressure starts rising under the forefoot 
but still within normal limits (Veves et al., 1991, Lyons et al., 2006). 
These abnormal patterns of pressure distribution and eventually raised pressure were 
highly associated with diabetic neuropathy (Frykberg et al., 1998, Bus et al., 2005, 
Fernando et al., 2014). Although a transfer of pressure from the heel and the toes to 
metatarsal heads leads to an increased forefoot pressure in patients with diabetic 
neuropathy (Rich and Veves, 2000), raised midfoot and hindfoot pressures were also 
reported (Bacarin et al., 2009), with an increased forefoot/hindfoot ratio in sever diabetic 
neuropathic foot (Caselli et al., 2002). 
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2.1.5 Factors Influence Foot Pressure in Diabetic Foot 
The elevated plantar pressure found in association with diabetes is multifactorial. 
Although a correlation exists between neuropathy and high plantar pressure, other factors 
including vascular deficit, limitation in joint mobility and foot disorders have also been 
considered. 
2.1.5.1 Neuropathy  
Diabetic peripheral neuropathy (DPN) is one of the most common complications of 
diabetes mellitus with a prevalence ranging from 13 to 68% among patients with diabetes 
(Van Dieren et al., 2010, Fernando et al., 2013). It is believed that approximately 50% of 
patients with diabetes will develop DPN within 10 to 15 years of diabetes diagnosis 
(Cavanagh et al., 1993) and this risk increases with the longer duration of the disease and 
poor glycaemic control (Alam et al., 2017). 
DPN is typically described as a chronic, symmetrical, length-dependent polyneuropathy 
which is attributed to metabolic and microvascular alterations associated with diabetes 
(Tesfaye et al., 2010). Peripheral neuropathy in patients with diabetes may be sensory, 
motor and/or autonomic. 
Sensory neuropathy results in a decrease or loss of the protective sensations that impedes 
the identification of repetitive or isolated trauma to the foot which may occur during 
simple daily activities such as walking or within narrow ill-fitting footwear (Veves et al., 
1992, Mueller et al., 2008). Also, proprioception impairment will result in the inability to 
make adjustments to different surfaces/loads experienced during walking and therefore 
affecting balance (Alam et al., 2017).  A decrease in walking speed and stride length and 
prolonged stance phase were also reported (Fernando et al., 2013) which eventually 
results in a prolonged mechanical loading, leading to skin breakdown and ulceration. 
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Motor neuropathy leads to muscle dysfunction and degeneration, limited joint mobility 
and subsequent deformities that lead to altered foot pressures (Abboud et al., 2000, Rao 
et al., 2007, Rao et al., 2010, Guiotto et al., 2013). Autonomic neuropathy results in 
diminished sweating and skin dryness. Dehydrated skin loses its elastic properties and 
therefore, its ability to adapt to the foot movement, plus causing the skin tending to break 
easily. It also predisposes to callus formation under areas of increased pressure, which in 
turn, further alter foot pressures (Murray et al., 1996, Abouaesha et al., 2001). All this 
together will cause an altered pressure pattern in the neuropathic foot, inability to properly 
distribute high pressures, leading to the maintenance of high pressures and damaging the 
already altered soft tissue and subsequently skin breakdown (Martinez Santos, 2016). 
Although elevated plantar pressures and neuropathy are found to frequently coexist in 
association with diabetes (Hazari et al., 2016), a direct causal relationship is thought to 
be speculative, as increased and abnormal plantar pressures have been reported in some 
diabetic patients with no signs or symptoms of neuropathy, independently associated with 
ulceration (Frykberg et al., 1998), and lower peak plantar pressures have been reported 
in diabetic patients with neuropathy than patients without neuropathy whilst performing 
different daily-life activities (Guldemond et al., 2007). Furthermore, the progression of 
diabetic neuropathy was not found to influence plantar pressure distribution (Bacarin et 
al., 2009). Thus changes in foot pressure distribution in diabetes may be related to other 
factors that result in abnormal foot function and structural foot pathology, not only to 
neuropathy (Bevans, 1992, Lazaro-Martinez et al., 2011, Flynn, 2014). 
2.1.5.2 Soft Tissue Changes 
Soft tissue changes in diabetic foot have been frequently correlated with elevated plantar 
pressure (Murray et al., 1996, Bevans and Bowker, 1999, Abouaesha et al., 2001, Rao et 
al., 2006, Wrobel and Najafi, 2010, Searle et al., 2017). Patients with diabetes have been 
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found to develop atrophy/relocation of the heel and forefoot fat pads and stiffer plantar 
tissues than non-diabetic subjects (Bus et al., 2004, Cheung et al., 2006, Pai and Ledoux, 
2010, Ledoux et al., 2016, Naemi et al., 2016). 
The plantar soft tissue interface acts as an efficient shock absorber, to dampen the effects 
of impact forces during gait. Structural changes due to pathological conditions such as 
diabetes can result in altered mechanical properties of the foot soft tissues that impair its 
cushioning effect and reduce its capacity to uniformly distribute loads. Additionally, the 
repetitive excessive loading that patients do not recognise, due to the commonly 
associated neuropathy, can also make changes to the mechanical behaviour of soft tissues. 
Reduced flexibility means that these tissues are less able to distribute pressure via 
deformation which makes them more vulnerable to trauma and significantly increases 
plantar pressure (Abouaesha et al., 2001, Sun et al., 2011, Martinez Santos, 2016, Naemi 
et al., 2016). 
Hyperkeratosis (callus formation) is a common presentation under high-pressure areas. It 
allows the skin to better resist repetitive traumas, though, itself can act as an extrinsic 
source of stress to further elevate the plantar pressure on its location that regular removal 
of callus was found to be associated with a significant drop in foot pressure (Young et al., 
1992, Pitei et al., 1999). A variety of diabetic factors and complications may contribute 
to the development of callus and it is considered a significant risk factor in diabetic foot 
(Murray et al., 1996, Hamatani et al., 2016, Yazdanpanah et al., 2018). Yet, it is 
contradictory whether patients with diabetes may produce more callosities than those 
without diabetes or if it is only an association to the pre-existing risk factors (Bevans and 
Bowker, 1999, Flynn, 2014, Arosi et al., 2016). 
Another soft tissue change that can alter foot biomechanics and influence the foot loading 
in diabetic patients is diminished joint mobility. The limited joint mobility in diabetic foot 
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has been linked to neuropathy as well as, the longstanding hyperglycaemia with the 
accumulation of advanced glycosylation end products (AGEs) that may change the 
structural properties of different collagen-containing tissues of the foot including; 
tendons, ligaments and joints capsules (Wrobel and Najafi, 2010, Abate et al., 2013, 
Gerrits et al., 2015). These structural changes were noted in the increased thickness of 
diabetic foot tendons (Bolton et al., 2005, Giacomozzi et al., 2005). That subsequently 
leads to decreased elasticity and tensile strength, which result in joint instability causing 
subluxations as seen in Charcot joint or overall stiffness of the foot with the added effect 
of joint capsule contracture (Kim, 2013). The increased rigidity of diabetic foot joints is 
associated with elevated peak plantar pressure and pressure time integral, especially in 
the forefoot area. This raised pressure and prolonged loading time will add to the risk of 
ulceration (Fernando et al., 1991, Zimny et al., 2004, Rao et al., 2010, Guiotto et al., 
2013). Limited ankle joint dorsiflexion was the most reported in relation to elevated 
plantar pressure even independent of neuropathy (Searle et al., 2017) so that its routine 
screening was suggested as a tool to identify diabetic patients at increased risk of elevated 
plantar pressures and therefore diabetic foot complications (Searle et al., 2018). The 
progression of limited joint mobility with the presence of neuropathy, muscular 
dysfunction and atrophy leads to fixed deformities and high loading at the developed bony 
prominences, causing callus formation or the worst scenario, skin breakdown. 
2.1.6 Foot Pressures a Risk Factor in Diabetic Foot Ulcers  
Although the development of diabetic foot ulcers is multi-factorial, elevated plantar 
pressures have been frequently reported as a significant risk factor and predictive of foot 
ulceration in patients with diabetes (Veves et al., 1992, Frykberg et al., 1998, Pham et al., 
2000, Ledoux et al., 2013, Patry et al., 2013, Yazdanpanah et al., 2018). However, 
alteration in plantar pressure often coexists with other ulceration risk factors such as 
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neuropathy, peripheral arterial disease, muscular dysfunction, foot deformities and 
previous foot ulcers (Abboud et al., 2000, Plank et al., 2000, Bus et al., 2005, Guiotto et 
al., 2013). 
Foot pressures were measured in static and dynamic conditions, though, dynamic pressure 
measurement appears to be the more sensitive and reliable method for evaluating the at-
risk foot (Kim, 2013, Patry et al., 2013). Owings et al., (2009) proposed that examining 
in-shoe pressure is essential when considering foot ulcer risk in diabetic patients as they 
noted, barefoot peak pressure is a poor predictor of peak in-shoe pressure. Barefoot 
pressure was able to predict only 35% of the variance of in-shoe peak pressure (Owings 
et al., 2009). 
There have been several attempts to establish a pressure threshold that predicts the risk 
for development of foot ulceration in diabetic patients (Armstrong et al., 1998, Frykberg 
et al., 1998, Lavery et al., 1998, Owings et al., 2009, Waldecker, 2012). Although many 
threshold values have been proposed, a peak pressure threshold that possesses a high 
enough sensitivity and specificity for ulceration risk has not been definitively established, 
and the only certainty is that the higher the peak pressure, the higher the risk of diabetic 
foot ulceration (Armstrong et al., 1998, Plank et al., 2000, Waldecker, 2012). It is likely 
that each region of the foot has a different ulceration threshold pressure, depending upon 
its basic structure and tissue viability (Cavanagh and Ulbrecht, 1994, Plank et al., 2000, 
Bennetts et al., 2013). Patry et al., (2013) had anticipated that tissue repair threshold may 
not be the same as the tissue breakdown threshold in patients with DPN, with healed sites 
more prone to subsequent re-ulceration due to their lower tissue breakdown pressure 
threshold (Patry et al., 2013). Moreover, diabetic foot ulceration is a multifactorial 
pathology. It can be influenced by other factors such as peripheral vascular disease, 
neuropathy, duration of diabetes, glycaemic control, level of activity and lifestyle (Patry 
et al., 2013, Fawzy et al., 2014). The altered pressure represents only one factor within 
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the process, besides foot pressure itself can be affected by several elements (Wrobel and 
Najafi, 2010). Other factors to consider are the large variations in systems and ways of 
measuring, which make it difficult to compare between different studies or come to a 
consensus regarding the best system and the best way of obtaining a sensible and 
reproducible measurement (Patry et al., 2013, Martinez Santos, 2016). 
Along with the association between increased peak pressures and diabetic foot ulceration, 
there is also the cumulative effect of lower loads experienced over an extended period of 
time. For instance, the exposure of a moderately high pressure for a relatively long 
duration at a vulnerable site could be more damaging than a very high pressure introduced 
for a short duration (Plank et al., 2000). Therefore, lower walking speed and prolonged 
stance phase noted in diabetic patients (Brach et al., 2008, Fernando et al., 2013) will 
contribute to the rise in the cumulative stress of foot tissues due to the subsequent 
increased contact time. Another escalator for cumulative stress could be the repetitive 
minor trauma that may occur during different daily activities such as walking. Yet, 
subjects with diabetes and a history of previous ulcers may be more susceptible to plantar 
tissue injury, even at relatively low levels of cumulative tissue stress (Maluf and Mueller, 
2003). Here, Pressure-time integral (PTI) may be more valuable than peak pressure in 
estimating this cumulative effect of pressure over time at a specific area of the foot (Melai 
et al., 2011, Bus and Waaijman, 2013). PTI showed a significant increase in diabetic 
patients groups (Waldecker, 2012) and a higher sensitivity to changes related to footwear. 
Therefore, some authors recommended PTI routine investigation in the evaluation of 
diabetic footwear (Hsi et al., 2002, Sacco et al., 2009). 
Diabetic foot ulcers due to abnormal loading have been reported on both plantar and 
dorsal aspects of the diabetic foot (Haji Zaine et al., 2014, Kalburgi et al., 2017, Ousey et 
al., 2018). Nevertheless, it has been found that more than half of diabetic foot ulcers 
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(52%) were non-plantar (Figure 2.3) and the most frequent ulcer site was the dorsal or 
interdigital area of the toes (32%) (Prompers et al., 2007). 
 
Figure 2.3 Location of diabetic foot ulcers 
a) Dorsal/interdigital toes, b) Plantar toes, c) Plantar forefoot/midfoot, d) Plantar hindfoot, 
e) heel, f) Dorsal/lateral aspect foot (Prompers et al., 2007) 
Guidelines recommend routine inspection of both foot sides for any skin changes, in 
particular at the sites of common foot deformities that increase pressure, predisposing to 
skin breakdown on both aspects of the foot. For instance, the claw toe deformity, which 
combines metatarsophalangeal joints’ hyperextension with interphalangeal flexion or 
distal phalangeal extension (hammertoe). This buckling phenomenon causes an increased 
pressure on the digits’ dorsal surface, as well as on the plantar metatarsal heads. Another 
frequently seen foot deformity is Hallux Valgus, “Bunion”. The overlapping toes 
deformity can lead to pressure ulceration between the digits, on the dorsal or plantar 
surfaces of displaced digits, and over the medial first metatarsophalangeal joint (Figure 
2.4) (Lavery et al., 1998, Boulton et al., 2008). 
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Figure 2.4 Foot deformities sites as frequent locations for diabetic foot ulcers 
(Boulton et al., 2008) 
Dorsal ulcers are believed to be usually caused by ill-fitting footwear (Sabapathy and 
Madhu, 2016), tight-fitting non-adjustable straps that tend to prevent the footwear from 
slipping off especially in neuropathic patients (Premkumar et al., 2017) or in some 
cultures the frequent adoption of a specific prayer position (Chadwick et al., 2013). Ill-
fitting footwear may increase the risk of tissue damage at some foot sites as the lesser 
toes, to have more dorsal ulcers (up to 91%) than plantar (Peters et al., 2007), that was 
also found to be the least likely to heal as the infection spreads easily along the loose 
dorsal tissue planes and a large percentage of these lesser toe ulcers ended with an 
amputation (Lavery et al., 1998, Peters et al., 2007, Aragón-Sánchez et al., 2012, 
Sabapathy and Madhu, 2016). 
Yet, there are very few published studies on the assessment or management of dorsal or 
non-plantar ulcers (Caravaggi et al., 2003, Prompers et al., 2007). Most of the literature 
suggests the dorsal ulcers are due to friction with the footwear and should be managed 
simply through offloading as plantar ulcers and the prescription of customised footwear 
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with spacious toe boxes to accommodate deformities and ensuring the foot does not move 
within the footwear to avoid re-injury (Peters et al., 2007, Sabapathy and Madhu, 2016). 
Due to, the general belief that dorsal ulcers are caused by friction, which corresponds to 
the shear component of pressure, compounded by the lack of commercial devices that can 
measure shear forces, little research has been conducted to assess the role of pressure in 
diabetic dorsal foot ulcers (Shankhdhar et al., 2016). 
With the aim of this study to assess both surfaces of the foot, we started our work by 
exploring different available modalities that could be used in the measurement of the 
dorsal pressure. Literature regarding existing techniques is discussed in the next chapter 
with details for the study protocol development. 
2.2 ENDOTHELIUM 
2.2.1 Introduction 
The endothelium comprises the mono-cellular layer lines tunica intima, the innermost 
layer of all blood vessels’ wall. It represents a diffuse organ of over 700 g in the adult 
human, and consists of approximately 10 trillion (1013) cells, contributing close to 1.5% 
of the total body mass (Bakker et al., 2008, Triggle et al., 2012). The endothelium serves 
as an interface/barrier between the circulating blood components and other tissues. 
However, it is no longer considered a simple inert physical barrier, but it is believed to 
act as a complex organ with paracrine and autocrine functions that, plays a crucial role in 
the vascular as well as, the overall tissue homeostasis (Hadi and Suwaidi, 2007). 
Although endothelial cells share a common origin, some local differences exist in the 
endothelium of various vascular beds reflecting differing in the specialised functions of 
the hosting organs. In general, the endothelium facilitates a range of functions through a 
complicated system of chemical mediators that exerts effects on both the adjacent 
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vascular smooth muscle (VSM), located in the median layer of the blood vessels’ wall 
(tunica media) and the blood constituents in the blood vessels’ lumen. 
The endothelium has been known to respond to different stimuli including mechanical 
forces, oxidative and metabolic stresses, inflammation, hypoxia, and many other stresses 
while adapting different functions accordingly. These include; the production of 
vasoactive substances (vasodilators or vasoconstrictors) to regulate blood flow, actively 
regulates the delivery of nutrients and other macromolecules into the surrounding tissue, 
production of fibrinolysis or coagulation regulators to ensure the fluidity of blood and 
avoidance of bleeding, modulation of VSM including proliferation, migration and/or 
changes in the phenotypic characteristics, cascading pro-inflammatory or anti-
inflammatory changes, generation of oxidising and anti-oxidising agents and many others 
(Mombouli and Vanhoutte, 1999, Hadi and Suwaidi, 2007, Bakker et al., 2008). 
2.2.2 Endothelial Functions 
One of the key characteristics of the endothelium is the sensing of different 
chemical/hormonal and physical stimuli, in particular the mechanical forces related to 
shear stress with the flowing blood. This enables it to counteract, regulating the vascular 
tone through the production of various flow-dependent vaso-regulatory mediators in-
order to maintain tissues’ blood flow in response to local metabolic requirements, blood 
pressure or stress conditions. These chemical mediators included endothelium-derived 
relaxing factors (Vasodilators) e.g. Nitric Oxide (NO), Prostaglandins (in particular PGI2 
or Prostacyclin and PGE2) and Endothelium-derived Hyperpolarization Factor (EDHF), 
as well as endothelium-derived contracting factors (Vasoconstrictors) e.g. Endothelin-
1(ET-1), Angiotensin-II (AT-II) and Prostaglandins (PGH2/Thromboxane A2) (Verma 
and Anderson, 2002, Hadi and Suwaidi, 2007). 
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One of the first recognised mediators was an endothelium-derived relaxing factor, which 
was subsequently shown to be Nitric Oxide (NO) (Furchgott and Zawadzki, 1980, Ignarro 
et al., 1987, Palmer et al., 1987). NO is well known as the single most important molecule 
for vascular homeostasis and nearly all stimuli that produce vasodilatation do their effect 
through it. NO is produced through the conversion of the amino acid, L-arginine to L-
citrulline in the presence of molecular oxygen and cofactors, e.g. reduced Nicotinamide 
Adenine Dinucleotide Phosphate (Dihydro-nicotinamide adenine dinucleotide 
phosphate) (NADPH) and tetrahydrobiopterin (BH4), by the enzyme, NO-synthase 
(NOS). NOS type III or eNOS, constitutively expressed by the endothelial cells is 
enhanced after binding Ca2+/calmodulin and generates NO that rapidly diffuses to the 
VSM where it activates the enzyme guanylate cyclase. This results in the formation of 
cyclic guanine monophosphate (cGMP), activating a cGMP dependent protein kinase, 
which leads to an increased extrusion of Ca2+ in VSM cells and evoking relaxation thus 
vasodilation. Circulating agonists, such as Acetyl Choline (ACh), Bradykinin, Histamine 
and Serotonin, stimulate endothelial cells to dissociate NOS, permitting its activation and 
binding to Ca2+/calmodulin thus increase NO production. It was noted that physical 
stimuli such as shear stress caused by the increase in velocity of blood flow can stimulate 
the activation of endothelial NOS through a Ca2+/calmodulin independent pathway. The 
end result of both means is endothelium-dependent vasodilation which is proportional to 
the amount of NO released by the endothelium. Nitrates given in any way as in the 
management of angina, are NO donors. Circulatory NO, directly releasing cGMP in 
VSM, triggering a relaxation response which is known as Endothelium-independent 
vasodilatation (Figure 2.5) (Mombouli and Vanhoutte, 1999, Esper et al., 2006, 
Dhananjayan et al., 2016, Rafnsson, 2018). 
In addition to the potent vasodilator effect of NO, it mediates many other protective 
functions. It inhibits the expression of pro-atherogenic and pro-inflammatory cytokines, 
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chemokines and leukocyte adhesion molecules. Thereby limiting vascular recruitment of 
leukocytes, reducing vascular permeability, tissue oxidation, tissue inflammation, 
activation of thrombogenic factors, and platelets aggregation. It also inhibits VSM cells 
growth, proliferation and migration, an early sign of atherosclerosis. Hence, NO is 
considered an essential anti-atherogenic factor and the decrease in its production is 
thought to play a crucial role in vascular diseases such as atherosclerosis, hypertension 
and peripheral arterial disease (Nyström, 2005, Esper et al., 2006). Thereby, the 
assessment of vasodilator properties resulting from NO has become the most widely used 
end-point for assessment of endothelial function as it reflects the function of various 
properties of the endothelium (Matsuzawa and Lerman, 2014). 
 
Figure 2.5 The nitric oxide pathway in the vasculature 
Endothelial cells constitutively expressing nitric oxide synthase (eNOS) generate nitric oxide 
(NO) using L-arginine as a substrate together with certain cofactors NO then rapidly 
diffuses into vascular smooth muscle cells and binds to guanylate cyclase (gc). This event 
results in the formation of cyclic GMP (cGMP), activating a cGMP dependent protein 
kinase, which leads to an increased extrusion of Ca2+ from the cytosol inhibiting the 
contractile machinery and thereby evoking vasodilation. Production of NO can be further 
induced by e.g. ACh or by shear stress, which causes flow-meditated vasodilation. Nitrates, 
frequently used clinically in the management of angina, function as direct NO donors  (here 
exemplified by SNP) thereby causing vasorelaxation (Nyström, 2005) 
Endothelial cell 
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2.2.3 Assessment of Endothelial Functions 
Over the past few decades, the discovery of the endothelium’s crucial role in the 
regulation of vascular functions and the recognition of endothelial dysfunction as a key 
pathological condition in most, if not all cardiovascular adverse events, has led to a 
tremendous interest in endothelial research and ways of assessing its function as a 
predictor of cardiovascular health status, a potential therapeutic target and an essential 
marker in investigating the effects of different therapeutic interventions (Al-Qaisi et al., 
2008, Jezovnik, 2011). Several techniques have been used for exploring various aspects 
of endothelial pathobiology comprising, invasive and non-invasive methods, tests within 
coronary or peripheral arteries, and assessment of response to pharmacological agents 
and/or to hemodynamic provocation tests. However, there remains a considerable debate 
regarding the most appropriate way of assessing endothelial function. The ideal test 
should be safe, non-invasive, easy to perform, reproducible, repeatable, inexpensive, and 
standardised between laboratories. Moreover, the clinical use will prerequisite results to 
reflect the dynamic biology of the endothelium throughout the natural history of the 
cardiovascular disease. It must also define subclinical disease processes, as well as 
provide prognostic information for risk stratification in the later clinical phase of the 
disease. No single test currently fulfils these requirements and comprehensively assesses 
endothelial function, let alone the reported limited reproducibility and high inter-subject 
variability of the available methods (Gori, 2018, Small et al., 2019). Thus, the 
introduction of a technique specifically aimed at measuring endothelial function as a 
routine clinical tool in daily practice has not been established, nor has any method been 
recommended in clinical guidelines for planning primary or secondary prevention of 
vascular diseases (Deanfield et al., 2005, Deanfield et al., 2007, Flammer et al., 2012, 
Higashi, 2015, Gori, 2018, Small et al., 2019). 
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Endothelial function can be assessed by examining the endothelium’s capacity to perform 
its various physiologic functions, including regulation of vasomotor tone, expression of 
adhesion molecules and maintenance of an anti-thrombotic microenvironment 
(Matsuzawa and Lerman, 2014). The work of Ludmer, et al., 1986 was the first attempt 
to demonstrate the presence of endothelial dysfunction in atherosclerotic arteries. A 
paradoxical coronary artery vasoconstriction was induced by intracoronary infusion of 
acetylcholine in patients with atherosclerotic coronary arteries and endothelial function 
was measured. Changes in the blood vessel diameter were assessed by quantitative 
coronary angiography and changes in the coronary blood flow were examined by Doppler 
flow wire. This research drew attention to the functional manifestations of 
atherosclerosis, exaggerated vasoconstriction, as a consequence of poorly functioning 
endothelium (Ludmer et al., 1986, Flammer et al., 2012, Higashi, 2015). Although these 
early tests directly assess coronary circulation and are predictive of cardiovascular events, 
their invasive nature limits their use to patients requiring a coronary angiography for 
clinical indications and makes them very challenging if serial follow-up measurements 
are required (Deanfield et al., 2007, Small et al., 2019). Later, less invasive techniques 
were developed using the forearm circulation. Whereas peripheral techniques to assess 
endothelial function offer a more accessible, non- or less invasive surrogate approaches, 
certain phenomena cannot be explained by systemic endothelial dysfunction; it is likely 
that local factors (e.g. flow patterns) and local vascular bed function/dysregulation may 
also contribute to disease state as that observed at some branch’s points (El-Tamimi et 
al., 1994, Deanfield et al., 2005, Flammer et al., 2012). 
All available approaches have their advantages and disadvantages which have been 
extensively explored in the literature (Alam et al., 2005, Deanfield et al., 2005, Deanfield 
et al., 2007, Flammer et al., 2012, Flynn et al., 2012, Matsuzawa and Lerman, 2014, 
Higashi, 2015). Yet, the basic principle remains similar: healthy arteries, coronary or 
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brachial, dilate in response to reactive hyperaemia (flow-mediated vasodilatation, known 
as the ‘gold standard technique’) or after intra-arterial infusion of pharmacological stimuli 
including endothelium-dependent vasodilators such as ACh, bradykinin or serotonin, via 
the release of NO and/or other endothelium-derived vasoactive substances. Such 
endothelium-dependent vasodilatation is reduced or absent in response to disease states 
as in atherosclerosis. Additionally, exogenous NO donators (e.g. Glycerol-trinitrate, SNP) 
can be applied to differentiate endothelium-dependent vasodilatation from endothelium-
independent responses. An impaired endothelium-independent function is associated with 
structural vascular changes and malformations in VSM cells, rather than changes in the 
endothelium (Flammer et al., 2012, Harbin et al., 2018). 
Endothelial dysfunction is known to be a diffuse, systemic condition hence, the peripheral 
endothelial function (microvascular and macrovascular) have been able to correlate well 
with endothelial function in the coronary arteries (Anderson et al., 1995, Takase et al., 
1998, Khan et al., 2008) and have demonstrated to be a significant independent predictor 
of future cardiovascular events (Matsuzawa and Lerman, 2014). The accessibility of the 
skin makes it an appropriate site for the peripheral assessment of endothelial function. 
Skin microvascular function has been demonstrated to be an independent determinant of 
cardiovascular diseases in patients with type 2 diabetes (Yamamoto-Suganuma and Aso, 
2009). 
Therefore, the assessment of skin microvascular function could provide insights into the 
mechanism of the underlying disease changes, offer a prognostic marker and help in 
evaluating the effect of drugs in cardiovascular diseases (Roustit and Cracowski, 2013). 
Hence, investigating the skin vasculature response to loading foot pressures could add to 
the understanding of the mechanism leading to foot ulceration in diabetic patients (Flynn, 
2014). 
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Subcutaneous microvasculature function can be assessed in response to stimuli such as 
pharmacological agents, arterial occlusion or thermal alterations to reflect changes that 
occur in other important central vascular beds (Khan et al., 2008, Gutterman et al., 2016). 
Many methods are available to test this peripheral endothelial function while providing a 
direct or indirect indication of the changes in the subcutaneous microvascular perfusion. 
Laser Doppler flowmetry with iontophoresis to the skin on the dorsal as well as the plantar 
surfaces of the foot was the chosen technique to be utilised in the current research study. 
2.2.3.1 Laser Doppler Flowmetry (LDF) and Iontophoresis 
Laser Doppler Flowmetry (LDF) is a non-invasive method of measuring microvascular 
blood flow in the tissues and the real-time changes in perfusion under various conditions 
or during provocation testing. The technique is based on measuring the Doppler Effect or 
better known as “Doppler shift”. It comprises detecting the wavelength changes in the 
reflected beam of laser light which scatters upon hitting moving blood cells. The 
magnitude and frequency of such wavelength changes correspond to the number and 
velocity of blood cells. A laser Doppler instrument output often gives “flux”, the signal 
used for flow measurement. Flux is an indirect (relative) index of perfusion. It is the 
product of velocity and concentration of moving blood cells within the measured volume, 
known to be proportional to the real blood flow and expressed as arbitrary perfusion units 
(PU) or millivolts (1PU = 10 mV). Utilising standardised protocols and controlling 
external environmental factors including temperature, movement and/or reflection 
artefacts and removal of topical agents, are essential for the reliability and reproducibility 
of the technique. Yet, there are some limitations that motivate the ongoing research in 
both the instrumentation and theoretical aspects of the technique. Major limitations 
include; the influence of the tissues’ optical properties on the perfusion signal, motion 
artefact noise, lack of quantitative units for perfusion, lack of knowledge of the depth of 
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measurement and the biological zero signal (perfusion measured at no flow condition)  
(Cracowski et al., 2006, Rajan et al., 2009, Small et al., 2019). 
There are two techniques available in practice, laser Doppler perfusion monitoring 
(LDPM) and laser Doppler perfusion imaging (LDPI). 
Laser Doppler perfusion monitor (usually referred to as LDF) is the one-point 
measurement method, which involves the placement of a laser probe in direct contact 
with the skin surface. The single-point fibre-optic probe is connected to a delivery fibre 
from the source semiconductor laser diode, as well as a collection fibre for detection and 
processing of the backscattered signal from tissues (Figure 2.6). The measurement depth 
and sampling volume depend on the wavelength and the fibre separation used. In normal 
skin with a standard fibre separation probe and the often-used wavelength is 780 nm, the 
measuring depth is 0.5–1.5 mm into the dermis and the measurement volume is 
approximately 1mm3. It can detect dermal blood flow without the influence from the flow 
in the underlying skeletal muscles from a single point or vessel at any time with a high 
sampling frequency (often 32 Hz) (Low et al., 2020). Therefore, it provides continuous, 
real-time flow information and any variations in response to different tested conditions 
or given stimuli. 
37 
 
Figure 2.6 Laser Doppler Flowmetry assessment of skin blood flow 
A beam of laser light is emitted from a fibre-optic probe (Sender), light reflected on hitting 
moving blood cells undergoes a change in wavelength (Doppler shift) while light hitting 
static objects is unchanged, the information is picked up by a returning fibre (receiver), 
converted into an electronic signal (Low et al., 2020) 
As LDPM assesses blood flow over a small volume, it offers the advantage of constant 
measurement of blood flow at the specified examined location which could be detrimental 
in monitoring the reactive flow and the study of the dynamics of the dilator response. 
However, this affects the reproducibility of the procedure, mainly due to the spatial 
variability resulting from the inherently inhomogeneous microvasculature related to the 
skin anatomy. Reproducibility has been improved by using “integrated probes”. These 
probes are composed of multiple collecting fibres to cover a larger skin area thus 
increasing the spatial resolution. Fibres are positioned in a ring around a central light 
delivery fibre and averaging the signal from different scattering volumes, decreasing 
spatial variability (Turner et al., 2008, Rajan et al., 2009, Roustit and Cracowski, 2013). 
The integrated probe also helps to solve the problem of fibre-based noise from movement 
artefacts, where light delivery and detection are on the same probe (Rajan et al., 2009). 
LDPM does not provide any visual information for morphological or density assessment 
of the tested vascular bed like those produced with LDPI. This limits its use to quantitative 
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flow studies rather than qualitative morphological assessments (Deegan and Wang, 
2019). 
Laser Doppler perfusion imager (LDPI) provides 2D images, mapping the skin blood 
flow into coloured pixels which represent the scanned perfusion values. The laser beam 
is illuminated from a specific distance above the skin surface, reflected by a computer-
driven mirror, to progressively scan the area of interest while detecting a fraction of the 
reflected backscattered light from tissues (Roustit and Cracowski, 2012). Figure 2.7 
shows the setup of LDPI system. 
 
Figure 2.7 LDPI 
(a) A schematic diagram showing the typical arrangement of LDPI setup. (b) LDPI of an 
index finger before, directly after, 3 min after, and 10 min after immersion in iced water. 
The 6-level colour scale represents relative low–high tissue perfusion (Deegan and Wang, 
2019) 
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LDPI offers a non-contact assessment of the skin perfusion which may be desirable in 
clinical situations as for wound assessment. Also, it maps the perfusion from a larger 
surface area (up to 50 cm × 50 cm is possible) and can give the average perfusion of a 
heterogeneous tissue in a single measurement. Thus, reduces the spatial variability caused 
by vascular in-homogeneities and improves results reproducibility. However, LDPI is 
much slower than LDPM. It gives a “snapshot” of the perfusion at a given point of time, 
producing a series of images or “scans”. A few minutes may be required to capture one 
image, making rapid variations in the skin blood flow over the larger areas more difficult 
to record. Additionally, tissue motion and physical movements of the subjects produce 
more artefacts in a non-contact measurement technique such as LDPI than with 
monitoring using the LDF probe fixed on the skin (Rajan et al., 2009). 
As the LDPI technique cannot measure blood flow continuously, its output signal has a 
lower temporal resolution compared to LDF and can no longer be considered a real-time 
imaging modality. This problem can be partially resolved by reducing the area to be 
scanned and/or increasing the scan speed which may result in producing slightly less 
detailed images. To attempt to address this issue some recent imagers have used a multi-
channel laser Doppler line. Many studies are not concerned with the dynamics of the 
cutaneous response that prerequisite the single point continuous flow assessments, but 
instead they focus more on the maximum response at a given stimulus/time point and the 
larger perfusion maps which can be adequately acquired by LDPI (Turner et al., 2008, 
Rajan et al., 2009, Roustit and Cracowski, 2012, Roustit and Cracowski, 2013, Deegan 
and Wang, 2019). 
A single point LDF was chosen in the current study, as it required the contact feature of 
the LDF probe in delivering the premeasured in-shoe foot pressure while assessing the 
changes in the skin perfusion. 
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A major limitation of laser Doppler flowmetry is that no exact measure of blood flow can 
be extracted. However, a linear relationship between the laser Doppler signal and the 
microvascular blood flow has been established. Therefore, the relative laser Doppler 
signal or flux is mostly used to assess the microvascular reactivity, by challenging the 
examined vascular bed with various functional tasks. Among the tests used in 
combination with laser Doppler, the most common are iontophoresis of vasoactive drugs, 
post-occlusive reactive hyperaemia, and thermal provocations (Cracowski et al., 2006, 
Roustit and Cracowski, 2012). 
Iontophoresis in conjunction with LDPM and LDPI have been utilised in the literature. It 
has been frequently used to investigate and evaluate microvascular perfusion changes in 
response to local administration of vasoactive drugs across the skin in many pathological 
conditions, such as diabetes mellitus and peripheral arterial disease. Iontophoresis has 
been widely used as a non-invasive, convenient and simple pharmacological tool for 
transdermal drug administration (Roustit and Cracowski, 2012). Its principle mechanism 
is based on the transfer of charged molecules across the skin using a direct low-intensity 
electric current (Figure 2.8). The molecules of the drug to be delivered are either 
positively or negatively charged in a solution and will migrate across the skin under the 
influence of the applied monopolar current according to the rule that like charges repel 
each other (Turner et al., 2008). 
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Figure 2.8 Schematic diagram for the delivery of positive drug ions  
(D+) such as ACh. For negatively charged ions, such as SNP, the current to the chamber is 
reversed. Current is delivered by an iontophoretic device connected to a computer that 
controls iontophoretic settings and collects the data (Noon et al., 1998) 
The rate and quantity of the drug delivered depend on the concentration and the pH of the 
solution, the magnitude of the applied current and its duration and the nature of the skin 
surface. The main iontophoresis applications with Laser Doppler, involve a time-
controlled delivery of a vasoactive drug, mostly ACh or SNP (although other substances 
have also been used e.g. bradykinin), onto a patch of the subject’s skin, while the blood 
flow response is recorded by laser Doppler, to assess microvascular endothelium-
dependent and independent vasodilation, respectively. The use of LDPI allows perfusion 
measurement over the entire distribution of the administered drug, whereas laser Doppler 
flowmetry restricts blood flow measurements to single points in the distribution. A typical 
set up for laser Doppler iontophoresis is shown in Figure 2.9. 
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Figure 2.9 Laser Doppler iontophoresis equipment 
(a) Example of the combination of the iontophoresis equipment with the Moor LDF probe 
(b) Example of the combination of the iontophoresis equipment  with the Moor LDPI system 
(Smirni, 2018) 
The Iontophoresis equipment comprises a reference electrode and a ring-shaped chamber 
which is fitted with an internal electrode and will be filled with the vasoactive drug. The 
two electrodes are connected to a controller with the polarity of the chamber (active) 
electrode having the same charge of the vasoactive drug (e.g., chamber positive for ACh 
and negative for SNP). The circuit is completed by attaching the chamber and the 
reference electrode on the skin of the testing subject, and finally filling the chamber with 
the solution of the vasoactive agent. Under the influence of the applied current, the 
charges of the chamber electrode will repel the charges of the same polarity drug inducing 
the transfer of the molecule into the skin (Smirni, 2018).  
There are different approaches for the electric current application in iontophoresis, 
depending on the substance used and the protocol chosen. Either, a protocol with a 
continuous application of current, or, more often, intermittent (interval) application of 
constant or increasing current is utilised (Lenasi, 2011). However, in any procedure, the 
electric current used is very weak (less than 100μA), hence it is usually a painless 
procedure. Additionally, iontophoresis offers a non-invasive delivery of vasoactive drugs 
without the trauma associated with intradermal injection (microdialysis) that may 
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influence the skin blood flow. The quantity of the drug to be delivered is also too small 
to have any systemic effects, and avoids the first-pass metabolism, although, mild allergic 
reactions and skin irritation have been reported (Alam et al., 2005, Turner et al., 2008, 
Lenasi, 2011). 
Several methodological issues need to be considered when using LDF with iontophoresis. 
For instance, all factors that could be a source of variability when assessing cutaneous 
microvascular reactivity should be kept at a minimum and must be controlled whenever 
possible, to remain constant throughout the procedure. Such factors include; subject-
related elements, such as age group, the subject position (supine is the best posture to 
maintain throughout the measurement process in addition to subjects lying completely 
still to avoid movement artefacts), prior physical activity and mental stress, previous 
consumption of food, beverages containing caffeine or alcohol, smoking (subjects should 
refrain from tobacco, caffeine and food ingestion for a period of at least 2 hours prior to 
assessments), diseases and any vasoactive drug intake, menstrual cycle and the use of oral 
contraceptives, and the time of day when measurements are taken (temporal variations 
affiliated to; circadian rhythm, inter-day variability, seasonal variations). Also, 
environmental-related factors may influence the LDF signal such as room temperature 
(preferably set at 22-24°C), air humidity and movement of the adjacent air. Altogether, 
prerequisite subjects to reset for an appropriate acclimatisation period (at least 20 
minutes) before any measurements are taken (Lenasi, 2011, Roustit and Cracowski, 2012, 
Roustit and Cracowski, 2013). Skin resistance, which varies significantly between 
individuals, is another vital factor that influences the efficiency of the procedure. Skin 
resistance varies between different skin sites and depends on other elements such as skin 
hydration status, thickness and nature (glabrous or non-glabrous) (Ramsay et al., 2002). 
To minimise skin resistance, a general good practice is to clean the area where the 
iontophoresis electrodes are applied with an alcohol swab and gently rub the skin using 
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an adhesive tape to strip off the epidermis, clearing away any lipids or dead 
skin/keratinocytes (Turner et al., 2008, Lenasi, 2011). Visible veins and hairy regions 
should be avoided and if any shaving is required, this has to be done at least 24 hours 
prior to data collection to avoid any associated skin flare response (Low et al., 2020). 
Another issue allied to the iontophoresis technique, is the confounding effect of current-
induced vasodilation, referred to as ‘galvanic response’. The exact mechanism of this 
current-induced hyperaemia remains debatable. Proposed explanations include the 
induction of an axon reflex, competition between ions of the active substance and the 
vehicle used to dilute it (Turner et al., 2008, Roustit and Cracowski, 2013). Topical 
anaesthesia before iontophoresis can minimise this nonspecific current-induced 
vasodilation but does not completely abolish the response and can impact upon the results. 
Thus, the addition of a control site is recommended to allow a quantitative correction of 
this issue. The magnitude of the current-induced-vasodilation was found to be dependent 
on the vehicle used. A range of preparations has been used, including deionized water, 
tap water, sodium chloride, mannitol solutions, as well as different cellulose gels. The use 
of deionized water as a vehicle limits the adjunction of competing ions, therefore 
enhancing the iontophoretic transport. Deionised water causes excessive current-induced 
vasodilation when used on its own, however, when a vasoactive drug such as ACh or SNP 
is added, the electrical characteristics of the resulting solution become different and the 
resistance of water was reduced (Khan et al., 2004). 
2.2.3.2 Assessment of Endothelial Functions in Diabetes Mellitus  
The endothelium has been found to be susceptible to develop pathological changes in 
both Type 1 and Type 2 Diabetes Mellitus (Bertoluci et al., 2015, Dhananjayan et al., 
2016). No single definition would cover the possible pathological changes in the 
endothelial function that is known as “Endothelial dysfunction”. This condition of 
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endothelial dysfunction is characterised by an alteration in the endothelium regulating 
functions, resulting in impaired vasodilation and a pro-inflammatory and pro-thrombotic 
status that favours the development of atherosclerosis and vascular complications 
associated with several cardiovascular and metabolic diseases including diabetes. In 
addition to endothelial dysfunction being known as a key initial event in the development 
of atherosclerosis, it is also one of the earliest signs of insulin resistance that appears to 
precede overt hyperglycaemia as in patients with Type 2 Diabetes, suggesting a cause-
effect relationship (Balletshofer et al., 2003). Signs of endothelial dysfunction were 
evident in diabetes, irrespective of the presence or absence of complications (Dinh and 
Veves, 2005). Furthermore, endothelial dysfunction was found to precede the 
development of diabetes in individuals with impaired glucose tolerance (Caballero et al., 
1999, Vehkavaara et al., 1999) as well as, determined in healthy nondiabetic subjects who 
have a first-degree relative with Type 2 Diabetes (Balletshofer et al., 2000). Therefore, 
endothelial dysfunction may represent a potential link between diabetes and 
atherosclerosis that would contribute to further understanding of the progression of 
vascular complications and end-organ damage in diabetes and provide an early target for 
preventing diabetic vascular diseases. In fact, there is evidence that treatment with 
metformin can assist in decreasing cardiovascular risk in patients with Type 2 Diabetes 
through ameliorating endothelial dysfunction (De Jager et al., 2014, Stehouwer et al., 
2015). 
However, a large variety of contributing mechanisms, which are still incompletely 
understood, have been proposed for the development of endothelial dysfunction in 
diabetes. Nevertheless, the high prevalence of other associated cardiovascular risk factors 
with diabetes, such as dyslipidaemia, hypertension, obesity, or a combination of these 
factors are also well known to negatively impact upon endothelial function (De Vriese et 
al., 2000, Hadi and Suwaidi, 2007, Tabit et al., 2010). 
46 
Reduced production and/or bioavailability of NO is considered one of the 
fundamental/initial elements of endothelial dysfunction, hence, assessment of 
endothelium-dependent vasodilatation, in particular, using the iontophoresis technique, 
offering a reproducible and accessible investigation, is commonly used to study 
endothelial functional changes in diabetes. Furthermore, advances in non-invasive 
techniques such as LDF which can reliably quantify skin microvascular blood flow and 
evaluate endothelial reactivity, have made it possible to study these endothelial functional 
changes in diabetes that contribute to the endothelium’s lack of exerting the appropriate 
response to stress and injury, leading to various diabetic vascular complications including 
diabetic foot. It is generally believed that both structural and functional microvascular 
pathological changes contribute to the risk of tissue breakdown and poor wound healing 
in diabetic foot ulceration (Dinh and Veves, 2005, Chao and Cheing, 2009). Additionally, 
endothelial dysfunction was found to be an independent predictor of peripheral diabetic 
neuropathy, a key contributor to diabetic foot disease (Roustit et al., 2016). 
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CHAPTER 3 STUDY DESIGN AND METHODS 
3.1 DORSAL FOOT PRESSURE MEASUREMENTS 
Little research has been conducted to investigate Dorsal Foot Pressure and its impact on 
high-risk feet such as diabetic foot. Much research has been carried out into plantar 
pressure measurements, abnormalities and effect on tissue viability and blood flow, 
particularly when investigating pathologies such as diabetes mellitus. 
Further studies would be beneficial in understanding the reason for the high prevalence 
of non-plantar ulcers and lower healing rates of foot wounds located on the dorsal surface 
(Eneroth et al., 2004). Furthermore, a better understanding of dorsal foot pressure and its 
implications will help to inform future footwear design to achieve better comfort, injury 
prevention and performance improvement (Greenhalgh et al., 2012, Rupérez et al., 2012, 
Mei et al., 2014). 
It is generally agreed that there is a minimal pressure exerted on the dorsal surface of the 
foot (Walker et al., 2015), hence, the lack of commercial devices available for dorsal foot 
pressure measurement. Therefore, in order to investigate the dorsal foot pressure, the 
current study began by exploring different means that could be used to measure the dorsal 
foot pressure and subject suitability for the study group. Available devices found will be 
discussed in the following section. 
3.1.1 Smart Socks 
Although a range of Smart Socks is available, they were mostly in exploratory prototypes 
at the time this research project commenced. Textile-based systems such as Smart Socks 
use embedded textile pressure sensors weaved or knitted in a specific pattern, making it 
possible to create a pressure-sensitive fabric with the desired number of pressure-sensing 
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sites. This approach has been used previously to develop sock-based systems for temporal 
gait analysis, and plantar foot pressure distribution/control in medical and sports 
applications (Preece et al., 2011, Perrier et al., 2014, Oks et al., 2017, Mokhlespour 
Esfahani and Nussbaum, 2018). 
An example of these smart socks included Sensoria® Fitness Smart Sock (Figure 3.1) 
(Esposito et al., 2015). Each sock is infused with three proprietary textile sensors under 
the plantar area to detect foot pressure and conductive fibres relay data collected by these 
sensors to an anklet. When connected to the sock, the anklet communicates continuously 
with a mobile app through Bluetooth Smart. Another product that was proposed from the 
same manufacturer to use in the current study was the Sensoria® Developer Kit. This kit 
allows the development of a customised sensor strip. The sensor strip is essentially a strip 
of fabric containing the textile pressure sensors that enables placement of sensors to the 
desired location including the dorsal surface of the foot (Sensoria®). 
 
Figure 3.1 Sensoria® Fitness Smart Sock (Sensoria®) 
Anklet 
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Further research evaluating this smart garment technology was published after the current 
study began (Rosenberg et al., 2016, Raviglione et al., 2017, Yeung et al., 2019). 
Other available Smart socks were also designed with pressure sensors embedded into the 
plantar surface only e.g. Texisense Smart Sock “Texisocks” (TexisocksTM, Perrier et al., 
2014) and DAid® Pressure Sock System (Oks et al., 2016, Oks et al., 2017). The 
Texisense smart socks were later modified to measure dorsal foot pressure and correlate 
it with footwear comfort (Herbaut et al., 2016). 
Another two smart sock prototypes were found under investigation, aiming at recording 
pressure distribution around the whole foot whilst walking. These were the Alpha-Fit 
GmbH - Smart Sock (Alphafit, Koydemir and Ozcan, 2018), and the SmartSox project 
by a research group at the University of Arizona (Najafi et al., 2017). 
3.1.2 In-Shoe Pressure Measurement Inserts 
In-shoe pressure measurement insoles/inserts were the only method used by the very few 
studies found in the literature that examined the characteristics of dorsal foot pressure. 
Greenhalgh et.al. 2012 adapted an F Scan in-shoe pressure insole to measure pressure 
across the lateral side of the dorsum of participants’ feet. Although the insoles were 
designed to measure in-shoe plantar pressure, these sensors can be trimmed to the desired 
shape to measure pressure over any desired area. The insert was cut and inserted into the 
participant’s sock on the lateral side of their right foot’s dorsal surface with a small piece 
of a double-sided adhesive tape to hold the sensor in place (Figure 3.2) (Greenhalgh et 
al., 2012). 
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Figure 3.2 Adapted pressure sensor inserted into a sock 
 (Greenhalgh et al., 2012) 
The F Scan® in-shoe pressure measurement system uses micro-thin insoles (0.1 mm) with 
multi-laminate construction. The F Scan® insoles record pressure with ranges of 50-75 
psi/345-517 KPa (sensitive) to 125 psi/862 KPa (standard). They offer a high spatial 
resolution with 960 resistive technology sensing elements spaced at 5 mm intervals 
(Tekscan Inc). This design allows the insole to be cut to fit any individual shoe size. 
Unfortunately, the advantage of these insoles being so thin, makes them prone to 
wrinkling both when being inserted within the shoe and while walking; this may lead to 
track failure and faulty data collection. The system also suffers from calibration issues 
with the sensitivity of the insoles declining as much as 20% with multiple uses (Abboud 
and Rowley, 1996, Urry, 1999, Nicolopoulos et al., 2000). 
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Another TekscanTM system used in detecting dorsal foot pressure is FlexiForce® sensors 
(Olaso et al., 2007, Rupérez et al., 2012, Takesue et al., 2019). Similar discrete pressure 
sensors, FSA (Vista Medical, Winnipeg, Manitoba, Canada) were also used by Cheng 
and Hong, 2010 to quantify the subjective perception of fit of running shoes (Figure 3.3) 
(Cheng and Hong, 2010). 
 
Figure 3.3 Anterior view of FSA pressure sensors attachment 
 (Cheng and Hong, 2010) 
These thinner flexible piezoresistive pressure sensors can be customised according to the 
prerequisite tested area (Tekscan, Abdul Razak et al., 2012). However, it was noted that 
the response of this type of sensors is sensitive to folding which causes measurement 
errors and therefore may lead to potential bias (Herbaut et al., 2016). 
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The most reliable method used in the literature is Pedar (Novel®) In-shoe pressure 
measurement system. First attempts involved placing a custom-designed rectangular 
capacitance sensor pad on the dorsal side of the foot and correlating pressure distribution 
with perceived comfort (Jordan and Bartlett, 1995a, Jordan and Bartlett, 1995b, Jordan et 
al., 1997). The dorsal pad could not be used in conjunction with the plantar insole 
therefore data were collected from the insole and dorsal pad separately. A significant 
correlation was noted between pressure and comfort, the lower the dorsal pressure, the 
better the perceived comfort. 
Pedar in-shoe plantar pressure measurement insoles have been used for the determination 
of plantar and dorsal pressure in patients who had undergone rotationplasty. This surgical 
procedure alters the anatomical position of the foot so that the foot is rotated to a vertical 
posterior-facing position. The insoles were worn inside the sock during walking with the 
prosthesis (Figure 3.4) (Hillmann et al., 2000). 
 
Figure 3.4 Schematic of the rotated foot and the prosthesis 
The Pedar insoles were placed inside the customised prosthetic shoe  
(Hillmann et al., 2000) 
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The measurements were able to describe the main areas of loading for the plantar as well 
as the dorsal aspect of the foot within the shaft of the prosthesis (Figure 3.5). Although 
pressure distribution characteristics on the dorsal aspect were recorded, due to the altered 
position and function of the foot, the data could not be generalised to participants who 
had not undergone this surgical intervention (Greenhalgh et al., 2012). 
 
Figure 3.5 Average plantar (left) and dorsal loading (right) patterns 
 in a rotationplasty patient 
The photo of the rotated foot of the same patient indicating a callosity on the medial dorsum 
of the foot over the tarsometatarsal joint that corresponds to the pressure peak on the dorsal 
loading pattern (Hillmann et al., 2000) 
Hagen et al. (2008, 2010) used Pedar dorsal insoles to investigate the effects of different 
shoe-lacing patterns on dorsal pressure distribution and the perception of comfort and 
stability during running. The insoles were inserted into a specifically sewn pocket 
attached to the inside of the shoe’s tongue. Planter loading was recorded using 
piezoelectric force platforms (Kistler 9281 B). Different shoe lacing patterns may affect 
the dorsal pressure; however, the loosest lacing may not be the most comfortable and a 
certain amount of lacing tightness is necessary to feel comfortable in running shoes 
(Hagen et al., 2008). The study concluded that knowledge of the location of the peak 
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dorsal pressures would be useful for new tongue constructions and lacing systems to 
improve comfort in running shoes (Hagen et al., 2008, Hagen et al., 2010). 
Mei et al., 2014 also used the Novel® in-shoe measurement system to study the difference 
of plantar pressure and upper pressure among three types of sports shoes. A Pedar plantar 
pressure measurement insole and four pressure sensor chips were utilised to obtain plantar 
and dorsal pressure. Novel Pedar pressure sensor chips were positioned on the dorsal side 
of the foot at the medial first metatarsophalangeal joint, lateral fifth metatarsophalangeal, 
the contact position between just under the medial condyle and medial-upper and the 
contact position between just under the lateral condyle and lateral-upper (Figure 3.6) (Mei 
et al., 2014). 
 
Figure 3.6 Position of Novel insole (black) and sensor chips (blue) 
(Mei et al., 2014) 
Although the plantar pressure distribution among the three pairs of shoes compared in the 
study was not significantly different, a great difference of upper pressure existed within 
different sports shoes (Mei et al., 2014). 
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3.1.2.1 Pedar In-Shoe Pressure Measurement System 
The Novel® Pedar system is considered one of the most popular and reliable in-shoe 
pressure measurement devices that can monitor local loads between the foot and the shoe 
(Murphy et al., 2005, Hurkmans et al., 2006, Putti et al., 2007, Gurney et al., 2008, 
Ramanathan et al., 2010). It has been shown to have lower variance across sensors when 
compared to F Scan (Quesada et al., 1997) and the best repeatability for plantar pressure 
collection during dynamic activities (Martinez Santos, 2016). 
Thus, for the current research project, the Pedar dorsal pads and plantar insoles 
were chosen to be used for pressure data collection within the tested footwear. 
The Pedar insoles have a matrix of sensors arranged in rows and columns to cover the 
entire area of the foot studied during walking. The highly conforming, elastic sensor 
insoles are made of capacitive sensors. These sensors measure the change in capacity 
related to a change in distance between two conducting wires which varies with different 
loading. These insoles are connected by cables to a body-mounted transmitter box which 
transfers the final pressure data to the computer workstation via a wireless connection 
using a Bluetooth® telemetry. Data can then be observed in real-time on the computer 
screen. The Pedar-x® system has the capacity to record in-shoe pressure at a sampling 
frequency of up to 100Hz (Novel Gmbh). 
With the aid of the Novel TruBlu® calibration device (Figure 3.7), all sensors of the Pedar 
insoles are individually calibrated using known air pressures. The computer-assisted 
procedure uses a bladder and air cylinder to load the insole to a chosen pressure evenly 
over the insole surface. Calibration guarantees accurate and reproducible data (Novel 
Gmbh).  
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Figure 3.7 Novel TruBlu® calibration device 
Pedar dorsal pads (Figure 3.8) are available in two sizes: VD (equal to 38/39 European 
shoe size) and XD (equal to 42/43 European shoe size). Pedar insoles have sensor 
thickness of 1.9 mm and house 85–99 capacitive sensors. Individual sensors, measure an 
area that approximately equates to 1cm2 per sensor, and can be calibrated to a pressure 
range of 15 - 600 KPa (Novel Gmbh). 
 
Figure 3.8 Pedar dorsal pads 
Come in 2 sizes VD (left); equal to 38/39 European Shoe Sizes 
 and XD (Right); equal to 42/43 European Shoe Sizes 
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3.2 PILOT STUDY 
3.2.1 Introduction and Background 
Many factors have been investigated in the literature as having a role in diabetic foot ulcer 
formation. The current research experiment aims at simultaneous studying two of the 
major ulcer contributors namely, loading pressure and microvascular abnormalities, 
investigating the impact of pressure application on peripheral blood flow in diabetic foot. 
In particular, the changes in the endothelial response under applied pressure on both 
dorsal and plantar surfaces of the foot in patients with Type 2 Diabetes and a matched 
control group of non-diabetic individuals. The study planned to utilise a custom-made 
pressure delivery equipment, which was able to apply the premeasured dorsal and plantar 
in-shoe pressures on the study groups’ feet while recording blood flow measurement. This 
device was designed to deliver a known pressure while housing a Laser Doppler 
Flowmetery probe that acts as the endpoint of pressure delivery and assesses the skin 
blood flow changes in response to the iontophoresis of an endothelium-dependent 
vasodilator, acetylcholine, and endothelium-independent vasodilator, sodium 
nitroprusside. The pressure delivery equipment was developed and validated to 
investigate the impact of replicated barefoot walking plantar pressure on endothelial 
function of the superficial blood vessels supplying the plantar aspect of the forefoot in 
subjects with diabetes mellitus (Flynn, 2014). 
The premeasured pressure was delivered via a spring housed within the device’s metal 
tube allowing for an unimpeded movement. A measuring gauge was attached to indicate 
the pressure delivered and this pressure could be set and adjusted via a control dial (Figure 
3.9). The spring selected for pressure delivery had a known rate of 4 N/mm. Full 
specifications are shown in Table 3.1 (Lee Springs). 
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Figure 3.9 The pressure delivery system diagram 
The Laser Doppler Flowmetery probe attached to the pressure delivery equipment (left) 
(Flynn, 2014) 
 
Table 3.1 Compression Spring (used on the plantar surface) Specifications  
(Lee Springs) 
Part Number LC 029BB 11M 
Outside Diameter 4.775 mm 
Hole Diameter 5.156 mm 
Wire Diameter 0.736 mm 
Load At Solid Length 47.282 N 
Free Length 22.224 mm 
Rate 4.00 N/mm 
Solid Length 10.261 mm 
Rod Diameter 3.098 mm 
Number of Coils 11.5  
Total Coils 13.5  
Finish ZINC PLATE AND BAKE PER ASTM B633  
 
The Laser Doppler Flowmetery probe that was used as the surface contact for pressure 
delivery, had a radius of 3 mm, thus a surface area of 28.274 mm2. Utilising the principle 
of pressure equals force/area, the pressure delivery system was capable of delivering a 
pressure ranging between 141KPa to 1343KPa (Table 3.2).  
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Table 3.2 Pressure values correspond to the displayed pressure delivery device dial readings  
(When Spring Rate = 4N/mm, LDF Probe surface area =28.274 mm2) 
Pressure Device  
Dial reading 
Force Rate 
N/mm 
Pressure N/mm2 Pressure K Pa 
0.5 2 0.07 70.74 
1 4 0.14 141.47 
1.5 6 0.21 212.21 
2 8 0.28 282.95 
2.5 10 0.35 353.68 
3 12 0.42 424.42 
3.5 14 0.50 495.15 
4 16 0.57 565.89 
4.5 18 0.64 636.63 
5 20 0.71 707.36 
5.5 22 0.78 778.10 
6 24 0.85 848.84 
6.5 26 0.92 919.57 
7 28 0.99 990.31 
7.5 30 1.06 1061.05 
8 32 1.13 1131.78 
8.5 34 1.20 1202.52 
9 36 1.27 1273.25 
9.5 38 1.34 1343.99 
These ranges fit well with the pressure to be collected on the plantar aspect of the foot. 
However dorsal pressure noted in the literature (Jordan and Bartlett, 1995a, Mei et al., 
2014) and those detected in our laboratory while testing the Pedar dorsal pads had much 
lower values, of approximately 100KPa (Figure 3.10), and therefore could not be 
delivered by the same spring used for plantar surface testing. 
 
Figure 3.10 Provisional peak pressure data  
shows the difference in values between dorsal and plantar peak pressures 
0
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This imposed the need to conduct a pilot study to acquire an average range for the peak 
dorsal pressure values, in order to determine the correct spring to be used within the 
pressure delivery equipment to investigate the pressure effect upon the dorsal surface of 
the foot. 
Another factor that had been highlighted while formulating the measurement procedures, 
was the anticipated effect of the difference in shoe type, shape and manufacturing material 
on the dorsal pressure measurement. Significant differences have already been recorded 
in peak dorsal pressure between different types of sports shoes (Mei et al., 2014). 
Similarly, different pressure distribution patterns were displayed when the Pedar dorsal 
pad was tested in our laboratory using different types of shoes that were all belonging to 
the same subject (Figure 3.11). 
 
Figure 3.11 Testing Pedar Dorsal pad in different types of shoes of the same subject 
These findings necessitated the search for a standardised shoe to be used for this project. 
A standard pair of shoes with a clear upper surface (Figure 3.12), used in the Institute of 
Motion Analysis and Research (IMAR) laboratory to teach referred subjects how to 
choose their best shoe fit, was tested first. It was hoped that the clear upper surface would 
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guarantee the standard placement of the dorsal pad. However, the very stiff shoe material 
made it challenging to use, especially with the need for repeated walking trials. The fear 
of inducing foot injury to the known high-risk feet of diabetic participants excluded these 
shoes from being used in the current project. 
 
Figure 3.12 Standard shoes with a clear upper surface 
The best choice found, was one of the orthopaedic footwears that is frequently prescribed 
for patients with high-risk feet at Tayside Orthopaedic and Rehabilitation Technology 
(TORT) Centre’s orthotic clinic. The Chaneco Diabetic shoes, Calais (for men) and 
Venice (for ladies), are frequently provided for diabetic patients referred to the orthotic 
clinic. These shoes are available off-the-shelf or with some orthotic modification as 
custom moulded insoles. They can be supplied either with lace or straps (Figure 3.13), 
however, according to the orthotist recommendation, patients have a preference for laces, 
and therefore, the lace type shoes were used for the current research. 
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Figure 3.13 Orthopaedic shoes supplied with laces (right) and straps (left) 
After finding the most suitable shoes, the study began to explore the best method of 
holding the dorsal pad in place when recording the in-shoe pressure measurement during 
walking. Methods used in the literature include placing the measuring sensors inside 
participants’ socks (Greenhalgh et al., 2012) or into a sewn pocket attached to the inside 
of the shoe’s tongue (Hagen et al., 2010). Chaneco has provided one shoe sample with a 
strap attached to the shoe tongue to hold the Pedar dorsal pad while conducting the 
measurement procedure (Figure 3.14). 
 
Figure 3.14 Sample shoe with a strap attached to the shoe tongue 
Dorsal pressure measurement with the dorsal pad inserted inside socks compared with 
placing it into the strap stitched to the bottom of the shoe tongue showed the socks to be 
more reliable. Socks allowed good adjustment of the measuring pad on the foot asperities. 
Thus, dorsal pressure recorded in socks was more representative of the real experienced 
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pressure than that with the strap holding the measuring pad at one end which may have 
modified the pressure distribution pattern as seen in Figure 3.15. Also, the tested subject 
felt more comfortable with the pad inserted in socks procedure. Consequently, the study 
proceeded using socks. 
 
Figure 3.15 Dorsal pressure distribution while inserting Pedar Dorsal pad 
in socks (right) vs shoe tongue strap (left) 
All these factors uncovered while designing the study protocol necessitated the need for 
conducting a pilot study to achieve the following objectives: 
• Quantify a range for peak pressure values on the dorsal surface of the foot in a 
group of non-diabetic volunteers using the Pedar dorsal pad. This will help to 
determine the rate for the spring to be used in the pressure delivery equipment to 
investigate the pressure effect on the dorsal surface of the foot 
• Test the equipment and conduct a provisional comparison between dorsal and 
plantar pressure values recorded in participants’ own comfortable shoes and then 
when wearing size-matched tested orthopaedic shoes 
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• Investigate the time of occurrence of the dorsal peak pressure during the gait 
cycle. It was hypothesised that simultaneous in-shoe plantar pressure 
measurement can help in timing of dorsal peak pressure by correlating it with the 
well-known time of plantar peak pressure in the gait cycle 
• Test the iontophoresis protocol to be used in endothelial function assessment on 
the dorsal surface of the foot and assesses its repeatability to be used on both 
dorsal and plantar surfaces of the foot 
3.2.2 Participants 
Initially, ethical approval was sought and granted from the University of Dundee 
Research Ethics Committee (Appendix 1). A volunteer recruitment poster for the study 
was advertised in Ninewells Hospital, University of Dundee notice boards and circulated 
via the University e-Newsletter (Appendix 2). Non-diabetic adult volunteers (males and 
females), age range 18 to 75 with no known underlying lower limb vascular or 
neurological conditions were invited to participate in the study. Exclusion criteria 
included any foot deformity, amputation or underlying pathology of the spine/lower limbs 
which results in an inability to walk unaided. All subjects were provided with a written 
information sheet (Appendix 3) and informed consent (Appendix 4) to be signed prior to 
any participation. 
Thirteen non-diabetic adult volunteers were recruited from the university staff and student 
populations (Table 3.3). The study group consisted of 7 females (53.8%) and 6 males 
(46.2%). Age at the time of testing ranged from 22 to 62 years old with mean age ± SD 
of 32 ± 10.8 years. Body mass index (BMI) ranged from 20.7 to 46.9 kg/m2 with mean 
BMI ± SD of 27.8 ± 7.9 kg/m2. UK shoe sizes of participants ranged from 4 to 10 with 
the mean ± SD being 7 ± 2.  
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Table 3.3 Demographic data distribution of the pilot study 
Demographic data (n=13) Range (Mean ± SD) 
Sex 
Female 7 (53.8%) 
Male 6 (46.2%) 
Age (years) 22-62[32.31±10.85] 
Height (m) 1.51-1.82[1.66±0.09] 
Weight (kg) 49-120[76.08±21.04] 
BMI [Weight/(Height)^2] 20.66-46.88[27.84±7.92] 
UK Shoe size 4-10[6.69±2.36] 
 
3.2.3 Pressure Data Collection 
Pedar dorsal pads and plantar insoles were calibrated using the Novel TruBlu® calibration 
device (Figure 3.7). This calibration device applies a homogeneous air pressure on all 
sensors through incremental steps of pressure. An individual calibration curve for each 
sensor is then calculated and used during data acquisition. 
The dorsal pads were calibrated at lower values (up to 200KPa) to suit the anticipated low 
dorsal foot pressure while the plantar insoles were calibrated to record pressures up to 
600KPa, which is the recognised range of plantar pressure. For a simultaneous recording 
of dorsal and plantar pressure of the foot, each dorsal pad was coupled with one of the 
plantar insoles. Due to the result difference in calibration between the two measuring 
insoles, coupling was not possible with the Pedar data acquisition software. Therefore, 
Novel Pliance® mobile measurements box and data acquisition software were used as 
these were able to pair the dorsal pad with the plantar insole while having different 
calibration ranges. Yet, the dorsal pressure values were represented to correspond to the 
higher calibration range of the plantar insoles (as if the dorsal pad were calibrated at 
600KPa, not 200KPa). The correct dorsal pressure values were later obtained by dividing 
the extracted peak pressure values by 3. 
A Pedar dorsal pad, labelled left, was inserted into a standardised sock to be secured onto 
the dorsal surface of the participant’s right foot and connected to the left cable of the 
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Pliance® mobile measurements box. A matched shoe size, right-sided Pedar plantar insole 
was placed inside the right side of the tested shoes and connected to the right cable of the 
Pliance® mobile measurements box (Figure 3.16). Any excess length of cable was 
fastened around the participant’s lower limb using Velcro tabs to avoid cables getting in 
the way while walking. The transmitter (fastened around the waist) wirelessly transferred 
recorded data to a PC via a Bluetooth dongle. 
 
Figure 3.16 In-shoe measurement system connection 
(right) Placement into participants’ shoes (left) 
Pressure differences were recorded on the dorsal surface in the standing position, so zero 
check is recommended before testing (Jordan and Bartlett, 1995a). Therefore, after 
placement, subjects were asked to raise their right foot into a horizontal non-weight 
bearing position on a chair with a loosened shoelace to offload both the dorsal pad and 
the plantar insole before any recording was made (Figure 3.17). Subjects were then asked 
to tie their shoelace the way they usually do to feel comfortable (either the shoes they 
were wearing, if applicable or the orthopaedic shoes provided). 
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Figure 3.17 Offloading the dorsal pad and plantar insole before pressure recording 
Participants, wearing each type of footwear, were asked to do six walking trials at their 
own self-selected speed along a 6-meter-long walkway. Simultaneous in-shoe dorsal and 
plantar pressures of the right foot were recorded (Figure 3.18) with the participants 
wearing first their own comfortable shoes followed by wearing the size-matched 
orthopaedic shoes provided. 
 
Figure 3.18 In-shoe pressure recorded on dorsal and plantar surfaces 
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The orthopaedic shoes were provided with two extra insoles to offer more customisation 
of the shoe’s depth. One of these extra insoles was removed for comparison with the full-
insole orthopaedic shoes and participants’ own shoes. 
Data were trimmed to have at least three good steps in each trial for processing. Foot 
Masks were then defined; one for the whole plantar surface and another for the dorsal 
surface.  Peak pressure, defined as the highest pressure in any sensor across a given mask, 
were exported into Microsoft Excel spreadsheet to compare the three tested shoe 
conditions on both plantar and dorsal surfaces of participants’ feet. The data were then 
imported to a Statistical Package of Social Science (SPSS) software for statistical 
analysis. 
3.2.4 Pilot Study Results 
Statistical comparison was conducted using the General Linear Model to estimate the 
Peak Pressure Means across successful steps in all trials for each subject in each tested 
condition. Analysis of variances and Post Hoc test: Least Significant Difference (LSD) 
were used to determine the significance of differences between the three tested conditions 
within for both dorsal and plantar surfaces. 
Pairwise Comparisons of Estimated Marginal Means showed a significant difference in 
in-shoe peak pressure between participants’ shoes and the orthopaedic shoes on the dorsal 
surface (p<0.001). However, no significant difference was detected on the plantar surface 
(p>0.05). Furthermore, removing one of the extra insoles supplied with the orthopaedic 
shoes revealed a significant increase in plantar pressure (p<0.05) when compared to full 
insole orthopaedic shoes. No significant differences were noted on the dorsal surface 
within the orthopaedic shoes on removing the extra insole. 
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Table 3.4 The three tested shoe conditions peak plantar pressure and peak dorsal pressure (KPa). 
Own shoes, Orthopaedic shoes and Orthopaedic shoes-1 insole 
Whole foot In-shoe pressure Own shoes Ortho Shoes Ortho Shoes-1 
Peak Plantar Pressure 
(KPa) 
Mean ± SD 269.20±49.38 267.37±46.50 283.27±61.40 
Range 170-385 162.5-397.5 165-452.5 
Peak Dorsal Pressure 
(KPa) 
Mean ± SD 75.18±28.40 55.66±21.97 54.38±20.21 
Range 33.33-147.5 27.5-123.33 27.5-100 
 
 
Figure 3.19 Plantar Peak Pressure in own shoes, orthopaedic shoes  
and orthopaedic shoes-1 insole conditions 
 
Figure 3.20 Dorsal Peak Pressure in own shoes, orthopaedic shoes  
and orthopaedic shoes-1 insole conditions 
These results show how the design of the orthopaedic shoes with a deeper box, effectively 
offloaded the dorsal surface of the foot. The noted significant reduction in pressure will 
ultimately lower the risk of skin trauma and the development of pressure ulcers on the 
dorsum of the foot (Pinzur et al., 2005). However, the insignificant difference between 
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participants’ own shoes and the orthopaedic shoes recorded on the plantar surface and the 
significant increase in plantar pressure when removing one of the insoles in the 
orthopaedic shoes, confirms the difficulty of predicting the effect of therapeutic footwear 
as found by other studies in the literature (Ashry et al., 1997, Praet and Louwerens, 2003). 
Therefore, in-shoe plantar pressure measurement remains an essential tool for the 
evaluation of at-risk feet prior to therapeutic footwear prescription and/or any insole 
adjustment implementation (Waaijman et al., 2012, Bus et al., 2016a, Bus et al., 2016b). 
The results of this pilot study show the reliability of this in-shoe pressure measurement 
system in detecting dorsal pressure simultaneously with the plantar pressure and was 
therefore used in the final experimentation setting. Furthermore, dorsal pressure variation 
across different testing conditions demonstrates the capability of the dorsal pressure 
assessment to be used as a guidance tool to effectively improve the design and evaluation 
of footwear, especially in high-risk feet as in diabetes. This will eventually provide a 
better offloading approach that may reduce the risk of pressure-related diabetic foot 
ulcers. 
Although this pilot study simultaneously recorded in-shoe plantar and dorsal pressures, it 
was not possible, at this point in the research, to produce the time extraction software. 
There was an issue with defining the events of the gait cycle and detecting when exactly 
dorsal peak pressure occurs. The pattern of dorsal peak pressure varied extensively across 
participants and multiple peaks in a sawtooth pattern were sometimes observed. Later, in-
house software was developed, which was able to define the gait cycle by the first plantar 
peak pressure that was believed to correspond to heel strike, as the starting event of each 
gait cycle. The plantar peak pressure data were correlated with the dorsal peak pressure 
and dorsal maximum force as it showed more homogenous and clear peaks on the 
produced graphs. This software was used for processing the final experiment data. 
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3.2.5 Setting the Pressure Delivery System  
As discussed earlier, the pressure delivery equipment developed and validated by Flynn 
(2014) was used (Figure 3.9) in the final procedure to study the effect of loading pressure 
on the endothelial response in the feet of patients with Type 2 Diabetes and a matched 
control group of non-diabetic individuals. One of the main objectives of the pilot study 
was to obtain a range of values for dorsal peak pressure to guide in identifying the 
appropriate spring for the pressure delivery equipment, to be used in delivering the 
premeasured pressure on the dorsum of the foot while recording the changes in blood 
flow via the enclosed LDF probe. The pilot study data indicated dorsal peak pressure 
across all subjects within different testing conditions, to range between 27.5KPa and 
147.5KPa (Table 3.4). 
The outcome of the investigation of available springs showed that it would be more 
practical to use two springs. A spring with a rate of 0.39 N/mm (full specifications are 
shown in Table 3.5) to be used with lower pressure values and the other with a rate of 
0.50 N/mm (full specifications are shown in Table 3.6) for higher pressure values. This 
made it easier to tune the control dial on the pressure delivery equipment across different 
anticipated pressures recorded on the dorsum of participants’ feet. 
Table 3.5 0.39 N/mm Compression Spring Specifications 
 (Lee Springs) 
Part Number LC 016AB 12S 
Outside Diameter 3.759 mm 
Hole Diameter 3.962 mm 
Wire Diameter 0.406 mm 
Load At Solid Length 7.036 N 
Free Length 25.400 mm 
Rate 0.39 N/mm 
Solid Length 7.543 mm 
Rod Diameter 2.743 mm 
Number of Coils 15.8  
Total Coils 17.8  
Finish PASSIVATE PER ASTM A967  
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Table 3.6 0.5 N/mm Compression Spring Specifications 
(Lee Springs) 
Part Number LC 016AB 11M 
Outside Diameter 3.759 mm 
Hole Diameter 3.962 mm 
Wire Diameter 0.406 mm 
Load At Solid Length 8.451 N 
Free Length 23.825 mm 
Rate 0.50 N/mm 
Solid Length 7.112 mm 
Rod Diameter 2.743 mm 
Number of Coils 14.7  
Total Coils 16.7  
Finish ZINC PLATE AND BAKE PER ASTM B633  
 
These springs are capable of delivering pressure values demonstrated in, respectively 
Table 3.7 and Table 3.8. It was noted that the 0.39 N/mm spring was the one mostly used 
except in two cases where the 0.50 N/mm spring was used instead because the dorsal 
pressure recorded was very high and difficult to accommodate within the equipment 
control dial. 
Table 3.7 Pressure values correspond to the displayed pressure delivery device dial readings 
(When Spring Rate = 0.39 N/mm, LDF Probe surface area = 28.274 mm2) 
Pressure Device  
Dial reading 
Force Pressure N/mm2 Pressure K Pa 
0.5 0.195 0.007 6.90 
1 0.39 0.014 13.79 
1.5 0.585 0.021 20.69 
2 0.78 0.028 27.59 
2.5 0.975 0.034 34.48 
3 1.17 0.041 41.38 
3.5 1.365 0.048 48.28 
4 1.56 0.055 55.17 
4.5 1.755 0.062 62.07 
5 1.95 0.069 68.97 
5.5 2.145 0.076 75.86 
6 2.34 0.083 82.76 
6.5 2.535 0.090 89.66 
7 2.73 0.097 96.56 
7.5 2.925 0.103 103.45 
8 3.12 0.110 110.35 
8.5 3.315 0.117 117.25 
9 3.51 0.124 124.14 
9.5 3.705 0.131 131.04 
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Table 3.8 Pressure values correspond to the displayed pressure delivery device dial readings  
(When Spring Rate = 0.5 N/mm, LDF Probe surface area = 28.274 mm2) 
Pressure Device  
Dial reading 
Force Pressure N/mm2 Pressure K Pa 
0.5 0.25 0.009 8.84 
1 0.5 0.018 17.68 
1.5 0.75 0.027 26.53 
2 1 0.035 35.37 
2.5 1.25 0.044 44.21 
3 1.5 0.053 53.05 
3.5 1.75 0.062 61.89 
4 2 0.071 70.74 
4.5 2.25 0.080 79.58 
5 2.5 0.088 88.42 
5.5 2.75 0.097 97.26 
6 3 0.106 106.10 
6.5 3.25 0.115 114.95 
7 3.5 0.124 123.79 
7.5 3.75 0.133 132.63 
8 4 0.141 141.47 
8.5 4.25 0.150 150.31 
9 4.5 0.159 159.16 
9.5 4.75 0.168 168.00 
To test the pressure delivery equipment, a set of known forces was applied by placing 
weights of known values, on the top of the device while in an upright position and 
checking the dial readings. Accurate readings were registered, and a linear relationship 
was observed between forces applied and readings on the device scale, indicating good 
repeatability of the equipment. 
In the final experiment, a rigid post-surgical boot was used to hold the limb securely and 
also clamp the pressure delivery equipment housing the LDF probe while recording the 
blood flow changes and delivering pressure (Figure 3.21). This setup was established to 
prevent any movement during the procedure, that may produce artefacts in the LDF 
reading and/or alter the pressure applied as adjusted on the device dial. The customised 
boot had a fleece lining for subject comfort and a metal plate attached to the foot 
backplate, which is adjustable in two directions, height and depth (Figure 3.22). This 
allows the position of the pressure delivery device to be altered to ensure that the LDF 
probe was held in the correct position against the skin surface. This system design worked 
well when applying pressure while recording blood flow changes on the plantar surface 
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of the foot (Flynn, 2014). However, to test the dorsum of the foot an extra part was 
required to hold the pressure delivery equipment opposite the other side of the foot. 
 
Figure 3.21 The pressures delivery system 
measuring blood flow using LDF while delivering pressure  
on the plantar surface of the foot (Flynn, 2014) 
 
Figure 3.22 The post-surgical boot with the adjustable baseplate 
 (Flynn, 2014) 
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Testing the equipment on the dorsum of the foot began with adding an extra bar to be 
attached to the metal plate attached to the boot’s foot backplate (Figure 3.23). However, 
the topography on the dorsum of the foot was more dome-shaped than the relatively flat 
surface found on the plantar of the foot. The rigid structure of this setup failed to attain a 
flush position of the LDF probe against the skin. Applying pressure by the pointed edges 
of the probe rather than the whole surface area can change the pressure values intended 
to be delivered. This may cause subjects to experience more pain or discomfort which 
will lead to mental stimulation and affect the blood flow in the area under pressure. 
Moreover, with the anticipated lengthy procedure, there will be a potential increase in the 
risk of skin breakdown due to the pressure application on such a small surface area of the 
probe edges. 
 
Figure 3.23 Original setting for investigating the plantar surface of the foot 
 (left), when adding a bar for testing the dorsum of the foot (right) 
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On searching for a more flexible means for holding the equipment on the dorsum of the 
foot, it was decided to use the Snake Shape Arm with the Magnetic Base Holder shown 
in Figure 3.24. The connecting arm bends freely like a snake, providing infinite flexibility. 
It can also be locked rigidly in almost any position by a controlling lever situated at its 
base. It is fitted to an ON/OFF switchable magnetic base with a 40kg (400N) pull that 
holds it solidly on ferrous metal surfaces, either vertically or upside down (RS PRO). This 
provided a flexible clamp that enabled easy adjustment of the LDF probe orientation on 
the dorsum of the foot with secured fixation. 
 
Figure 3.24 the Snake Shape Arm with the Magnetic Base Holder 
The magnetic base was mounted and allowed to move along a metal bar fixed to the bed 
on which participants lay during data collection. All parts were covered by foam sheets 
to prevent any injury to subjects while positioning their feet (Figure 3.25). To ensure the 
subject’s foot would not move downwards via the pressure applied on the dorsum of the 
foot, the adapted boot was firmly fixed to the end of the bed. This helped to maintain the 
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correct and stable positioning of the equipment as well as the subject’s foot during the 
data gathering procedure. 
 
Figure 3.25 Setting equipment for the data collection on the dorsum of the foot 
3.3 IONTOPHORESIS PROCEDURE 
3.3.1 Equipment 
Iontophoresis combined with the single point LDF was the technique chosen to assess 
endothelial function on both foot surfaces in the study groups. The ability to monitor 
changes in the blood flow whilst in contact with the skin, allows the LDF probe to act as 
a component of the pressure delivery system to transfer the premeasured pressure as well 
as assess blood perfusion changes in response to iontophoresis. This setup was tested, and 
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the probe was found durable enough to deliver the pressures measured on the plantar 
surface of the foot (Flynn, 2014). 
The instrumentation used in the current study was moorVMS-LDF2 Dual channel Laser 
Doppler Perfusion and Temperature Monitor combined with battery-powered MIC2™ 
Iontophoresis Controller. Data were recorded and processed using moorVMS-PC 
recording and analysis software (Moor® Instruments Ltd.). The LDF probe transmits a 
low power laser light (Maximum output power 2.5mW) of the temperature-stabilised 
output laser diode at 785nm. For safety, both participant and operator wore protective 
laser goggles when the laser was on. 
The VP2T, straight LDF probe with fibre separation of 0.5mm, body 30mm in length and 
a diameter of 6mm was used. The optical properties of probes may change over time thus, 
the probe was calibrated prior to use and on a regular basis (every 6 months) or if a 
warning calibration message was displayed. The calibration began by checking and 
cleaning the optical surfaces of the probe tip and probe connector with a soft non-abrasive 
cloth provided with the instrument. The calibration solution (the motility flux standard) 
uses a thermal (Brownian) motion of polystyrene microspheres in water to produce the 
reference signals required (Flynn, 2014). As it is temperature dependent, the flux standard 
solution needs to be at a stable temperature. This was achieved by leaving the vial of the 
motility standard liquid in the temperature-controlled room (between 20°C and 24°C) 
where the calibration was conducted, for 30 minutes prior to use in order to reach room 
temperature. The container was next shaken gently for 10 seconds and left to rest for 2 
minutes and placed in the middle of the base of the assembled calibration stand (Figure 
3.26). The probe was connected and calibrated with the channel of the system to be used. 
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Figure 3.26 Calibration of the LDF probe 
Assembled calibration stand holding the standard solution and clamping the LDF probe 
The probe was secured by the clamp on the calibration stand, with the fibre optic lead 
unsupported, and the probe tip pointing downwards in the centre of the calibration 
solution without any contact with the container. Following the running of a successful 
calibration, the software displays a ‘Calibration successful’ message. 
MIC-ION1R-P1, a direct ion chamber, was utilised for iontophoresis (Figure 3.27). The 
chamber was constructed from Perspex with an internal platinum wire electrode running 
around its inner surface. It has a central aperture or drug chamber of 9.5 mm, and an 
overall diameter of 36 mm. The drug chamber can accommodate the LDF probe and 
allows some space for the drug solution around the probe during the pressure delivery 
procedure. The chamber has two small upper holes connected by a drill which allows the 
flow of solutions and top up when required. This ion chamber offered the best solution 
retention and contact in the vertical position that was anticipated for the iontophoresis 
procedure on both foot surfaces. It was also strong enough to endure the pressure applied 
through the delivery system (Flynn, 2014). 
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Figure 3.27 MIC-ION1R-P1 chamber (Moor® Instruments Ltd.) 
The vasoactive agents chosen for iontophoresis were acetylcholine (ACh) as an 
endothelium-dependent vasodilator and sodium nitroprusside (SNP) as an endothelium-
independent vasodilator for comparison. The vehicle for dissolving both vasoactive 
agents was deionised water. Because iontophoresis was conducted with the chamber fixed 
in a vertical position and the use of the pressure delivery equipment prevented inserting 
a cover to stop leakage and spillage, an inert thickening agent was added to help to 
maintain sufficient vasodilator solution in contact with the skin for iontophoresis. The 
solution, comprising 2% Methylcellulose and 2% of the vasoactive agent in deionised 
water, was reasonably viscous and did not impact the drug delivery (Flynn, 2014). 
Methylcellulose is a water-soluble derivative of pine pulp. It is colourless, odourless, non-
ionic and stable at room temperature. It is used as a thickener, binder, emulsifier and/or 
stabiliser in a variety of pharmaceutical products (Sigma Chemicals Ltd). Some authors 
have noted that using 2% Methylcellulose as a vehicle may eliminate the current-induced 
vasodilation known as the galvanic response (Noon et al., 1998) while others could not 
confirm this finding (Ferrell et al., 2002, Turner et al., 2008). Preparing Methylcellulose 
into a viscous solution needs some care as it tends to form a lumpy solution if improperly 
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dispersed when dissolved in water. The most convenient method recommended by the 
manufacture is to heat 1/3 of the required volume of water to at least 80°C then add the 
methylcellulose powder to the hot water with agitation until the particles are thoroughly 
wetted and evenly dispersed. The remainder of the water is then added as cold water and 
the solution is cooled to 0-5 °C for 20-40 min. Once it reaches the temperature at which 
it becomes water-soluble, the powder begins to hydrate and the viscosity increases. 
Agitation was continued for at least 30 minutes after the proper temperature was reached. 
However, the end solution had lots of micro-bubbles that needed to be cleared before it 
can be used in iontophoresis. The solution was placed overnight in a Vacuum chamber 
(Figure 3.28) to get rid of these bubbles prior to any use. 
 
Figure 3.28 Vacuum Chamber & Pump Kit (BACOENG) 
3.3.2 Iontophoresis Protocol 
3.3.2.1 Introduction 
The last objective of the pilot work was to choose and test the iontophoresis protocol to 
be used in the final experiment to assess endothelial function on the dorsal as well as the 
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plantar surfaces of the foot. The plan was to use the same protocol tested and used by 
Flynn, 2014, however, on reproduction of the protocol on the dorsal surface of the foot, 
the sought response was not attained. Different protocols routinely used in our laboratory 
were explored with both ACh and SNP. Testing was carried out on 3 male and 3 female 
student volunteers in a temperature-controlled room of 24° ±1°C under the same 
conditions as would be followed in the final study; i.e. avoiding food ingestion and 
caffeine-based drinks for 2 hours prior to measurement and at least a10 minutes period of 
acclimatisation to the testing environment (as recommended in the laboratory Working 
Practice Document For The Assessment Of Vascular Function Using Laser Doppler 
Imaging And Iontophoresis). The protocol that ensured a sufficient, sustained vascular 
response to a plateau that did not return to baseline by the end of measurement was chosen 
and tested for repeatability. 
3.3.2.2 Testing the Iontophoresis Protocol Repeatability 
Volunteers from the pressure pilot study were asked to participate in testing the 
repeatability of the iontophoresis protocol. Nine adults (6 males and 3 females) were 
recruited. They were non-diabetic, non-smoker, with no underlying lower limb vascular 
or neurological conditions, no history of cardiovascular disease and taking no medication. 
Testing was carried out on two separate sessions, at least two days apart. Each assessment 
was held in the same controlled environment following 10-20 minutes acclimatisation 
period, at the same time of day following at least two hours abstention from ingesting 
food and caffeine. 
The volunteers were initially acclimatised in the temperature-controlled room of 24° 
±1°C for a period of 10-20 minutes where details of the procedure were explained, and 
information sheets provided before consent forms were signed. Subjects were asked to 
adapt adopt a supine position with their feet at heart level and ensure no movement for 
83 
the duration of the measurement session. Due to the laboratory setting, the right foot was 
the selected side for testing. Prior to any application, the tested skin sites on the dorsum 
of participants’ right foot was prepared by stripping the epidermal surface with an 
adhesive tape then gently cleaning the area with an alcohol swab and deionized water. 
The site was left to dry before the iontophoresis drug chamber was attached using double-
sided adhesive tape. 
It was ensured that the polarity of the chamber electrode had the same charge as the 
vasoactive drug. A reference electrode with the reverse charge was attached to a 
conductive hydrogel pad to be stuck onto the anterior surface of the participants’ legs. 
The solution of 2% of the vasoactive drug and 2% Methylcellulose in deionised water 
was dispensed into the chamber using a sterile syringe, ensuring no air bubbles were 
trapped between the LDF probe and the skin. 
The tested protocol began by delivering a 0µA current for a baseline reference period of 
60 seconds (Label 1). This was followed by 14 spells of iontophoresis, 60 seconds each 
(Label 2-15), using a 100µA current. Finally, drug-free perfusion with 0µA current was 
recorded for 120 seconds (Label 16). Statistical data were extracted from the recording 
software into a Microsoft Excel sheet. 
There were some movement artefacts during the early trials, therefore, noise filtration 
was implemented and median perfusion values for each iontophoresis period were 
extracted. The Peak of Maximum Response for each measurement was calculated from 
the average of all maximum perfusion values of the 16 iontophoresis periods and was 
found to have a mean ±SD of 132.37 ±50.31 PU. Mean perfusion values in each period 
were examined to check for differences with median values which were primarily sought 
to avoid false extreme values due to artefacts. 
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Interclass Correlation Coefficient (ICC) with absolute agreement and average measure 
was utilised to assess the repeatability of data. Using median perfusion values (Table 3.9), 
the ICC was 0.945, 95% confidence interval (CI) between 0.840-0.996, ANOVA F 
=155.496, p <0.0001. This indicated good repeatability of the protocol. 
On retesting for protocol repeatability using the mean values of perfusion (Table 3.10), 
the same good repeatability was noted. The ICC was 0938, 95% C.I. (0.859-0.998), F 
value= 165.827, p <0.0001. That confirmed the repeatability of the protocol and the 
decision was taken to use this protocol in the final study on both dorsal and plantar 
surfaces of the foot. 
Table 3.9 Mean and Standard Deviation (SD) for perfusion Median values (PU) during each 
iontophoresis periods 
Iontophoresis periods Current Mean SD 
Label 1 0µA 16.24 17.60 
Label 2 100µA 22.06 22.92 
Label 3 100µA 42.97 37.87 
Label 4 100µA 64.63 39.25 
Label 5 100µA 80.22 36.23 
Label 6 100µA 90.66 41.16 
Label 7 100µA 94.70 43.79 
Label 8 100µA 97.41 43.56 
Label 9 100µA 97.64 39.50 
Label 10 100µA 99.99 38.79 
Label 11 100µA 97.29 39.53 
Label 12 100µA 99.66 38.75 
Label 13 100µA 100.02 39.38 
Label 14 100µA 100.39 40.08 
Label 15 100µA 102.42 41.73 
Peak of Max response  132.37 50.31 
ICC  0.945 (C.I. 0.840-0.996) 
ANOVA  F=155.496, P <0.001** 
Probability (P-value) *P <0.05 was considered significant. **P <0.001 was considered as highly significant. P 
>0.05 was considered insignificant. 
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Table 3.10 Mean and SD for Mean of perfusion values (PU) during each iontophoresis periods 
Iontophoresis periods Current Mean SD 
Label 1 0µA 16.72 17.99 
Label 2 100µA 23.26 23.20 
Label 3 100µA 44.77 38.26 
Label 4 100µA 66.02 39.49 
Label 5 100µA 81.89 36.44 
Label 6 100µA 92.22 41.01 
Label 7 100µA 96.07 43.61 
Label 8 100µA 98.86 43.37 
Label 9 100µA 99.41 39.95 
Label 10 100µA 101.43 39.14 
Label 11 100µA 99.22 39.10 
Label 12 100µA 101.49 39.09 
Label 13 100µA 101.78 39.69 
Label 14 100µA 102.16 40.47 
Label 15 100µA 104.09 42.21 
ICC 0.938 (C.I. 0.859-0.998) 
ANOVA F=165.827, P<0.001** 
Probability (P value) *P <0.05 was considered significant. **P <0.001 was considered as highly significant.  
P >0.05 was considered insignificant. 
3.4 APPLICATION OF THE STUDY PROTOCOL 
All procedures were conducted at the Institute of Motion Analysis and Research (IMAR), 
Tayside Orthopaedic and Rehabilitation Technology (TORT) Centre, University 
Department of Orthopaedic and Trauma Surgery, Ninewells Hospital and Medical 
School, University of Dundee. Ethical approval was sought and granted from London-
Hampstead Research Ethics Committee with Research sponsor from NHS Tayside-
University of Dundee (Appendix 5, 6). Conducting the pilot work and ending with a 17-
minute iontophoresis protocol to be repeated 6 times on each foot surface, revealed that, 
completing the procedure in one session would be too long for participants. Diabetic 
patients, in particular, might be distressed by the long fasting period associated with the 
study procedures. Thus, a substantial amendment was submitted to complete the study 
over two sessions, each of 3 hours duration, and further approval for this amendment was 
granted (Appendix 7, 8). 
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3.4.1 Participants 
The sample size was determined according to the following equations, where the power 
of analysis aimed at 80% or 0.8 (Armitage et al., 2002). 
Estimate sample size n 
𝑛 > 2 [
(𝑍2α+𝑍2𝛽)𝜎
𝛿
]
2
 (1) 
Where α represents the probability of occurrences of type I error which = 0.05, β 
represents the probability of occurrences of type II error which =0.2 and σ is the standard 
deviation (SD). 2α = 0.05, 1-β=0.8, δ=AveX1-AveX2, and Z2α and Z2β are fixed, e.g. in 
normal distribution equal to 1.96 and 0.842, respectively. Thus,  
𝑛 > 2 [
(2.802)𝜎
𝛿
]
2
 (2) 
As, p=0.05, when Null hypothesis (H0) is rejected, the Type 1 Error is 0.05 (α). If H0 is 
accepted, how much is the Type 2 Error (β)? Take β as 0.2, power = 1-β = 0.8 or 80%. 
The study used σ as 80 KPa, based on the maximum standard deviation of Peak Pressure 
from Putti et al. 2007 (Putti et al., 2007). We used δ = 100 KPa which in clinical practice 
could be considered as significant when examining normal foot in-shoe pressure. Based 
on the above, n = 10, thus, the minimum number of subjects to be recruited in order to 
reach 80% power of analysis should be 10 or more. We were looking to recruit 30 
participants in each group (study and control). However due to difficulties in recruitment 
of the study age group and the lengthy protocol we were content with the number recruited 
which were more than the prerequisite numbers. 
Recruitment posters (Appendix 9) were in Ninewells Hospital, University of Dundee 
notice boards and circulated via the University e-Newsletter, NHS Tayside Volunteering 
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Services emails. Caldicott Guardian Approval was applied for and granted (Appendix 10) 
to access the Rehabilitation Technology Information Service (ReTIS) database at TORT 
Centre, in order to recruit patients from those attending orthotic clinics at the centre. 
However, most patients had foot deformities or amputation which would impact upon 
foot pressure measurement and were thus, excluded from the study. 
Volunteers with diabetes suitable for inclusion in the study were identified from diabetic 
patients registered on the Scottish Diabetes Research Network (SDRN). This is an 
electronic database of diabetic patients who are willing to take part in diabetes research 
and have agreed to be contacted regarding research for which they may be a good match. 
This research register uses the latest clinical data on each patient’s records to identify 
suitable patients for studies, thus increasing the recruitment rate and decreasing the screen 
failure rate. Database Search criteria were: Resident in Tayside, Type 2 Diabetes, No 
active ulceration, No foot amputation, Palpable peripheral pulsation, No vascular 
intervention (CABG or Carotid Endarterectomy event), Present protective sensations. A 
list was issued, and invitation letters were posted with return slips included (Appendix 
11, 12). Subjects who returned their slips with the agreement to participate were contacted 
via telephone and further details provided. If individuals showed interest, the information 
sheet and an invitation letter to attend on their available dates were issued. 
The issued patients' list included 969 subjects, 283 who had chosen letter as the mean of 
contact were approached and invitation letters were posted. Forty-five subjects returned 
slips with No to participate, 90 returned with willing to take part or interested in knowing 
further details about the study. Thirty subjects living in Dundee were randomly selected 
to be phoned in-order to explore their potential involvement. Six subjects found the 
procedure too lengthy, two were taking part in other research and two had foot deformity 
which excluded them from participation. Twenty subjects accepted to take part on an 
88 
agreed date, two did not attend, three had their pressure data collected but were unable to 
complete the iontophoresis procedure and fifteen had the entire protocol completed. 
The noted age for participants with diabetes was above 50 years old, which is the common 
presentation age for patients with Type 2 Diabetes. Consequently, the study aimed at 
recruiting non-diabetic volunteers from the matching age group, which was difficult due 
to the prerequisite commitment to our lengthy protocol. Volunteers with no history of 
diabetes, from both sexes, in the age range from 50 to 75 years old with no known 
underlying lower limb vascular or neurological conditions were invited to participate in 
the study. Exclusion criteria included foot deformity, amputation or underlying pathology 
of the spine/lower limbs which results in an inability to walk unaided. It should be noted 
that subjects were asked about their medical history, in particular, diabetes mellitus and 
vascular problems, however, no testing of blood glucose was carried out. 
Twenty-two non-diabetic volunteers were invited to participate; however, two subjects 
were unable to lie still to complete the iontophoresis protocol. 
Both groups’ subjects were provided with a written information sheet, a full explanation 
of the study and informed consent to be signed prior to any participation (Appendix 13, 
14, 15). 
The subjects in the diabetes group were advised to review their participation with their 
GP/diabetician, the needed fasting period (approximately 5 hours) and any diet and 
diabetes medications changes/arrangement they should follow before and after the study 
session prior to any visit. Additionally, blood sugar was checked at the end of the session 
using Accu-Chek Performa Blood Glucose Meter, to ensure diabetic patients are safe to 
send home after the lengthy procedure. If a low blood sugar was detected a sugary 
beverage was provided. 
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Prior to the procedure, a short interview was conducted with each volunteer. Details such 
as age, sex, occupation, smoking history, alcohol intake, exercise routine, general health, 
medications history and mode of management for diabetes, any comorbidity, past history 
of any foot/back surgery or vascular intervention were obtained. Assessment of the lower 
limbs was then carried out by checking skin appearance and any foot deformity. Weight 
and height were recorded and Body Mass Index (BMI) was calculated using the equation 
BMI = weight (kg) / height2 (m). 
3.4.2 In-Shoe Foot Pressure Measurement 
Initially, in-shoe dorsal and plantar walking foot pressures were recorded from the 
participants’ right foot when they were wearing their own comfortable shoes and then 
when they were wearing the size-matched orthopaedic shoes we provided (Chaneco 
Diabetic shoes). Tests in own shoes were performed within the participants’ usual 
footwear they have chosen to bring to the measurement session. This included sports 
shoes, walking boots, slip-on shoes and Oxford-style shoes. This would give an accurate 
representation of participants’ foot pressure within their usual footwear chosen for their 
regular daily activities. 
A Pedar dorsal pad, labelled left (for coupling), was inserted into a standardised sock to 
be secured onto the dorsal surface of the participant’s right foot and connected to the left 
cable of the Pliance® mobile measurements box. A shoe size-matched, right-sided Pedar 
Plantar insole was placed inside the right side of the tested shoes and connected to the 
right cable of the Pliance® mobile measurements box. The same procedures used in the 
pilot study were followed, and these are explained in section 3.2.3 of this chapter. On the 
session day, the average of Peak Pressure (the highest pressure in any sensor across a 
given mask/ trial) across the 6 walking trials was calculated in each tested shoes for both 
dorsal and plantar surfaces of the foot using on-monitor data. These Peak Pressure values 
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were used later for the Pressure delivery equipment during the assessment of endothelial 
function under the applied pressure. Collected pressure data were later extracted for 
analysis using Novel Automask, Novel Group Editor, and Novel Group Mask Evaluation 
software. For the plantar surface of the foot, the IMAR Pedar Mask was used. This mask 
was developed in IMAR laboratory for analysis of in-shoe pressure measured by Pedar 
Insoles. The software is set to create areas (masks) automatically based upon a 
predetermined algorithm. The algorithm recognises the footprint dimensions and defines 
the areas as percentages. It expresses the boundary between midfoot and heel as 73% of 
the foot length and between midfoot and forefoot as 45% of the foot length. A mask was 
developed for the dorsum of the foot guided by the IMAR Pedar Mask. The heel areas 
were cut off and toes areas were smaller (one row less than plantar) and divided into two 
masks instead of three. This was more appropriate with the smaller area covered by the 
dorsal pad in contrast to the larger plantar insole. 
The foot was divided into 21 anatomical areas (masks). Masks from M01 to M09 
corresponded to areas on the dorsal surface and M10 to M21 to the plantar surface of the 
foot (Figure 3.29). The masks’ names and areas they represented on the footprint are 
shown in Table 3.11. The 21-area mask was applied to subjects’ data files for extraction 
accordingly. However, due to the difference in the start and end points between the dorsal 
and plantar masks, the software was unable to resize masks with changes in the foot size 
and the subsequent differences in the insole used. Therefore, masks had to be created 
individually according to each subject’s shoe size. 
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Figure 3.29 Footprint masks 
Table 3.11 Masks names and anatomical areas covered 
Mask Number Mask Name Anatomical Areas 
M01 DT Med Dorsum Toes Medial Side 
M02 DT Lat Dorsum Toes Lateral Side 
M03 DMH 1 Dorsum 1st metatarsal head 
M04 DMH 2 Dorsum 2nd metatarsal head 
M05 DMH 3 Dorsum 3rd metatarsal head 
M06 DMH 4 Dorsum 4th metatarsal head 
M07 DMH 5 Dorsum 5th metatarsal head 
M08 DM midfoot Dorsum Medial midfoot 
M09 DL midfoot Dorsum Lateral midfoot 
M10 PT 1 Plantar Toes 1 (greater toe) 
M11 PT 2 Plantar Toes 2 (second toe) 
M12 PT 3 Plantar Toes 3 (3rd-5th toes) 
M13 PMH 1 Plantar 1st Metatarsal Head 
M14 PMH 2 Plantar 2nd Metatarsal Head 
M15 PMH 3 Plantar 3rd Metatarsal Head 
M16 PMH 4 Plantar 4th Metatarsal Head 
M17 PMH 5 Plantar 5th Metatarsal Head 
M18 PM midfoot Plantar Medial midfoot 
M19 PL midfoot Plantar Lateral midfoot 
M20 PM heel Plantar Medial heel 
M21 PL heel Plantar Lateral heel 
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Group Editor software allows the combination of foot pressure data for analysis. Two 
groups were created using Group Editor software: patients and control groups. Group 
Mask Evaluation software was then used for group evaluation and IMAR software for 
Novel Data Extraction was used to extract data in a spreadsheet suitable for statistical 
analysis. From parameters available to be extracted by the Novel software, those 
considered to be the most clinically relevant and frequently discussed in the literature 
were chosen. These included Peak Pressure (PP), Pressure-Time Integral (PTI), Contact 
Area (CA) and Maximum Force (MF). All extracted data were uploaded into SPSS for 
statistical analysis. 
In-house software was developed to extract the time of PP on the dorsum of the foot 
during the gait cycle. The software interface is shown in Figure 3.30. 
 
Figure 3.30 PP time extraction software 
 Based on earlier testing of the Pedar dorsal pad and the work done by Jordan and Bartlett 
(1995a), dorsal pressure may show some exertion in the swing phase as well the stance 
phases of the gait cycle (Jordan and Bartlett, 1995a). Jordan and Bartlett (1995a) reported 
two force activities, a low force activity exerted just before the foot contacts the ground 
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and a higher force just prior to the foot leaving the ground. They anticipated that these 
force peaks coincided with dorsiflexion of the foot during the gait cycle. This observation 
would endorse the significance of dorsal pressure assessment, as also being present during 
the non-contact phase of the gait cycle, in contrast to the plantar pressure that is only 
recorded during the stance phase. The simultaneous measurement of plantar and dorsal 
pressures enabled the current study to determine the time of the dorsal PP in relation to 
the well-recognised plantar PP. The software defined the beginning of the gait cycle by 
the first peak plantar pressure which was believed to correspond to the heel strike event 
of the gait cycle. The peak plantar pressure data were correlated with the peak dorsal 
pressure and the peak dorsal force. Maximum dorsal force showed more homogenous and 
clear peaks on the produced graphs than the dorsal PP, hence was included in the analysis. 
3.4.3 Assessment of Endothelial Response to the Iontophoresis of Vasoactive 
Solutions with Simultaneous Loading of Pressure  
Assessment of the endothelial function was carried out over two sessions using the LDF 
VP2T probe (Moor® Instruments Ltd.) to monitor the blood flow response to the 
iontophoresis of the vasoactive agents, acetylcholine (ACh) (Miochol-E) and sodium 
nitroprusside (SNP) (Nitropurssiat Fides). The first session involved the assessment of 
the dorsal surface of the foot and the second session assessed the plantar surface. All 
subjects were instructed to avoid food ingestion and caffeine-based drinks for at least two 
hours prior to attending both sessions. Participants were asked to rest for 10-20 minutes 
in a temperature-controlled room of  24° ±1°C prior to any iontophoresis procedure. 
Shoes and socks/tights were removed before subjects rested in a supine position with the 
right foot placed in the customised boot fixed to the bed in order to support the foot 
comfortably during the procedure. The boot also holds the foot in a stable position for 
pressure delivery. 
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The skin over the area of interest was cleansed with an adhesive tape, gently rubbed with 
an alcohol swab then washed with deionized water. The iontophoresis chamber was 
attached to the skin using double-sided adhesive pads and the 2% solution of the 
vasoactive drug with 2% methylcellulose in deionised water was added. The polarity of 
the chamber electrode always matched the charge of the vasoactive drug used and a 
reference electrode with the reverse charge was attached to a conductive hydrogel pad to 
be stuck onto the anterior surface of participant’s right leg. The LDF probe housed in the 
pressure delivery equipment was then placed in position with the chamber’s central 
aperture. Fine-tuning for the dorsal surface testing was achieved with the snake arm and 
for the plantar surface, with the adjustable bar on the boot backplate. 
The spring used for the pressure delivery equipment changed according to the pressure 
values tested as detailed in Section 3.2.5. 
Iontophoresis was carried out with both ACh and SNP on both foot surfaces using the 
protocol tested in Section 3.3.2.2. The LDF probe was utilised to monitor changes in the 
blood flow as well as the mean to transfer the premeasured pressure. Iontophoresis was 
performed with no pressure applied then during loading with the average PP on the tested 
foot surface (calculated on the test day) in participants’ own comfortable shoes then under 
PP obtained in the size-matched orthopaedic shoes. In order to test the same area on the 
foot surface under different testing conditions, a waiting interval was required for the 
vasoactive agent to clear away. A different area was used for each tested condition 
because of time constraints. 
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3.5 STATISTICAL METHODS 
The collected data were analysed using the Statistical Package for the Social Sciences 
(SPSS) Version 22, IBM Corp. Quantitative data were expressed as mean± standard 
deviation (SD) and qualitative data were expressed as frequency and percentage. 
The following statistical tests were undertaken: 
• Independent-samples t-test of significance was used when comparing two means 
• Chi-square (x2) test of significance was used to compare proportions between 
qualitative parameters 
• A one-way analysis of variance (ANOVA) when comparing more than two means 
• Post Hoc test: Least Significant Difference (LSD) was used for multiple 
comparisons between different variables 
• Mann Whitney U test: for two-group comparisons in non-parametric data 
• Kruskall Wallis test: for multiple-group comparisons in non-parametric data 
• Interclass Correlation Coefficient (ICC) for assessment of repeatability 
• Pearson's correlation coefficient (r) test was used to assess the degree of 
association between two sets of variables 
• Spearman rank correlation test to assess the degree of association between two 
sets of variables 
The confidence interval was set to 95% and the margin of error accepted was set to 5%. 
The Probability (P) was considered significant as the following: 
– P <0.05 was considered significant 
– P <0.001 was considered as highly significant 
– P >0.05 was considered no significant differences 
96 
CHAPTER 4 RESULTS 
4.1 STUDY GROUPS CHARACTERISTICS 
Twenty subjects with Type 2 Diabetes agreed to take part in the study. However, two did 
not attend and three had their pressure data collected but were unable to complete the 
iontophoresis procedure. Therefore, 18 subjects with Type 2 Diabetes were investigated 
for in-shoe foot pressure and 15 had the entire protocol completed. Twenty-two non-
diabetic volunteers were invited to participate in the study; although, two subjects were 
unable to lie still to complete the iontophoresis protocol, ending with a total of 20 subjects 
without diabetes were included for the blood flow data in the control group. 
Control group and diabetes group characteristics matched and showed no significant 
differences (p>0.05) in demographic data, body features, shoe size, smoking history, 
alcohol intake and their exercise activities. Characteristics of both study groups are 
demonstrated in Table 4.1. There were participants in both study groups who suffered 
from high blood pressure. Due to the common combination of high blood pressure and 
Type 2 Diabetes, as well as its frequent presentation in this study age group, hypertension 
was the only cardiovascular risk factor that was not excluded on recruitment in both study 
groups. Medication history for both study groups and different modalities of diabetes 
control noted in subjects with diabetes are illustrated in Table 4.2 and Table 4.3, 
respectively. The descriptive statistics and significance values for the investigated 
parameters are supplied in the tables included in Appendix 16. 
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Table 4.1 Control and diabetes groups characteristics 
Regarding; demographic data, body features, shoe size, smoking history, alcohol intake and regular 
exercise activities 
Characteristics 
Control group 
(n:22) 
Diabetes group 
(n:18) 
p 
Sex 
Female 11 (50.0%) 8 (44.4%) 
0.726 # 
Male 11 (50.0%) 10 (55.6%) 
Age (years) 
Mean±SD 63.38±7.09 65.73±6.01 
0.271 
Range 51.24-73.65 52.55-74.29 
Height (m) 
Mean±SD 1.67±0.09 1.66±0.10 
0.615 
Range 1.52-1.83 1.51-1.81 
Weight (kg) 
Mean±SD 75.97±12.40 81.69±13.13 
0.166 
Range 55-100 57.7-108.9 
BMI 
[weight/(height)^2] 
Mean±SD 27.12±3.38 29.81±4.56 
0.039 
Range 20.65-32.65 21.45-39.26 
Shoe size 
Mean±SD 7.09±2.14 7.22±2.13 
0.847 
Range 4-10 4-10 
Smoking 
No 21 (95.5%) 18 (100.0%) 
0.919 # 
Yes 1 (4.5%) 0 (0.0%) 
Alcohol intake 
Daily/Regularly 5 (22.7%) 1 (5.6%) 
0.105 # 
 
Weekly/ Moderate 2 (9.1%) 1 (5.6%) 
Mild 2 (9.1%) 3 (16.7%) 
Limited/ Occasional 7 (31.8%) 6 (33.4%) 
No 6 (27.3%) 7 (38.9%) 
Exercise activities 
Golf 1 (4.5%) 0 (0.0%) 
0.352 # 
 
Gym and Golf 0 (0.0%) 1 (5.6%) 
Gym and Swimming 1 (4.5%) 0 (0.0%) 
Kayaking and Walking 0 (0.0%) 1 (5.6%) 
Pilates 1 (4.5%) 0 (0.0%) 
Running and Cycling 1 (4.5%) 0 (0.0%) 
Skating, dancing and 
Swimming 
1 (4.5%) 0 (0.0%) 
Walking 10 (45.5%) 10 (55.6%) 
Walking and Cycling 3 (13.6%) 0 (0.0%) 
Walking and Gym 
machines 
1 (4.5%) 0 (0.0%) 
Walking and 
Swimming 
0 (0.0%) 1 (5.6%) 
Walking and Exercise 
classes 
0 (0.0%) 1 (5.6%) 
Walking and Zumba 0 (0.0%) 1 (5.6%) 
No exercise 3 (13.6%) 3 (16.7%) 
BMI: Body mass index 
#: is for comparison done by Chi-square test. Other characteristics are compared using Independent Sample t-
test. p>0.05 No Significance (NS)); *: p<0.05 Significant (S); **: p<0.001 Highly Significant (HS) 
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Table 4.2 Medication history 
Medications Control group (n:22) Diabetes group (n:18) 
Calcium 1 (4.5%) 0 (0.0%) 
Anti-hypertensives 6 (27.3%) 17 (94.4%) 
Statins 4 (18.2%) 16 (88.9%) 
Thyroxin 1 (4.5%) 1 (5.6%) 
No medications 14 (63.6%) 0 (0.0%) 
Table 4.3 Mode of management of Diabetes Mellitus 
Mode of management 
(n:18) 
Diet control 4 (22.2%) 
Insulin 5 (27.8%) 
Metformin 5 (27.8%) 
Other Oral hypoglycaemics 10 (55.6%) 
 
4.2 IN-SHOE FOOT PRESSURE ASSESSMENT 
In-shoe walking pressures exerted on dorsal and plantar surfaces of participants’ right 
foot were recorded within participants’ own comfortable shoes which they selected to use 
for the assessment session as well as within the size-matched orthopaedic shoes provided. 
Peak Pressure (PP), Pressure-Time Integral (PTI), Contact Area (CA) and Maximum 
Force (MF) were examined for differences between the two tested shoe conditions within 
each study group and differences between groups across the 21-areas/foot masks defined 
in Table 3.11. 
4.2.1 Peak Pressure 
The first pressure parameter studied, was Peak Pressure (PP), defined as the highest 
pressure in any sensor across a given mask (area). Both study groups showed a 
significantly higher total dorsal PP in participants’ own shoes than within the orthopaedic 
shoes (p <0.001 in both groups). Figure 4.1 illustrates the differences between the two 
tested shoe conditions across foot areas in each study group. Own shoe PP was 
significantly different from that recorded in the orthopaedic shoes, across all foot areas 
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under study, except area DT Med in diabetes group which was not significantly different 
(p= 0.222) between the two tested shoe conditions. 
 
Figure 4.1 Differences between Orthopaedic Shoes and Own Shoes PP means in the study groups 
The small squares represent differences in Total PP; one for p <0.05 Significant (S), 
two for p <0.001 Highly Significant (HS) 
The highest dorsal PPs were recorded on area DMH1 in own shoes in both study groups 
(Mean±SD 55.51±27.94 KPa in control group and Mean±SD 65.43±32.86 KPa in 
diabetes group). Other significantly high dorsal PPs in participants’ own shoes were seen 
on area DT Lat (Mean±SD 46.76±22.60 KPa) in control group (Figure 4.2) and area DM 
midfoot (Mean±SD 52.10±24.84 KPa) in diabetes group (Figure 4.3). 
The highest dorsal PP areas in the orthopaedic shoes were area DM midfoot in both 
groups (Mean±SD 36.76±16.04 KPa in control group and Mean±SD 41.01±13.46 KPa in 
diabetes group) followed by area DT Lat (Mean±SD 32.33±14.49 KPa) in control group 
and area DMH1 in diabetes group (Mean±SD 37.57±14.40 KPa). 
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Figure 4.2 Orthopaedic Shoes and Own Shoes Dorsal PP means in control group 
*: p <0.05 Significant (S); **: p <0.001 Highly Significant (HS) 
 
Figure 4.3 Orthopaedic Shoes and Own Shoes Dorsal PP means in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
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Overall Plantar PP was significantly higher in participants’ own shoes than the 
orthopaedic shoes in both study groups (p<0.001 in control group and p=0.006 in diabetes 
group). The control group (Figure 4.4) showed significantly higher Plantar PP in 
participants’ own shoes on metatarsal heads areas and toes areas except PT1, plus a 
significantly higher PP in the orthopaedic shoes on area PM midfoot. However, diabetes 
group showed no significant differences between the two shoes across all plantar foot 
areas except PT1 (Figure 4.5). 
Control group had the highest own shoe plantar PP recorded on area PMH1 (Mean±SD 
241.55±82.79 KPa) which was also significantly different from the orthopaedic shoes. 
The highest orthopaedic shoe PPs in the control group were seen on heel areas which 
were not significantly different from own shoes plantar PP. Diabetes group had the same 
highest plantar PP areas’ distribution, but all were not significantly different between the 
two shoe conditions. 
 
Figure 4.4 Orthopaedic Shoes and Own Shoes Plantar PP means in control group 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.5 Orthopaedic Shoes and Own Shoes Plantar PP means in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
Comparing PP between groups in each tested shoe is summarised in Figure 4.6. No 
significant differences between groups were observed in the whole dorsal surface PP 
within participants’ own shoes as well as the orthopaedic shoes. 
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Figure 4.6 Differences between study groups in PP means within own and orthopaedic shoe conditions 
The small squares represent differences in Total PP; one for p <0.05 (S), two for p <0.001 (HS) 
However, significant differences were noted in most of the dorsal foot areas within own 
shoes except DMH4 and DL midfoot. Significantly higher means recorded with diabetes 
group within own shoes on area DMH1 (Mean±SD 65.43±32.86 KPa) then area DM 
midfoot (Mean±SD 52.10±24.84 KPa). While all toes areas, 2nd, 3rd and 5th metatarsal 
areas were significantly higher with control in own shoes (Figure 4.7). The comparison 
of dorsal PP between groups in the orthopaedic shoes (Figure 4.8) followed a similar 
pattern except in areas DT Med/and DMH3 which changed to no significant differences 
between groups in the orthopaedic shoes. Same as in own shoes but with a reversed order, 
where the orthopaedic shoes showed a significantly higher PP in diabetes group on area 
DM midfoot with Mean±SD of 41.01±13.46 KPa followed by area DMH1 with 
Mean±SD of 37.57±14.40 KPa. Area DMH2 was also, significantly higher in diabetes 
group within the orthopaedic shoes (Mean±SD 26.99±13.60 KPa). 
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Figure 4.7 Control group and diabetes group Dorsal PP means in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.8 Control group and Diabetes group Dorsal PP means in the Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
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Plantar surface total PP was not significantly different between groups in participants’ 
own shoes but significantly higher in diabetes group within the orthopaedic shoes 
(p=0.013). By looking at different plantar areas within own shoes (Figure 4.9), it was 
noted that heel areas showed no significant differences between groups and the highest 
plantar PP was recorded on area PMH1 (Mean±SD 253.56±95.54 KPa in diabetes group 
and Mean±SD 241.55.56±82.79 KPa in control group) which also had no significant 
differences between groups. Yet, heel areas had the highest plantar PPs in the orthopaedic 
shoes (Figure 4.10) that were significantly higher among diabetes group (PL heel 
Mean±SD 257.99±45.13 KPa and PM heel Mean±SD 249.26±40.56 KPa) when 
compared to control (PL heel Mean±SD 235.78±46.22 KPa and PM heel Mean±SD 
233.94±48.77 KPa). The midfoot areas had significantly higher plantar PP in diabetes 
group than control in both shoe conditions. Toes and metatarsal heads areas within 
participants’ own shoes had significantly higher Plantar PP with control group except for 
areas PT1, PMH1 and PMH2 which were not significantly different between groups. All 
toes areas were significantly different between groups within the orthopaedic shoes with 
higher plantar PP recorded with the control group. Metatarsal heads areas mostly showed 
no significant differences between groups in Plantar PP within the orthopaedic shoes 
except for areas PMH2 and PMH4 which were significantly higher in diabetes group. 
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Figure 4.9 Control group and diabetes group Plantar PP means in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.10 Control group and diabetes group Plantar PP means in the Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
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4.2.2 Pressure Time Integral 
Another parameter examined, was Pressure Time Integral (PTI) in KPa.s (KPa*seconds). 
It is defined as the time integral of the peak pressure measured in any sensor within the 
specified region during one-foot step, calculated as the area under the peak pressure 
versus time curve of a particular region (Waaijman and Bus, 2012). The differences 
between PTI in the two tested shoes across different foot areas in each study group are 
illustrated in Figure 4.11. 
 
Figure 4.11 Differences between Orthopaedic Shoes and Own Shoes PTI means in the study groups 
The small squares represent differences in Total PP; one for p <0.05 (S), 2 for p <0.001 (HS) 
Total dorsal surface PTI was significantly higher in subjects’ own shoes (p<0.001) in both 
study groups. Control group had significantly higher dorsal PTI, in participants’ own 
shoes on areas DT Lat, DMH1, DMH2, DMH3 and DM midfoot. In diabetes group, 
significant differences with also higher PTI in own shoes were found on dorsal areas DT 
Med, DMH1, DMH5, DM midfoot, DL midfoot. 
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Although DT Med showed no significant differences in PTI between the two shoes in the 
control group plus no significant differences in PP in diabetes group, it had a significantly 
higher PTI in the orthopaedic shoes in diabetes group. Both study groups showed the 
highest PTI recorded on area DM midfoot within own shoes (Mean±SD 95.59±74.50 
KPa.s in control group and Mean±SD 145.62±101.63 KPa.s in diabetes group) as well as 
orthopaedic shoes (Mean±SD 79.39±43.87 KPa.s in control group and Mean±SD 
106.91±61.94 KPa.s in diabetes group) with significantly higher PTI in own shoes than 
orthopaedic shoes in both groups. 
 
Figure 4.12 Orthopaedic Shoes and Own Shoes PTI means on the dorsal surface in control group 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.13 Orthopaedic Shoes and Own Shoes PTI means on the dorsal surface in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
Total plantar surface PTI was not significantly different between the two shoes in the 
control group (p=0.507). However, the orthopaedic shoes showed a significantly higher 
plantar PTI than own shoes in the diabetes group (p = 0.044). The plantar surface showed 
significantly higher PTI within the orthopaedic shoes in plantar areas PT1, PT2, PM 
midfoot and PM heel in control group. Plantar areas with also significantly higher PTI 
within the orthopaedic shoes were found on areas PT1, PT2, PT3, PMH2, PMH3, PMH4, 
PM heel and PL heel in the diabetes group. 
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Figure 4.14 Orthopaedic Shoes and Own Shoes PTI means on the plantar surface in control group 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.15 Orthopaedic Shoes and Own Shoes PTI means on the plantar surface in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
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The whole dorsal surface PTI showed no significant differences between groups within 
own shoes as well as the orthopaedic shoes (Figure 4.16). 
 
Figure 4.16 Differences between study groups PTI means within own and orthopaedic shoe conditions 
The small squares represent differences in Total PP; one for p <0.05 (S), two for p <0.001 (HS) 
Yet, own shoes dorsal PTI showed significant differences between groups on all areas on 
the dorsal surface except area DMH1. Mean values were mostly higher in control group 
except for midfoot areas that were significantly higher in diabetes group. Also, the 
orthopaedic shoes dorsal PTI showed significant differences between groups in areas 
DMH1 and DM midfoot with higher means recorded in the diabetes group and areas DT 
Lat, DMH4 and DMH5 with higher means in the control group. Again, DM midfoot had 
the highest dorsal PTI in both study groups within the two shoe conditions. 
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Figure 4.17 Control group and diabetes group PTI means on the dorsal surface in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.18 Control group and diabetes group PTI means on the dorsal surface in Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
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On the plantar surface, the significant difference between the study groups in the whole 
surface PTI was only present within the orthopaedic shoes (p=0.002). Yet, the own shoes 
PTI showed significant differences between groups in areas PT1, PT2, PT3, PMH1, 
PMH4, PM midfoot and PL midfoot. Diabetes group had significantly higher PTI on 
PMH1 and midfoot areas when compared with control in own shoe condition. Plantar 
toes areas, (PT1, PT2, PT3), were significantly higher in the control group within 
orthopaedic shoes, the same as they were in own shoes. Significant differences with 
higher means in the diabetes group were found in plantar areas PMH1, PMH2, PM 
midfoot, PL midfoot PM heel and PL heel within the orthopaedic shoes. 
 
Figure 4.19 Control group and diabetes group PTI means on the plantar surface in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.20 Control group and diabetes group PTI means on the plantar surface in Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
4.2.3 Contact Area 
Total Contact area (CA) on the dorsal surface showed significant differences between the 
two tested shoe conditions with higher CA within the orthopaedic shoes than own shoes 
in both study groups (Figure 4.21). 
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Figure 4.21 Differences between Orthopaedic Shoes and Own Shoes CA means in the study groups 
The small squares represent differences in Total PP; one for p <0.05 (S), two for p <0.001 (HS) 
Significant differences between the two tested shoes were only noted in CA on the 
midfoot areas (DM midfoot and DL midfoot) in the control group, with higher CA means 
recorded in the orthopaedic shoes. In diabetes group, significant differences between the 
two tested shoes were found in dorsal areas DMH2, DMH5 and DL midfoot with higher 
means also noted in the orthopaedic shoes. 
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Figure 4.22 Orthopaedic Shoes and Own Shoes CA means on the dorsal surface in control group 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.23 Orthopaedic Shoes and Own Shoes CA means on the dorsal surface in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
0
5
10
15
20
25
30
C
o
n
ta
ct
 A
re
a
 (
cm
2
)
Area/Mask
Orthopaedic Shoes Own Shoes
0
5
10
15
20
25
C
o
n
ta
ct
 A
re
a
 (
cm
2
)
Area/Mask
Orthopaedic Shoes Own Shoes
117 
No significant differences were noted between the two shoes on the plantar surface in 
total CA with both study groups. Also, same no significant differences were noted across 
all plantar areas in the control group. While only area PM midfoot in the diabetes group 
showed significant difference with higher means found in own shoes. 
 
Figure 4.24 Orthopaedic Shoes and Own Shoes CA means on the plantar surface in control group 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.25 Orthopaedic Shoes and Own Shoes CA means on the plantar surface in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
Both shoe conditions showed no significant differences between groups in total CA on 
dorsal as well as plantar surfaces (Figure 4.26). 
 
Figure 4.26 Differences between study groups CA means within own and orthopaedic shoe conditions 
The small squares represent differences in Total PP; one for p <0.05 (S), two for p <0.001 (HS) 
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However, on examining individual foot areas, own shoes had significant differences in 
CA between groups in dorsal areas DT Med, DT Lat, DMH2, DMH5 and DM midfoot. 
One significant difference between groups was found on the plantar surface in own shoes 
which was recorded in area PM midfoot with higher mean noted in the diabetes group. 
 
Figure 4.27 Control group and diabetes group CA means on the dorsal surface in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.28 Control group and diabetes group CA means on the plantar surface in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
Comparing CA between groups in the orthopaedic shoes showed significant differences 
with higher means in control group in areas DT Med, DMH4 and DMH5 on the dorsum 
and no significant differences between groups in all plantar areas. 
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Figure 4.29 Control group and diabetes group CA means on the dorsal surface in the Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.30 Control group and diabetes group CA means on the plantar surface in the Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
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4.2.4 Maximum Force 
Maximum Force (MF) measured in Newtons (N), showed significant differences between 
orthopaedic and own shoes in the control group for the whole surface MF on both foot 
surfaces (Figure 4.31). 
 
Figure 4.31 Differences between Orthopaedic Shoes and Own Shoes MF means in the study groups 
The small squares represent differences in Total PP; one for p <0.05 (S), two for p <0.001 (HS) 
Most areas on the dorsal surface in the control group were similar to total MF, showing 
significantly higher means in participants’ own shoes, except midfoot areas which were 
not significantly different between the two shoes. 
The plantar surface in the control group had significantly different MF in areas PT3, 
PMH3, PMH4, PMH5, PM midfoot, PL midfoot and PL heel that were all higher in own 
shoes except PL heel which was higher in the orthopaedic shoes along with the whole 
plantar surface MF. 
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Figure 4.32 Orthopaedic Shoes and Own Shoes MF means on the dorsal surface in control group 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.33 Orthopaedic Shoes and Own Shoes MF means on the plantar surface in control group 
*: p <0.05 S; **: p <0.001 HS 
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Total dorsal MF was significantly different between the two shoes in the diabetes group, 
but no significant differences were noted for the whole plantar surface MF. Diabetes 
group showed significant differences between the two tested shoes’ MF on the dorsal 
surface in metatarsal and midfoot areas, with higher means recorded in participants’ own 
shoes, and no significant differences between the two shoes on toes areas. 
Plantar surface in diabetes group showed significantly higher MF in orthopaedic shoes in 
PMH2 and significantly higher MF in own shoes in PM midfoot and PL midfoot. 
 
Figure 4.34 Orthopaedic Shoes and Own Shoes MF means on the dorsal surface in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.35 Orthopaedic Shoes and Own Shoes MF means on the plantar surface in diabetes group 
*: p <0.05 S; **: p <0.001 HS 
MF had no significant differences between groups for whole dorsal surface MF in both 
tested shoes (Figure 4.36). 
 
Figure 4.36 Differences between study groups MF means within own and orthopaedic shoe conditions 
The small squares represent differences in Total PP; one for p <0.05 (S), two for p <0.001 (HS) 
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However, own shoes showed significant differences on dorsal areas DT Med, DT Lat, 
DMH2, DMH5 and DM midfoot with significantly higher means found in control group 
except for DM midfoot that was significantly higher in diabetes group. 
Whole plantar surface MF and all individual plantar areas except PMH2 were 
significantly different between groups within own shoes with higher means recorded in 
diabetes group in PMH1, midfoot and heel areas. Toes and metatarsal areas PMH3, 
PMH4 and PMH5 in own shoes had significantly higher MFs with control than diabetes. 
 
Figure 4.37 Control group and diabetes group MF means on the dorsal surface in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.38 Control group and diabetes group MF on the plantar surface in Own Shoes 
*: p <0.05 S; **: p <0.001 HS 
Though, between groups comparison for the whole surface MF within the orthopaedic 
shoes had no significant differences on the dorsal surface, a significantly higher total 
MF with diabetes than control was found on the plantar surface. 
MF revealed significant differences in dorsal areas DMH1, DMH2, DMH5, DM midfoot 
and DL midfoot. Significant differences on the medial side of the dorsal surface (DMH1, 
DMH2 and DM midfoot) in the orthopaedic shoes had significantly higher means in the 
diabetes group. Dorsal toes areas, DMH3 and DMH4 had no significant differences 
between groups in the orthopaedic shoes. 
Significant differences in MF between groups in the orthopaedic shoes were noted in most 
of the plantar areas except PMH4, PMH5 and PM midfoot which showed no significant 
differences between groups in the orthopaedic shoes. Plantar toes areas in the orthopaedic 
shoes were significantly higher in the control group while other significantly different 
plantar areas were higher in the diabetes group. 
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Figure 4.39 Control group and diabetes group MF means on the dorsal surface in the Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
 
Figure 4.40 Control group and diabetes group MF means on the plantar surface in the Orthopaedic Shoes 
*: p <0.05 S; **: p <0.001 HS 
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4.2.5 Time for Peak Pressure 
Software developed in our laboratory was used to extract the time of occurrence of Dorsal 
Peak Pressure during the gait cycle. There were no significant differences between the 
tested shoes in both study groups as well as between groups in both shoe conditions. 
All data extracted from the in-house software was examined for the frequency of 
occurrence of dorsal PP as a percentage of the gait cycle. The gait cycle phases with 
approximated timing of each event were demonstrated in Figure 4.41. 
 
Figure 4.41 Phases of gait cycle (Hartmann et al., 2010) 
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Dorsal PP existed through most of the stance phase as well as initial swing with sporadic 
presence in the mid and late swing. Dorsal PP also followed a 2-peak pattern similar to 
Plantar PP. However, the first Dorsal PP seemed to occur earlier in the stance phase than 
Plantar PP. Also, the time of the second Dorsal PP shifted from being terminal stance/pre-
swing in Plantar PP to a later timing that was more pre-swing/initial swing peak. 
Moreover, there was a noted existence of dorsal PP but with less frequency in the terminal 
stance period. Dorsal force followed a similar timing for peaks as the dorsal PP. 
Using all participants’ data as one group and comparing own shoes with orthopaedic 
shoes, showed a significant difference in the time of dorsal PP (p=0.047) with more 
frequent peaks occurring late in the swing phase within the orthopaedic shoes. 
 
Figure 4.42 Frequency of Plantar PP during the gait cycle in all tested conditions 
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Figure 4.43  Frequency of Dorsal PP during the gait cycle in all tested conditions 
 
Figure 4.44 Frequency of Dorsal Maximum Force during the gait cycle in all tested conditions 
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Figure 4.45 Frequency of Dorsal PP during the gait cycle in Orthopaedic Shoes across all participants 
 
Figure 4.46 Frequency of Dorsal PP during the gait cycle in Own Shoes across all participants 
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4.3 ASSESSMENT OF THE IMPACT OF PRESSURE ON 
ENDOTHELIAL FUNCTION 
Endothelial function under loading pressure was assessed via monitoring the response of 
foot skin superficial blood vessels to the iontophoresis of acetylcholine (ACh) an 
endothelium-dependent vasoactive agent, and sodium nitroprusside (SNP) an 
endothelium-independent vasodilator, measured with the single-point laser Doppler 
flowmetry (LDF). Iontophoresis was carried out on dorsal and plantar surfaces of the right 
foot of subjects from both study groups using the protocol tested and detailed in section 
3.3.2.2. Iontophoresis of the vasoactive agents was conducted on each foot surface with 
no pressure applied, under the average PP in participants’ own comfortable shoes then 
the average PP in the size-matched orthopaedic shoes which were calculated from the 
foot surface PP values in that shoes on the testing session. 
We had the same issue of movement artefacts with some participants’ recordings as in 
the testing for the protocol repeatability. Thus, noise filtration was performed prior to any 
data extraction for analysis and values for the median of perfusion in each iontophoresis 
period were examined plus the mean values. Peak of Maximum Response was calculated 
from the average of all maximum perfusion values of the 16 periods of the iontophoresis 
protocol. We also examined the changes from baseline in endothelial response to the 
iontophoresis of vasoactive agent reflected in the percentage of change in blood flow from 
baseline (0µA current) which was calculated as:  
Change in response =  (Peak of Maximum Response - Baseline blood flow)  X 100 = % 
                                                                Baseline blood flow  
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According to the Central Limit Theorem, “as the number of the sample increases, the 
closer its variation is to the variance of the society”. Thus, distribution can be considered 
approximate naturally when the sample size becomes 30 or more (Walpole et al., 2017). 
As our sample/ study population was more than 30 (40 for pressure data and 35 completed 
the whole study with iontophoresis), we followed the Central Limit Theory and assumed 
normal distribution of our data. However, to confirm the results of data analysis, perfusion 
data for Peak of Maximum Response and Change in response that mostly did not follow 
a normal distribution pattern were also examined using non-parametric statistical tests. 
Median flux values showed similar analysis results as Mean flux values, and this was also 
confirmed when using non-parametric statistical test analysis of Peak of Maximum 
response and change in response. Data for both study groups were extracted, analysed 
and the findings are illustrated in the following section. Tables for the descriptive 
statistics and significance values supplied in the tables included in Appendix 16. 
4.3.1 Comparison of Flux Values Under the Three Tested Pressure 
Conditions Within the Study Groups  
4.3.1.1 Blood Flow Changes in Control Group 
Comparing the flux values recorded on the dorsal surface of the foot in the control group 
during the iontophoresis of ACh showed significant differences between the resting/no 
pressure condition and own shoes as well as orthopaedic shoes’ pressure applications 
(p<0.001) at all the iontophoresis protocol periods, Peak of Maximum response and 
change in response. 
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Own shoes and orthopaedic shoes pressures application were only significantly different 
in the change in response (p<0.001) with higher flux changes recorded under the 
orthopaedic shoes’ PP (flux median change in response %  Mean±SD 192±80.08%) when 
compared to own shoe effect (flux median change in response % Mean±SD 
149.65±66.86%). Similar differences between the three tested pressure conditions were 
noted in response to SNP iontophoresis with the lone significant difference between 
orthopaedic shoes and own shoes’ pressure applications found in the change in response 
from bassline flux (p <0.001). 
 
Figure 4.47 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of ACh on the dorsal surface in control group 
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Figure 4.48 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of SNP on the dorsal surface in control group 
 
Table 4.4 Comparison between the three tested pressure conditions changes in flux in response to the 
iontophoresis of ACh on the dorsal surface in control group using: Kruskal Wallis test 
Iontophoresis 
Dorsum No 
pressure 
Dorsum Ortho 
pressure 
Dorsum Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 137.3 17.5a 14.3a 
<0.001** 
IQR 38.0 7.9 3.5 
Change in response % 
(Using Flux Median) 
Median 725.81 184.32a 143.66ab 
<0.001** 
IQR 448.36 76.88 64.19 
Change in response % 
(Using Flux Mean) 
Median 682.84 165.96a 130.83ab 
<0.001** 
IQR 414.58 72.72 58.58 
p >0.05 NS; *p <0.05 S; **p <0.001 HS. IQR: interquartile range 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Figure 4.49 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of ACh on the dorsal surface in control group 
 
Figure 4.50 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of ACh on the dorsal surface in control group 
 
Table 4.5 Comparison between the three tested pressure conditions changes in flux in response to the 
iontophoresis of SNP on the dorsal surface in control group using: Kruskal Wallis test 
Iontophoresis 
Dorsum No 
pressure 
Dorsum Ortho 
pressure 
Dorsum Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 135.7 23.0a 14.1a 
<0.001** 
IQR 54.2 26.7 5.6 
Change in response % 
(Using Flux Median) 
Median 497.15 191.68a 133.65ab 
<0.001** 
IQR 237.84 119.32 49.79 
Change in response % 
(Using Flux Mean) 
Median 482.65 167.99a 119.89ab 
<0.001** 
IQR 234.56 114.29 42.17 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
0
50
100
150
200
250
Dorsum No
pressure
Dorsum Ortho
pressure
Dorsum Own
pressure
P
ea
k
 o
f 
M
a
x
im
u
m
im
u
m
 r
e
sp
o
n
se
 (
P
U
)
0
200
400
600
800
1000
1200
Dorsum No
pressure
Dorsum Ortho
pressure
Dorsum Own
pressure
C
h
a
n
g
e 
in
 r
e
sp
o
n
se
 (
U
si
n
g
 M
ed
ia
n
) 
%
138 
 
Figure 4.51 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of SNP on the dorsal surface in control group 
 
Figure 4.52 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of SNP on the dorsal surface in control group 
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Plantar surface showed the same relationship between the three tested conditions as on 
the dorsal surface. Significant reduction in blood flow (p<0.001) was noted from no 
pressure/resting condition in all periods of the iontophoresis protocol as well as Peak of 
Maximum response in response to the iontophoresis of both the vasoactive drugs under 
own shoes’ PP and orthopaedic shoes’ PP. However, the higher changes in response under 
the orthopaedic shoes’ pressures were not significantly different from those under own 
shoe pressure in response to the iontophoresis of ACh nor SNP. 
 
Figure 4.53 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of ACh on the plantar surface in control group 
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Figure 4.54 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of SNP on the plantar surface in control group 
 
Table 4.6 Comparison between the three tested pressure conditions changes in flux during the iontophoresis of 
ACh on the plantar surface in control group using: Kruskal Wallis test 
Iontophoresis 
Plantar No 
pressure 
Plantar Ortho 
pressure 
Plantar Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 214.5 8.6a 7.8a 
<0.001** 
IQR 135.3 4.0 3.3 
Change in response % 
(Using Flux Median) 
Median 471.80 140.35a 120.80a 
<0.001** 
IQR 341.59 61.32 67.34 
Change in response % 
(Using Flux Mean) 
Median 442.23 125.68a 111.71a 
<0.001** 
IQR 330.58 51.66 61.98 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Figure 4.55 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of ACh on the plantar surface in control group 
 
Figure 4.56 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of ACh on the plantar surface in control group 
 
Table 4.7 Comparison between the three tested pressure conditions changes in flux during the iontophoresis of 
SNP on the plantar surface in control group using: Kruskal Wallis test 
Iontophoresis 
Plantar No 
pressure 
Plantar Ortho 
pressure 
Plantar Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 195.0 7.7a 7.5a 
<0.001** 
IQR 132.7 3.4 3.8 
Change in response % 
(Using Flux Median) 
Median 619.20 123.24a 113.57a 
<0.001** 
IQR 693.98 83.48 56.70 
Change in response % 
(Using Flux Mean) 
Median 580.73 113.08a 99.44a 
<0.001** 
IQR 657.85 78.95 40.63 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Figure 4.57 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of SNP on the plantar surface in control group 
 
Figure 4.58 Comparison between the three tested pressure conditions’ Change in response %  
(Using Flux Median) during the iontophoresis of SNP on the plantar surface in control group 
4.3.1.2 Blood Flow Changes in Diabetes Group 
ACh iontophoresis showed significant differences (p<0.001) between the no pressure 
condition and orthopaedic shoes as well as own shoes’ pressure conditions in all flux 
parameters on both dorsal and plantar surfaces of the foot. However, no significant 
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differences were detected between the own shoes and orthopaedic shoes’ pressure 
conditions in any of flux values, Peak of Maximum response or Change in response. 
Alternatively, SNP iontophoresis revealed significant differences between the two tested 
shoes’ pressures application in the change in response values on both dorsal and plantar 
surfaces (p <0.001). Though, it maintained the same no significant difference relationship 
between the two shoes’ pressures application as in response to ACh in flux values through 
the iontophoresis protocol and Peak of Maximum response as well as the significant 
differences detected between the no pressure condition and each shoes’ pressure 
application. 
 
Figure 4.59 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of ACh on the dorsal surface in diabetes group 
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Figure 4.60 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of SNP on the dorsal surface in diabetes group 
 
Figure 4.61 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of ACh on the plantar surface in diabetes group 
0
20
40
60
80
100
120
140
160
F
L
U
X
 (
P
U
)
Iontophoresis Period
Dorsum No pressure Dorsum Ortho pressure Dorsum Own pressure
0
50
100
150
200
250
300
F
L
U
X
 (
P
U
)
Iontophoresis Period
Plantar No pressure Plantar Ortho pressure Plantar Own pressure
145 
 
Figure 4.62 Means of flux median under the three tested pressure conditions in response to the iontophoresis 
of SNP on the plantar surface in diabetes group 
 
Table 4.8 Comparison between the three tested pressure conditions changes in flux during the iontophoresis of 
ACh on the dorsal surface in diabetes group using: Kruskal Wallis test 
Iontophoresis 
Dorsum No 
pressure 
Dorsum Ortho 
pressure 
Dorsum Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 135.5 19.6a 13.9a 
<0.001** 
IQR 82.5 7.7 5.1 
Change in response % 
(Using Flux Median) 
Median 432.46 138.91a 130.57a 
<0.001** 
IQR 306.74 74.53 52.89 
Change in response % 
Using Flux (Mean) 
Median 416.30 128.38a 120.62a 
<0.001** 
IQR 295.99 66.41 45.79 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Figure 4.63 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of ACh on the dorsal surface in diabetes group 
 
Figure 4.64 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of ACh on the dorsal surface in diabetes group 
 
Table 4.9 Comparison between the three tested pressure conditions changes in flux during the iontophoresis of 
SNP on the dorsal surface in diabetes group using: Kruskal Wallis test 
Iontophoresis 
Dorsum No 
pressure 
Dorsum Ortho 
pressure 
Dorsum Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 158.2 17.8a 17.9a 
<0.001** 
IQR 93.6 9.1 7.6 
Change in response % 
(Using Flux Median) 
Median 646.21 139.55a 164.57ab 
<0.001** 
IQR 450.85 53.12 81.43 
Change in response % 
(Using Flux Mean) 
Median 618.07 122.62a 149.86ab 
<0.001** 
IQR 430.25 43.33 73.40 
p >0.05 NS; *p <0.05 S; **p <0.001 HS. 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Figure 4.65 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of SNP on the dorsal surface in diabetes group 
 
Figure 4.66 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of SNP on the dorsal surface in diabetes group 
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Table 4.10 Comparison between the three tested pressure conditions changes in flux during the iontophoresis of 
ACh on the plantar surface in diabetes group using: Kruskal Wallis test 
Iontophoresis 
Plantar No 
pressure 
Plantar Ortho 
pressure 
Plantar Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 302.3 11.0a 11.1a 
<0.001** 
IQR 160.5 4.3 4.0 
Change in response % 
(Using Flux Median) 
Median 521.80 119.06a 125.08a 
<0.001** 
IQR 562.09 51.10 58.00 
Change in response % 
(Using Flux Mean) 
Median 495.48 107.53a 111.98a 
<0.001** 
IQR 541.38 40.32 47.25 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
 
 
Figure 4.67 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of ACh on the plantar surface in diabetes group 
 
Figure 4.68 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of ACh on the plantar surface in diabetes group  
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Table 4.11 Comparison between the three tested pressure conditions changes in flux during the iontophoresis of 
SNP on the plantar surface in diabetes group using: Kruskal Wallis test 
Iontophoresis 
Plantar No 
pressure 
Plantar Ortho 
pressure 
Plantar Own 
pressure 
p 
Peak of Maximum 
response (PU) 
Median 237.8 14.3a 9.2a 
<0.001** 
IQR 107.7 19.0 3.5 
Change in response % 
(Using Flux Median) 
Median 319.17 136.23a 106.81ab 
<0.001** 
IQR 140.20 85.07 45.60 
Change in response % 
(Using Flux Mean) 
Median 297.90 119.60a 93.05ab 
<0.001** 
IQR 134.05 65.19 37.43 
p >0.05 NS; *p <0.05 S; **p <0.001 HS. 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
 
 
Figure 4.69 Comparison between the three tested pressure conditions’ Peak of Maximum response (PU) 
during the iontophoresis of SNP on the plantar surface in diabetes group 
 
Figure 4.70 Comparison between the three tested pressure conditions’ Change in response % (Using Flux 
Median) during the iontophoresis of SNP on the plantar surface in diabetes group 
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4.3.2 Comparison Between Control Group and Diabetes Group Flux Values 
4.3.2.1 Changes on the Dorsal Surface 
Blood flux in response to the iontophoresis of ACh under no pressure applied on the 
dorsum of the foot showed no significant differences between the two study groups in all 
iontophoresis periods and Peak of Maximum response. Although a significantly higher 
change from baseline (p=0.037) recorded in the control group (Flux median Change in 
response %; Mean±SD 756.05±467.04%) when compared to change in response in 
diabetes group (Flux median Change in response %; Mean±SD 450.48±319.52%). 
Iontophoresis of SNP under no pressure conditions on the foot dorsum showed no 
significant differences between study groups in all flux parameters including change in 
response from baseline blood flow. 
 
Figure 4.71 Control group and diabetes group means of flux median on the dorsum of the foot with no 
pressure applied during the iontophoresis of ACh 
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Figure 4.72 Control group and diabetes group means of flux median on the dorsum of the foot with no 
pressure applied during the iontophoresis of SNP 
 
Table 4.12 Comparison between control group and diabetes group blood flux changes on the dorsum of the foot 
with no pressure applied during the iontophoresis of ACh using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 137.3 38.0 74.5 233.47 
0.903 
Diabetes 135.5 82.5 40.1 369.01 
Change in response % 
(Using Flux Median) 
Control 725.81 448.36 238.36 1905.94 
0.041* 
Diabetes 432.46 306.74 104.75 1113.00 
Change in response % 
(Using Flux Mean) 
Control 682.84 414.58 228.69 1771.97 
0.047* 
Diabetes 416.30 295.99 102.61 1065.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS. 
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Figure 4.73 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
dorsum of the foot with no pressure applied during the iontophoresis of ACh 
 
Figure 4.74 Comparison between control group and diabetes group Change in response % on the dorsum of 
the foot with no pressure applied during the iontophoresis of ACh 
Table 4.13 Comparison between control group and diabetes group blood flux changes on the dorsum of the foot 
with no pressure applied during the iontophoresis of SNP using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 135.7 54.2 56.26 242.25 
0.365 
Diabetes 158.2 93.6 67.04 413.13 
Change in response % 
(Using Flux Median) 
Control 497.15 237.84 153.91 1087.50 
0.280 
Diabetes 646.21 450.85 214.20 1607.15 
Change in response % 
(Using Flux Mean) 
Control 482.65 234.56 157.04 1065.78 
0.280 
Diabetes 618.07 430.25 212.22 1572.60 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
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Figure 4.75 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
dorsum of the foot with no pressure applied during the iontophoresis of SNP 
 
Figure 4.76 Comparison between control group and diabetes group Change in response % on the dorsum of 
the foot with no pressure applied during the iontophoresis of SNP 
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The dorsal surface showed a significant difference between groups at baseline period 
(0µA/60 seconds) when applying the orthopaedic shoes’ pressure (p=0.034 with flux 
median and p=0.045 with flux mean). Yet only the first minute of ACh iontophoresis 
protocol when using flux median values maintained this significant difference (p=0.035). 
No other significant differences were then found between groups on the continuation of 
the iontophoresis protocol, in Peak of Maximum of response nor in the change in response 
percentage. The orthopaedic shoes’ PP also, did not reveal any significant differences 
between groups in response to the SNP iontophoresis on the dorsal surface of the foot as 
seen with the no pressure condition. 
Applying own shoes’ PP on the dorsum of the foot did not exhibit any significant 
differences between groups in response to the iontophoresis of ACh nor SNP in any of 
the blood flux values, Peak of Maximum response or change in response from baseline. 
 
Figure 4.77 Control group and diabetes group means of flux median on the dorsum of the foot under PP in the 
orthopaedic shoes in response to the iontophoresis of ACh 
*: p <0.05 S 
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Figure 4.78 Control group and diabetes group means of flux median on the dorsum of the foot under PP in the 
orthopaedic shoes in response to the iontophoresis of SNP 
 
Table 4.14 Comparison between control group and diabetes group blood flux changes on the dorsum of the foot 
with pressure in Orthopaedic shoes applied during the iontophoresis of ACh using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 17.5 7.9 11.18 48.47 
0.434 
Diabetes 19.6 7.7 8.39 37.53 
Change in response % 
(Using Flux Median) 
Control 184.32 76.88 113.73 458.38 
0.125 
Diabetes 138.91 74.53 40.97 307.95 
Change in response % 
(Using Flux Mean) 
Control 165.96 72.72 104.14 446.39 
0.134 
Diabetes 128.38 66.41 40.83 295.90 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
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Figure 4.79 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
dorsum of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh 
 
Figure 4.80 Comparison between control group and diabetes group Change in response % on the dorsum of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh 
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Table 4.15 Comparison between control group and diabetes group blood flux changes on the dorsum of the foot 
with pressure in Orthopaedic shoes applied during the iontophoresis of SNP using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 23.0 26.7 6.64 137.13 
0.467 
Diabetes 17.8 9.1 6.64 46.66 
Change in response % 
(Using Flux Median) 
Control 191.68 119.32 45.29 633.29 
0.111 
Diabetes 139.55 53.12 74.17 261.72 
Change in response % 
(Using Flux Mean) 
Control 167.99 114.29 38.69 616.06 
0.174 
Diabetes 122.62 43.33 74.17 216.61 
 p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
 
Figure 4.81 Comparison between control group and diabetes group Peak of Maximum response (PU ) on the 
dorsum of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP 
 
Figure 4.82 Comparison between control group and diabetes group Change in response % on the dorsum of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP 
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Figure 4.83 Control group and diabetes group means of flux median on the dorsum of the foot under PP in 
Own shoes in response to the iontophoresis of ACh 
 
Figure 4.84 Control group and diabetes group means of flux median on the dorsum of the foot under PP in 
Own shoes in response to the iontophoresis of SNP  
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Table 4.16 Comparison between control group and diabetes group blood flux changes on the dorsum of the foot 
with pressure in Own shoes applied during the iontophoresis of ACh using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 14.3 3.5 8.94 23.5 
0.491 
Diabetes 13.9 5.1 8.07 27.51 
Change in response % 
(Using Flux Median) 
Control 143.66 64.19 29.87 274.80 
0.588 
Diabetes 130.57 52.89 65.77 293.04 
Change in response % 
(Using Flux Mean) 
Control 130.83 58.58 30.63 263.45 
0.761 
Diabetes 120.62 45.79 64.24 255.00 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
 
Figure 4.85 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
dorsum of the foot with pressure in Own shoes applied during the iontophoresis of ACh 
 
Figure 4.86 Comparison between control group and diabetes group Change in response % on the dorsum of 
the foot with pressure in Own shoes applied during the iontophoresis of ACh 
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Table 4.17 Comparison between control group and diabetes group blood flux changes on the dorsum of the foot 
with pressure in Own shoes applied during the iontophoresis of SNP using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 14.1 5.6 6.64 24.99 
0.060 
Diabetes 17.9 7.6 9.37 36.44 
Change in response % 
(Using Flux Median) 
Control 133.65 49.79 36.83 252.02 
0.202 
Diabetes 164.57 81.43 84.80 340.80 
Change in response % 
(Using Flux Mean) 
Control 119.89 42.17 37.44 215.18 
0.193 
Diabetes 149.86 73.40 77.65 291.82 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
 
Figure 4.87 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
dorsum of the foot with pressure in Own shoes applied during the iontophoresis of SNP 
 
Figure 4.88 Comparison between control group and diabetes group Change in response % on the dorsum of 
the foot with pressure in Own shoes applied during the iontophoresis of SNP  
0
5
10
15
20
25
30
Control Diabetes
P
ea
k
 o
f 
M
a
x
im
u
m
im
u
m
 r
e
sp
o
n
se
 (
P
U
) 
0
50
100
150
200
250
300
Control Diabetes
C
h
a
n
g
e 
in
 r
e
sp
o
n
se
 (
U
si
n
g
 M
ed
ia
n
) 
%
161 
4.3.2.2 Changes on the Plantar Surface 
ACh iontophoresis at resting with no pressure applied on the plantar surface of 
participants’ foot, showed significant differences between the study groups in the baseline 
(0µA current) blood flow (p=0.046), with higher means noted in the diabetes group (flux 
median Mean±SD 71.80±43.65 PU) compared to control (flux median Mean±SD 
45.22±32.22 PU). This significant difference proceeded up to the 5th minute of the 
protocol in flux median data and 6th minute in flux means. No further significant 
differences were noted through the protocol, Peak of Maximum response or change in 
response percentage. Whereas iontophoresis of SNP under no pressure did not reveal any 
significant differences between groups in flux values, Peak of Maximum response or 
change in response on the plantar surface. 
 
Figure 4.89 Control group and diabetes group means of flux median on the Plantar of the foot with no 
pressure applied during the iontophoresis of ACh 
*: p <0.05 S 
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Figure 4.90 Control group and diabetes group means of flux median on the Plantar of the foot with no 
pressure applied during the iontophoresis of SNP 
 
Table 4.18 Comparison between control group and diabetes group blood flux changes on the Plantar of the foot 
with no pressure applied during the iontophoresis of ACh using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 214.5 135.3 33.39 588.58 
0.054 
Diabetes 302.3 160.5 47.67 662.91 
Change in response % 
(Using Flux Median) 
Control 471.80 341.59 46.74 1272.23 
0.791 
Diabetes 521.80 562.09 58.05 2298.87 
Change in response % 
(Using Flux Mean) 
Control 442.23 330.58 51.80 1240.94 
0.642 
Diabetes 495.48 541.38 58.37 2213.42 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
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Figure 4.91 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
Plantar of the foot with no pressure applied during the iontophoresis of ACh 
 
Figure 4.92 Comparison between control group and diabetes group Change in response % on the Plantar of 
the foot with no pressure applied during the iontophoresis of ACh 
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Table 4.19 Comparison between control group and diabetes group blood flux changes on the Plantar of the foot 
with no pressure applied during the iontophoresis of SNP using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 195.0 132.7 32.07 502.48 
0.193 
Diabetes 237.8 107.7 110.78 485.71 
Change in response % 
(Using Median) 
Control 619.20 693.98 16.21 2484.31 
0.123 
Diabetes 319.17 140.20 66.77 611.09 
Change in response % 
(Using Mean) 
Control 580.73 657.85 17.48 2348.29 
0.125 
Diabetes 297.90 134.05 62.81 585.86 
p >0.05 NS; *p <0.05 S; **p <0.001 HS. 
 
Figure 4.93 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
Plantar of the foot with no pressure applied during the iontophoresis of SNP 
 
Figure 4.94 Comparison between control group and diabetes group Change in response % on the Plantar of 
the foot with no pressure applied during the iontophoresis of SNP 
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Significant differences were recorded between groups when applying the orthopaedic 
shoes’ pressure during ACh iontophoresis on the plantar surface in flux median data; from 
bassline flow (0µA current) to 9th minute of the protocol and in 1st, 2nd, 6th, 7th and 8th 
minutes in the flux mean data. Yet, no significant differences were found in Peak of 
Maximum response or change in response percentage.  The first minute of SNP drug 
delivery (2nd minute in the protocol) was significantly different between groups but no 
other significant differences were found in response to SNP iontophoresis under the 
orthopaedic pressure on the plantar surface. 
 
Figure 4.95 Control group and diabetes group means of flux median on the Plantar of the foot under PP in the 
orthopaedic shoes in response to the iontophoresis of ACh 
*: p <0.05 S 
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Figure 4.96 control group and diabetes group median of flux on the Plantar of the foot under PP in the 
orthopaedic shoes in response to the iontophoresis of SNP 
*: p <0.05 S 
Table 4.20 Comparison between control group and diabetes group blood flux changes on the Plantar of the foot 
with pressure in Orthopaedic shoes applied during the iontophoresis of ACh using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 8.6 4.0 4.22 21.98 
0.061 
Diabetes 11.0 4.3 4.38 20.16 
Change in response % 
(Using Flux Median) 
Control 140.35 61.32 78.91 322.58 
0.372 
Diabetes 119.06 51.10 54.33 257.34 
Change in response % 
(Using Flux Mean) 
Control 125.68 51.66 77.08 255.98 
0.311 
Diabetes 107.53 40.32 48.11 198.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
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Figure 4.97 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
Plantar of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh 
 
Figure 4.98 Comparison between control group and diabetes group Change in response % on the Plantar of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh 
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Table 4.21 Comparison between control group and diabetes group blood flux changes on the Plantar of the 
foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 7.7 3.4 3.71 17.02 
0.084 
Diabetes 14.3 19.0 4.38 84.87 
Change in response % 
(Using Flux Median) 
Control 123.24 83.48 65.78 401.81 
0.922 
Diabetes 136.23 85.07 11.24 358.75 
Change in response % 
(Using Flux Mean) 
Control 113.08 78.95 59.46 372.83 
0.845 
Diabetes 119.60 65.19 12.92 270.93 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
 
Figure 4.99 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
Plantar of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP 
 
Figure 4.100 Comparison between control group and diabetes group Change in response % on the Plantar of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP 
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Although ACh iontophoresis under own shoes’ pressure resulted in significantly higher 
flux values in diabetes group through the iontophoresis protocol periods and in Peak of 
Maximum response (p<0.05), no significant differences were detected in the change in 
response in both median and mean flux data. SNP iontophoresis with own shoes’ pressure 
had significant differences between groups with higher flux values in the diabetes group 
in the early 7 minutes of the protocol in median data and 1st, 2nd  and 5th minutes in mean 
flux data. However, no significant difference was noted in Peak of Maximum response or 
change in responses percentage. 
 
Figure 4.101 Control group and diabetes group means of flux median on the Plantar of the foot under PP in 
Own shoes in response to the iontophoresis of ACh 
*: p <0.05 S; **: p <0.001 HS 
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Figure 4.102 control group and diabetes group means of flux median on the Plantar of the foot under PP in 
Own shoes in response to the iontophoresis of SNP 
*: p <0.05 S 
 
Table 4.22 Comparison between control group and diabetes group blood flux changes on the Plantar of the foot 
with pressure in Own shoes applied during the iontophoresis of ACh using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 7.8 3.3 3.8 16.92 
0.008* 
Diabetes 11.1 4.0 4.34 16.9 
Change in response % 
(Using Flux Median) 
Control 120.80 67.34 13.14 284.52 
0.663 
Diabetes 125.08 58.00 50.67 257.34 
Change in response % 
(Using Flux Mean) 
Control 111.71 61.98 14.61 267.80 
0.659 
Diabetes 111.98 47.25 48.11 198.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
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Figure 4.103 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
Plantar of the foot with pressure in Own shoes applied during the iontophoresis of ACh 
 
Figure 4.104 Comparison between control group and diabetes group Change in response % on the Plantar of 
the foot with pressure in Own shoes applied during the iontophoresis of ACh 
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Table 4.23 Comparison between control group and diabetes group blood flux changes on the Plantar of the foot 
with pressure in Own shoes applied during the iontophoresis of SNP using: Mann-Whitney test 
Iontophoresis Group Median IQR Min. Max. p 
Peak of Maximum 
response (PU) 
Control 7.5 3.8 4.78 22.03 
0.124 
Diabetes 9.2 3.5 4.45 17.42 
Change in response % 
(Using Median) 
Control 113.57 56.70 61.21 286.51 
0.793 
Diabetes 106.81 45.60 11.24 190.31 
Change in response % 
(Using Mean) 
Control 99.44 40.63 57.96 215.52 
0.834 
Diabetes 93.05 37.43 12.92 161.54 
p >0.05 NS; *p <0.05 S; **p <0.001 HS.  
 
Figure 4.105 Comparison between control group and diabetes group Peak of Maximum response (PU) on the 
Plantar of the foot with pressure in Own shoes applied during the iontophoresis of SNP 
 
Figure 4.106 Comparison between control group and diabetes group Change in response % on the Plantar of 
the foot with pressure in Own shoes applied during the iontophoresis of SNP 
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4.3.3 Correlation of Peak Pressure with Blood Flux Values 
Correlations were explored using Pearson correlation coefficient, between PP (KPa), on 
both foot surfaces within orthopaedic and own shoes, and the corresponding recorded flux 
(PU) at Baseline, prior to the delivery of any current (0µa/60 seconds), for flux median 
as well as flux mean values, Peak of Maximum response, Change in response for flux 
median and Change in response using flux mean. Two interactions with significant 
correlations were noted. In control group (Figure 4.107,4.108), dorsal PP in the 
orthopaedic shoes was significantly associated with the baseline blood flow at the start of 
ACh iontophoresis protocol with flux median (r=0.465 and p=0.039) as well as mean flux 
values (r=0.495 and p=0.026). In diabetes group, the only significant correlation detected 
(Figure 4.109), was between the dorsal PP in the orthopaedic shoes and Peak of Maximum 
response to SNP iontophoresis (r=0.45 and p=0.036). 
However, on investigating these significant correlations, the effect of outliers was 
uncertain. Spearman correlation tends to be more robust against outliers (Schober et al., 
2018). Therefore, those significant associations were re-assessed with Spearman rank 
correlation test and no significance was detected. 
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Figure 4.107 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Baseline Flux Median (PU) during 
the iontophoresis of ACh on the dorsal surface in control group 
 
Figure 4.108 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Baseline Flux Mean (PU) during 
the iontophoresis of ACh on the dorsal surface in control group 
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Figure 4.109 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Peak of Maximum response (PU) 
during the iontophoresis of SNP on the dorsal surface in diabetes group  
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CHAPTER 5 DISCUSSION 
5.1 INTRODUCTION 
Foot ulceration is a major complication of diabetes mellitus, known to result in enormous 
global morbidity, mortality and significant cost burden to healthcare systems. It is 
estimated that NHS England expenditure on the diabetic foot disease’s care (almost 1% 
of the health service budget) accounts for more than the combined cost of breast, prostate 
and lung cancers with more than 90% of that expenditure related to ulceration (Kerr et 
al., 2019). Yet, it is considered a preventable problem through evidence-based care 
(Lazzarini et al., 2018). Hence, appropriate care and work on prevention are paramount 
to reduce the risks to patients and the resultant economic burden to society. 
Various preventive interventions have been used in clinical practice and studied in the 
currently available literature. The International Working Group on the Diabetic Foot 
(IWGDF) has identified “Ensuring routine wearing of appropriate footwear” as one of the 
key preventive elements in its evidence-based 2019 guidelines on the prevention of foot 
ulcers in people with diabetes (Bus et al., 2019b). Patients with diabetes who are at 
moderate or high risk of foot ulceration, due to loss of protective sensation, peripheral 
artery disease, foot deformity or combinations of them are advised to wear properly fitting 
footwear that protects and accommodates the shape of their feet. This includes adequate 
length, width and depth of the footwear, in order to prevent a first foot ulcer (Van Netten 
et al., 2018). 
High plantar pressure has been shown to be a significant independent risk factor for foot 
ulceration in diabetic foot (Waaijman et al., 2014, Fernando et al., 2016). Furthermore, 
the consistent use of therapeutic footwear with demonstrated plantar pressure relieving 
effect has been shown to significantly prevent the recurrence of plantar ulcers (Uccioli et 
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al., 1995, Armstrong et al., 1998, Busch and Chantelau, 2003, Maciejewski et al., 2004, 
Ulbrecht et al., 2014, Fernando et al., 2016). 
Plantar pressure relieving effect needed for effective foot offloading was estimated to be 
a ≥30% reduction in PP during walking, or a PP of <200kPa (if measured with a validated 
and calibrated pressure measuring system with a sensor size of 2 cm2) (Bus et al., 2016b). 
It is still relatively expensive to evaluate or design footwear using pressure measurement, 
however it should be considered a cost-effective procedure when it can reduce foot ulcers 
by approximately 50% in at-risk patients (Bus and Van Netten, 2016, Bus et al., 2019a, 
Bus et al., 2019b). 
Currently, and to the best of our knowledge, there is no study that has investigated the 
effect of therapeutic footwear on the prevention of non-plantar lesions. However, ill-
fitting footwear has been identified as an important cause of non-plantar ulcers. 
Therefore, it has been strongly recommended to consider properly fitting therapeutic 
shoes, custom-made insoles, or orthosis in case of foot deformity for ulcer’s prevention.  
Properly fitting therapeutic footwear is particularly recommended for at-risk patients with 
diabetes who exhibit a pre-ulcerative sign, in order to change foot biomechanics and 
reduce pressure on vulnerable areas including previous ulcer location (Bus et al., 2016a). 
Our pilot study conducted with 13 non-diabetic volunteers, comparing PP in participants’ 
own shoes with commercially available orthopaedic shoes, commonly prescribed to at-
risk diabetic patients, demonstrated a significant difference in in-shoe PP on the dorsal 
surface (p<0.001). However, no significant reduction in PP was detected on the plantar 
surface within the orthopaedic shoes, which would question one of the main purposes of 
this footwear. This also emphasises the significance of foot pressure measurement prior 
to any therapeutic footwear prescription in order to optimise pressure distribution and 
achieve the anticipated pressure reduction within these therapeutic interventions. 
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The current study examined the in-shoe foot pressure on the dorsal and plantar surfaces 
of the foot within participants’ own shoes and one of the therapeutic footwear, commonly 
prescribed by the orthotic clinics for diabetic patients who are referred as having at-risk 
feet. Findings on both foot surfaces within the two shoes were compared between a group 
of subjects with Type 2 Diabetes and an age-matched control group of subjects without 
diabetes. The effect of pressure loading on endothelial function was also studied by 
monitoring the perfusion changes under pressure in response to the iontophoresis of two 
vasoactive agents, ACh, an endothelium-dependent vasodilator and SNP, an 
endothelium-independent vasodilator. 
5.2 IN-SHOE FOOT PRESSURE ASSESSMENT 
5.2.1 Dorsal Pressure  
Based on professional opinion for the best shoe upper, it is the shoe upper with a design 
that can accommodate the shape of the foot even with deformities. Strategies to achieve 
the best shoe upper in diabetic patients with high-risk feet have involved the use of soft 
materials or leather that can be stretched, avoiding stitches and providing extra depth to 
accommodate deformities or orthosis. Also, lace-up shoes are preferred to secure snug 
closure, prevent sliding or misalignment and accommodate any change in the foot volume 
due to oedema (Miller et al., 2000, Ulbrecht and Bus, 2020). 
The current study examined the in-shoe dorsal pressure in one of the therapeutic footwear 
(referred to throughout as “orthopaedic shoes”) that claims to consider the previously 
described features to best accommodate high-risk feet in patients with diabetes. There 
were no significant differences between the two study groups in dorsal PP within the 
orthopaedic shoes as well as in participants’ own shoes which they chose to bring to the 
testing session. However, both study groups had a significantly higher dorsal PP in 
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participants’ own shoes when compared with dorsal PP in the orthopaedic shoes. The 
same relationship was noted in the total dorsal surface PTI and MF. Dorsal PP’s findings 
match our pilot study outcomes and can be related to the deep toe-box and other 
characteristics considered in the materials and design of the orthopaedic shoes. Dorsal 
CA also showed no significant differences between groups in both tested shoe conditions. 
However, a significantly larger CA was recorded in the orthopaedic shoes in both study 
groups. The larger orthopaedic shoes’ dorsal CA has helped in delivering a better pressure 
distribution which could explain the significantly lower dorsal PP recorded in the 
orthopaedic shoes. On examining individual foot areas, the first metatarsal head (DMH1) 
had the highest dorsal PP values in participants’ own shoes. This foot area showed a 
significantly higher PP in own shoes than orthopaedic shoes in both groups and had 
significantly higher means in the diabetes group in both tested shoe conditions. Jordan 
and Bartlett (1995a) also observed the occurrence of the overall dorsal PP on the 
metatarsophalangeal joints and related this to being at the flex-line of the shoes during 
walking (Jordan and Bartlett, 1995a).  
The highest dorsal PP in the orthopaedic shoes moved to the medial midfoot area (DM 
midfoot) in both groups. However, DM midfoot in the orthopaedic shoes was 
significantly lower than in the participants’ own shoes and showed significantly higher 
values in the diabetes group in both tested shoe conditions. This may be related to the lace 
effect in the orthopaedic shoes. However, the diabetes group also experienced a 
significantly higher PP on DM midfoot in their own shoes where DM midfoot was the 
second-highest PP area after DMH1. Likewise, the highest dorsal PPs were previously 
reported on the medial side of the foot dorsum in running shoes independently of the 
lacing pattern (Hagen et al., 2008, Hagen et al., 2010). This may be related to the apical 
bony structure of the medial arch of the foot. Cheng and Hong (2010) recorded a greater 
PP on the lateral side of the foot dorsum, and Mei et al. (2014) argued that lateral 
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metatarsal region would be the best site to distinguish between different sports-feature-
oriented footwears (Cheng and Hong, 2010, Mei et al., 2014). However, Cheng and Hong 
(2010) used the flexible individual FSA sensors which are sensitive to folding causing 
measurement errors (Herbaut et al., 2016). MF had the same highest values sites as PP, 
however, DM midfoot showed no significant differences in MF between the two shoes in 
the control group and DMH1 showed no significant differences between groups in their 
own shoes. Both tested shoe conditions had the highest PTI on DM midfoot that was 
significantly higher in own shoes in both study groups. Midfoot areas had the largest 
dorsal CA within both shoes in the two study groups. Significantly higher values were 
seen in the orthopaedic shoes on the two midfoot areas in the control group and area DL 
midfoot in the diabetes group, while DM midfoot within own shoes had the only 
significant differences between groups on the midfoot. These results confirm previous 
work that dorsal pressure data varies depending on the fit between the foot and the tested 
footwear at each anatomical point/foot region (Jordan et al., 1997, Olaso et al., 2007, 
Rupérez et al., 2009). Therefore, the distinction between different footwear designs and 
attempts to improve them are possible through the study of the pressures caused by the 
footwear upper. 
The shoe upper design and properties can affect how loads, such as the majority of 
anterior and lateral forces acting on the foot during gait, are applied to the foot. Therefore, 
the shoe upper plays a critical role in maintaining comfort and preventing foot injury 
(Greenhalgh et al., 2012, Melvin, 2014). Yet foot pressure exerted by the shoe upper is 
one of the least studied (Olaso et al., 2007). Comfort perception usually reflects an 
appropriate footwear fit which is essential in vulnerable feet as those in patients with 
diabetes. A sensation of discomfort forewarns of potentially harmful situations such as 
excessive pressure which can lead to tissue damage or ulceration. Unfortunately, patients 
with diabetic foot are usually lacking this protective signal due to the development of 
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peripheral neuropathy. Additionally, comfort perception and discomfort threshold are 
very subjective and difficult to define or quantify. Most literature which investigated 
dorsal foot pressure attempted to relate the exerted pressure to footwear comfort 
perception (Jordan and Bartlett, 1995, Hagen et al., 2010, Herbaut et al., 2016). Dorsal 
pressure was thought to provide an objective measurement for comfort perception as well 
as a validated tool for a good shoe fit, as traditional methods in measuring foot size are 
insufficient to determine good footwear fit which is particularly critical in high-risk feet 
such as diabetic foot (Cheng and Hong, 2010). Despite the fact that 37% to 59% of 
diabetic foot ulcers in patients suffering from multiple foot ulcerations were seen in dorsal 
areas (Eneroth et al., 2004, Greenhalgh et al., 2012), no known study has examined the 
impact of the shoe upper and dorsal pressure in diabetic foot and the best shoe upper 
design to reduce foot injury in this vulnerable population.  
A comfortable fit in the orthopaedic shoes was perceived by subjects in both study groups 
which supports the significant negative correlations between dorsal PP and perceived 
comfort reported in earlier studies (Jordan et al., 1997, Cheng and Hong, 2010, Hagen et 
al., 2010, Herbaut et al., 2016). Jordan et al. (1997) tested 10 shoes, classified in two 
groups; 5 models were considered comfortable shoes and 5 as uncomfortable. They 
recorded dorsal pressure on the flex line and the lace areas of the dorsum of the foot and 
noted significantly higher PP and MF in the uncomfortable shoe group. However dorsal 
CA was significantly lower in the comfortable shoe group which is different from our 
findings in the orthopaedic shoes although retain a lower dorsal PP (Jordan et al., 1997). 
Alternatively, Jordan and Bartlett (1995b) noted that the decrease in comfort experienced 
with the shoe upper was accompanied by decreased forces and pressures, although no 
significant differences in dorsal PP and MF were found between the three shoes they 
tested (Jordan and Bartlett, 1995b). They attributed this relationship to the shoes upper’s 
inflexibility which did not allow the shoes to crease and exert pressure on the foot, and it 
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was this that had been perceived as decreased comfort. However, they also highlighted 
the low sampling frequency of the dorsal pad they used could have caused actual PP and 
MF to be missed. Others found no significant correlation between perceived comfort and 
dorsal pressure data (Hagen et al., 2008). However, a significant relationship was noted 
between dorsal PP and perceived stability which may have been the most valuable 
element that runners (tested population) would favour to prevent slipping within the shoe, 
hence reduce risk of injury. 
The current study examined the timing of dorsal PP during the gait cycle which showed 
no significant differences between the two tested shoes in both study groups. Also, there 
was no significant difference between groups in both shoe conditions. The frequency of 
occurrence of dorsal PP showed a two peaks pattern with an increase at initial 
contact/loading response as well as pre-swing/initial swing phases. Similar timing for an 
increase in dorsal PP was noted by Takesue et al. (2019) who used FlexiForce® sensors 
to record dorsal pressure and a footswitch for synchronisation of dorsal pressure with the 
phases of the gait cycle (Takesue et al., 2019). Earlier work of Jordan and Bartlett (1995a) 
described two dorsal force activities; a lower activity exerted just before the foot contacts 
the ground and a second higher force just prior to the foot leaving the ground (Jordan and 
Bartlett, 1995a). In the current study, the timing of dorsal MF peaks frequencies followed 
a similar pattern as PP. Shoe deformation with dorsiflexion of the foot in these phases of 
the gait cycle could be the reason for these two peaks. A significant difference in the time 
of dorsal PP between the two tested shoes was noted when using all participants’ data as 
one group with more frequent peaks occurring within the orthopaedic shoes at a late point 
in the swing phase. These observations endorse the significance of dorsal pressure 
assessment, being also present during the non-contact phase of the gait cycle. 
It is well-known that the choice of shoe upper can affect the comfort of a shoe, however, 
it is not known which of its properties has this effect. It could be the upper’s shape, the 
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volume it creates for the foot inside the shoe or the properties of the composition material 
that affect pressure and comfort (Melvin, 2014). Currently, orthotists, clinicians, and 
other professionals’ experience and judgment continue to be the mean for shoe upper’s 
provision to accommodate the foot in patients who cannot give adequate feedback for a 
good shoe fit (Olaso et al., 2007). However, dorsal pressure data would be more valuable 
in providing relevant information for footwear designers and manufacturers attempting 
to improve the comfort of their footwear. Identification of areas on the dorsum of the foot 
experiencing high PP can improve different features of footwear construction. For 
example, alterations based on pressure measurements in the material used in the shoe 
upper, the lacing system, or the protective footwear enhancements can assist in reducing 
the magnitude of dorsal pressure, and thus discomfort and injuries at various anatomical 
locations particularly in those with vulnerable feet. 
5.2.2 Plantar Pressure 
In-shoe plantar pressure measurement has been commonly used in both research and 
clinical settings, to effectively assess pressures experienced by patients who are at risk 
from a variety of foot problems including patients with diabetes mellitus (Cavanagh et 
al., 1992, Guldemond et al., 2007, Bacarin et al., 2009, Owings et al., 2009, Sacco et al., 
2009, Ledoux et al., 2013). It offers the advantage of collecting continuous, real life 
pressure data in subjects with vulnerable feet such as diabetic neuropathy who are mostly 
advised to always wear their footwear during daily activities to better distribute loads and 
reduce the chance of external trauma to their feet. Therefore, the current study favoured 
in-shoe plantar pressure measurement as it offers a more indicative, valid and reliable 
mean for plantar pressure assessment. 
The current study showed a significantly higher total in-shoe plantar PP within 
participants’ own shoes in both study groups. However, the differences were significant 
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in one foot area (PT1) in the diabetes group and area PM midfoot had even a significantly 
higher PP within the orthopaedic shoes than own shoes in the control group. Also, heel 
areas, a major concern site in diabetic foot (Younes et al., 2004), showed no significant 
differences between the two tested shoes in both study groups. Total plantar PTI showed 
no significant differences between the two shoes in the control group, although, medial 
plantar areas under toes, midfoot and heel were significantly higher in the orthopaedic 
shoes. The diabetes group, on the other hand, had a significantly higher total PTI within 
the orthopaedic shoes and the same relationship was seen across most of the foot areas 
except for the midfoot areas which were not significantly different between the two tested 
shoes in this study group. These minimal significant differences in PP seen in the diabetes 
group together with the significantly lower PTI in diabetes group’ own shoes could be 
explained by patients’ careful selection of their shoes due to their potential awareness of 
diabetic foot complications. Additionally, none of the participants in this study was 
known to have or show any signs of neuropathy which could have altered the perception 
of high loads. 
Examining differences between groups in own shoe revealed, no significant difference in 
total PP, although, midfoot areas were significantly higher in diabetes groups and lateral 
areas under the toes and metatarsal heads were significantly higher in the control group. 
Orthopaedic shoes showed a significantly higher total PP in the diabetes group compared 
to the control group. The same significant differences were seen in most of the plantar 
foot areas in the orthopaedic shoes, except the toes areas which were significantly higher 
in the control group. Yet, diabetes group displayed no deformity or signs of neuropathy, 
which would reinforce the previous finding that abnormalities in plantar pressure may 
precede clinical signs of diabetic neuropathy (Pataky et al., 2005, Tong et al., 2011). 
Similar to PP, no significant difference was detected in total PTI between groups in own 
shoes and the midfoot areas had significantly higher PTI in the diabetes group within own 
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shoes. The own shoes also showed a significantly higher PTI under the 1st metatarsal head 
in patients with diabetes while the 4th metatarsal area and all toes areas were significantly 
higher in the control group. The differences between groups in PTI within the orthopaedic 
shoes followed the same relationship as the PP, although the three medial metatarsal 
heads’ areas were significantly higher in diabetes group than control group within the 
orthopaedic shoes. Plantar CA generally demonstrated no significant differences across 
different comparison setting, with the only significant difference found in the diabetes 
group within own shoes under the medial midfoot area. The reduction in plantar pressure 
under the toes areas in the diabetes group in this study has been a frequent observation 
when compared with non-diabetes controls (Stokes et al., 1975, Ctercteko et al., 1981, 
Veves et al., 1991, Bacarin et al., 2009). The diabetes group also continued to 
demonstrate a shift of PP from the big toe to the first metatarsal head, which is one of the 
most likely sites to ulcerate (Plank et al., 2000, Bacarin et al., 2009, Dayer. and Assal., 
2009). Although PP under the 1st metatarsal head, a common location for plantar 
ulceration, showed no significant differences between groups in the two tested shoes, PTI 
was significantly higher within both shoes in the diabetes group. This emphasises the 
importance of evaluating not only PP but also its cumulative effect over time represented 
in PTI values as ulcer development can be influenced by the magnitude of pressure as 
well as the time of exposure to that pressure (Hsi et al., 2002). In fact, the current study 
finding could indicate that PTI may be the first detectable sign for plantar pressure 
changes even before PP increase or peripheral neuropathy can be tested (Tong et al., 
2011). Alternatively, heel areas, another common site for ulceration, retained the highest 
PP and PTI within the orthopaedic shoes which were significantly higher in the diabetes 
group than the control. PTI is increasingly used in evaluating plantar loading with high 
interdependency noted between PTI and PP (Keijsers et al., 2010, Waaijman and Bus, 
2012). However, the added value of PTI reporting was debatable in the literature and 
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changes in PTI can be affected by walking speed which was not recorded or standardised 
in the current study (Bus and Waaijman, 2013). 
Whole plantar surface MF showed no significant differences between the two tested shoes 
in the diabetes group, although midfoot areas were significantly higher within own shoes. 
The control group had a significantly higher total MF within the orthopaedic shoes that 
was only detected in the lateral heel area. The diabetes group recorded significantly higher 
MF than the control group in both tested shoe conditions. This was observed across 
different plantar areas except the toes which maintained a significantly lower MF. Highest 
MFs were recorded under the heel areas thus, even with significantly higher MF recorded 
in diabetes, MF distribution pattern was not yet different from the control group. Diabetic 
patients with neuropathy begin to exert extra force at the forefoot due to the subsequent 
impaired joint mobility, especially at the ankle joint, and intrinsic muscles atrophy 
(Srinivasan et al., 2001, Rahman et al., 2006). 
The tested orthopaedic shoes were an off-the-shelf selection with no insole modifications 
which are usually added in orthotic clinics. Yet, it was not expected to show the 
significantly high overall plantar PP and PTI in the diabetes group where no significant 
differences were noted between the study groups within participants’ own shoes. The 
diabetes group in this study, even with no neuropathy signs or symptoms, showed a 
reduction in pressure under the toes area. However, they continued to experience the same 
highest plantar pressure under the heel area as in the control group with no anterior 
displacement. This finding has frequently been described in earlier research works in 
particular with diabetic neuropathy (Caselli et al., 2002, Grimm et al., 2004, Pataky et 
al., 2005, Bacarin et al., 2009). 
The findings of the current study confirm the essential need for pressure measurement as 
a reliable screening tool to achieve effective offloading and optimise the production of 
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footwear tailored for patients with diabetes to assist in foot ulcers prevention (Bus et al., 
2011, Bus et al., 2016b, Jorgetto et al., 2019, Chatwin et al., 2020). 
5.3 IMPACT OF PRESSURE ON ENDOTHELIAL RESPONSE  
5.3.1 Introduction 
Mechanical stress related to prolonged and/or high externally applied pressure, leading to 
local ischaemia and subsequent damage, has been an important contributing factor to skin 
breakdown. Likewise, impairment in the blood flow response to mechanical stimuli is a 
key risk factor in the development of ulcers. Therefore, daily activities such as the simple 
act of walking, which involves repetitive mechanical trauma, may further damage skin 
microcirculation, including the endothelium, thus increasing the risk of ulceration. 
Diabetic foot has a multifactorial pathology and both increased plantar pressures, as well 
as the alteration in the local microvascular reactivity, have been found to be associated 
with diabetic foot ulceration (Fromy et al., 2002, Koïtka et al., 2004, Patry et al., 2013, 
Yih-Kuen et al., 2013, Pu et al., 2018). 
Flynn (2014) investigated the relationship between walking barefoot plantar pressures 
across six areas of the forefoot with the baseline flux measured with LDF in each of these 
areas in a group of 60 subjects with and without Type 2 diabetes. No significant 
association was found. There were no significant differences in barefoot PP or baseline 
flux between Flynn’s study groups and the author concluded that walking plantar pressure 
values did not influence the baseline resting perfusion, thus areas which experienced 
higher pressure during walking did not show altered perfusion when unloaded (Flynn, 
2014).  In the current study, negative correlations were generally noted between PP within 
the two tested shoes and blood flow parameters on dorsal and plantar surfaces of the foot 
in both study groups. However, the significant associations detected on the dorsal surface 
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may have been related to an outlier effect, and not a true reflection of the relation between 
PP and blood flow parameters. Therefore, Spearman rank correlation revealed no 
significant correlation between PP and changes in blood flow in response to acetylcholine 
and sodium nitroprusside under any of the testing conditions on dorsal or plantar surfaces 
in both study groups. This also agrees with the findings of Pu et al. (2018) who could not 
establish any significant correlation between in-shoe PP under the first metatarsal head 
and blood flow response to the accumulated pressure stimulus induced through walking 
on a treadmill in a group of 19 Type 2 diabetes patients with different peak plantar 
pressures. However, their study examined only one level of pressure stimulation and had 
limitations due to the large individual differences and small sample size (Pu et al., 2018). 
The current study simulated the premeasured dorsal and plantar in-shoe walking PPs to 
examine the influence of each foot surface’s pressure on its microvascular response to the 
iontophoresis of ACh, an endothelium-dependent vasodilator and SNP, an endothelium-
independent vasodilator. 
5.3.2 Impact of Loading Pressure on Endothelial Function on Dorsal Surface 
Both study groups showed a significant reduction in blood flow response to the 
iontophoresis of ACh and SNP when own shoes, as well as orthopaedic shoes pressure 
values, were applied on the dorsum of the foot. Although own shoes dorsal PP was 
significantly higher than orthopaedic shoes’ PP in both study groups, the control group 
showed a significantly higher change in ACh and SNP response under the orthopaedic 
shoes’ dorsal PP while the diabetes group only recorded a significant change in response 
with SNP use. The only significant difference between groups in changes in blood flow 
response under no pressure, own shoes PP and orthopaedic shoes PP on the dorsum of the 
foot was in flux change in response from baseline to the iontophoresis of ACh under no 
pressure, with a significantly higher change in response recorded in the control group. 
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There were no significant differences with ACh under own shoes’ PP and orthopaedic 
shoes’ PP, in addition to the no significant differences in response to SNP under any of 
the three pressure conditions. This goes with the no significant differences between 
groups in dorsal PP within the two tested shoes. However, these findings show an 
impairment in ACh endothelium-dependent vasodilation response on the foot dorsum in 
the diabetes group.  This demonstrates that the diabetes group could not achieve the same 
reactivity as the control under the significantly lower orthopaedic PP alongside the 
reduced ACh response in the resting condition. Even with no known complications 
amongst the study subjects, diabetes mellitus has altered the ability of the endothelium to 
react to ACh. 
Although no known study has investigated the simultaneous impact of dorsal PP 
application and blood flow response, there are a number of studies which agree with the 
current study findings that endothelium-dependent vasodilation response to iontophoresis 
of ACh was reduced in diabetic patients, particularly those without neuropathy, while the 
non-endothelium-dependent response to SNP was still preserved (Pitei et al., 1997, Arora 
et al., 1998, Hamdy et al., 2001, Koïtka et al., 2004). This emphasises the possibility of 
the early endothelium functional impairment in diabetes that can precede any structural 
changes affecting the vascular smooth muscle cells function, tested in the response to the 
endothelium-independent vasoactive agent, SNP (Johnstone et al., 1993, Vehkavaara et 
al., 1999, Singh et al., 2003, Schramm et al., 2006). Other investigators evaluated skin 
microvascular function on the dorsum of the foot and found early reductions in 
endothelium-dependent and independent responses, prior to any clinical presentation of 
macrovascular or microvascular complications. (Veves et al., 1998, Khan et al., 2000). 
Endothelium-dependent vasodilation is an important element in the inflammatory 
response involved in wound healing as well as the ability of the body to deal with local 
infection which can, in turn, lead to ulceration and gangrene. Therefore, this functional 
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ischaemia which has been expressed in the impaired ability of the microvasculature to 
efficiently produce endothelium-dependent vasodilation in response to mechanical stress, 
detected in the diabetes group, would play an important role in the predisposition of 
ulceration and the development of complications on the foot dorsum in patients with 
diabetes. 
5.3.3 Impact of Loading Pressure on Endothelial Function on Plantar 
Surface 
Both study groups showed a similar response on the plantar as that detected on the foot 
dorsum. When pressure values in both own shoes and orthopaedic shoes were applied 
there were a significant reduction from the resting (no pressure) blood flow response to 
the iontophoresis of ACh and SNP. Flynn (2014) noted the significant reduction in 
endothelial response to the iontophoresis of ACh and SNP started to occur even with the 
application of 50% of the barefoot plantar pressure. Further addition of the full (100%) 
walking pressure did not significantly reduce the blood flux from 50% pressure response 
(Flynn, 2014). 
Plantar PP in the current study was significantly higher within own shoes than orthopaedic 
shoes in both study groups. However, the control group had no significant differences in 
blood flow changes in response between own shoes and orthopaedic shoes plantar PP 
application with ACh as well as SNP.  The diabetes group maintained the same response 
on the plantar surface as they did on the dorsal surface. No significant differences found 
in the change in response from baseline in the diabetes group between the applications of 
the two shoes plantar PPs with ACh and a significantly higher change in response to SNP 
was noted under the orthopaedic shoes’ PP than the own shoes’ PP. However, Flynn 
(2014) noted a reduced capacity of the group with Type 2 diabetes to achieve 
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vasodilatation in response to SNP iontophoresis under plantar PP than the control group 
could do (Flynn, 2014). 
The diabetes group in the current study showed significantly higher blood flux values 
than the control group on the plantar surface in response to ACh iontophoresis in 
resting/no pressure, under orthopaedic PP and own shoes PPs. However, no significant 
differences from the control group were detected in changes in response from baseline 
flux with the iontophoresis of ACh as well as SNP under all three pressure conditions. 
The significantly higher flux values in the diabetes group were more apparent under the 
own shoes plantar PP with ACh iontophoresis as well as SNP but to a lesser extent with 
SNP than ACh. Yet, own shoes plantar PP demonstrated no significant differences 
between the study groups and the diabetes group experiencing a significantly higher 
plantar PP than the control group within the orthopaedic shoes. Flynn (2014) recorded no 
significant differences in barefoot plantar PP between study groups, however, Type 2 
diabetes group also maintained higher flux values than control throughout the delivery of 
pressure, at resting flux, 50% pressure and 100% pressure delivery with both vasoactive 
agents (Flynn, 2014). Current study’s findings also agree with Newton et al. (2005) who 
conducted a pilot study to investigate the effect of local pressure on microvascular 
function in the diabetic foot. Subjects with diabetes in their study displayed higher plantar 
pressures than the control group, as demonstrated within the orthopaedic shoes in the 
current study, but no significant difference was found in ACh response (Newton et al., 
2005). 
Significantly higher blood flux values on the plantar surface in the diabetes group than 
control were previously recorded by Cobb and Claremont (2002). These substantially 
elevated levels of blood flux in the diabetes group may suggest an over-perfused plantar 
tissue that may not blanch to the same extent as in control subjects. This indicates the 
inability of the plantar surface microcirculation in diabetic patients to adapt to dynamic 
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changes taking place during normal daily loading as in walking (Cobb and Claremont, 
2002). Impaired pressure-induced vasodilation and ineffective unloading response were 
previously reported in the foot of subjects with diabetes (Petrofsky et al., 2009). Damage 
of sympathetic fibres, an early component of diabetic neuropathy that can precede any 
clinical presentation, could have impacted the plantar surface microvascular 
haemodynamics including increased arteriovenous shunt flow and nutritive capillary flow 
at rest (Tooke and Brash, 1996). That could have resulted in the current study 
observations of increased blood flow recorded with diabetes group in comparison to 
control. 
Chronically raised plantar pressure areas in the diabetic foot can demonstrate an increase 
in the skin blood flow, compared with lower pressure areas on the same foot (Newton et 
al., 2005). This was thought to be a physiological response to repeated tissue trauma from 
the high pressure which could lead to the development of local inflammatory response in 
diabetic foot (Flynn, 2014). In the current study, no significant differences were detected 
between groups in the blood flux change in response to ACh as well as SNP from baseline 
on the plantar surface in resting/under no pressure, under orthopaedic PP or own shoes 
PP. However, high‐pressure plantar areas with increased blood flow have previously 
shown a reduced responsiveness of the endothelium‐dependent vasodilatation by ACh 
iontophoresis when compared with low pressure sites on the foot of patients with diabetes. 
(Newton et al., 2005). Therefore, further work is required to determine whether, and 
under what conditions, this additional hyperaemia in the diabetes group is protective or 
maladaptive. 
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5.4 CONTRIBUTION TO KNOWLEDGE 
This study successfully investigated dorsal foot pressure and evaluated the impact of 
pressure application on the dorsal as well as the plantar surfaces of the foot in a group 
with diabetes and a control group of subjects with no diabetes. 
Also, the results from the simultaneous investigation of endothelial function during 
pressure loading will add to the understanding of the interaction and the implications 
related to two of the major factors involved in the development of ulceration associated 
with diabetes: pressure alteration and endothelial dysfunction. 
The findings from the investigation of dorsal foot pressure distribution and its impact will 
benefit the design of future therapeutic footwear in-order to better prevent diabetic foot 
ulceration. 
5.5 LIMITATIONS OF THE STUDY  
Recruitment of subjects with Type 2 Diabetes was facilitated by the Scottish Diabetes 
Research Network (SDRN). However, the older age of the recruited participants with 
diabetes resulted in difficulty in recruiting non-diabetic volunteers from the same age 
group, due to the prerequisite commitment to our lengthy protocol. Thus, the number of 
recruited subjects was limited because of the study time constraint. 
It would have been preferred to collect all blood flow data on the same day to guarantee 
that all circumstances that can affect the blood flow response, such as food and caffeine 
intake, for each subject are identical for all the testing components. However, due to our 
lengthy iontophoresis protocol and the potential stress of long fasting associated with the 
study procedures particularly with diabetes group, the decision was made to collect data 
over two visits, yet participants still considered it a lengthy procedure. Therefore, possible 
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subject boredom and confined movement for a long duration may have caused some 
mental stimulation that may have affected the blood flux values. 
Defining areas with high pressures on each foot surface then evaluating the blood flow 
response under different pressure conditions at each of these areas, would have offered 
better comparable findings. However, in order to test the same area on the foot surface 
with the three pressure conditions, a recovery interval would have been required for the 
vasoactive agent to clear away. That would have further lengthened the testing sessions. 
Therefore, a different area was used for each testing condition to avoid any residual 
effects on the next element of the assessment. 
Carrying out measurements with subjects in the supine position may have not fully 
represented the blood flow as when the limb is dependent and loaded with the in-shoe 
walking pressure. However, this allowed the collection of data with minimal movement 
artefacts and to conduct the pressure loading simultaneously with the process of 
iontophoresis and blood flux measurement. 
The foot was stabilised in a boot to limit any movement with the addition of pressure and 
subjects were instructed to lie still at all times. Yet small movements were still possible 
and may have caused some artefacts in the LDF recording during the assessment. Also, 
the actual pressure value transferred through the pressure delivery equipment could have 
been altered. 
Every effort was taken to control the testing environment and clear written instructions 
were provided in which subjects were instructed to refrain from food and caffeine related 
drinks prior to assessment. However, there was no guarantee that participants followed 
the instructions or no evocation of mental stimulation or discomfort during the long 
testing period. All could have had an influence on the blood flow response and produced 
error in the flux readings obtained. 
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Although, one researcher conducted all testing procedures with prior training and every 
care was taken to limit possible errors, there is still a possible source of human error. 
5.6 SUGGESTIONS FOR FUTURE RESEARCH 
Including the low dorsal pressure, all PP values used in this study resulted in a significant 
reduction of blood flow response. It would be valuable to investigate different portions 
of PP measured on each foot surface in-order to detect the pressure threshold when these 
significant changes begin to occur. Also, further work could be undertaken to conduct a 
comparison between the microvascular response at foot areas with increased pressure and 
those experiencing lower pressures on both aspects of the foot. 
The diabetes group involved in this study were free from complications. It would be 
beneficial to investigate a larger and more variable group of patients with diabetes 
including subjects who are known to present with neuropathy and/or previous ulceration. 
Also, a larger sample containing more subjects of each gender would help in studying the 
influence of gender on the study outcomes. 
An interesting area of further study would be to investigate comfort in therapeutic 
footwear as most of the previous work was conducted on sport and casual footwear. 
Comfort is an important factor that influences diabetic patients’ compliance and 
adherence to the use of such footwear, which is essential to achieve their purpose of 
pressure relief and ulcer prevention (Maciejewski et al., 2004, Jorgetto et al., 2019). 
Finally, it would be interesting to conduct a prospective study on the effect of custom-
made footwear, designed to take into consideration a pre-assessment of the subject’s 
dorsal and plantar foot pressure distribution, on the development of the first ulcer and re-
ulceration prevention. 
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CONCLUSION 
The current study has investigated foot pressure experienced on both dorsal and plantar 
surfaces of the foot within participants’ own comfortable shoes and when wearing 
orthopaedic footwear, commonly prescribed for at-risk patients with diabetes. Findings 
were compared between subjects with Type 2 Diabetes Mellitus with no foot 
complications and an age-matched control group of subjects with no diabetes. 
There were no significant differences between the two study groups in dorsal PP within 
the orthopaedic shoes as well as in participants’ own shoes. However, both study groups 
had a significantly higher dorsal PP in their own shoes when compared with the 
orthopaedic shoes. The same relationship was noted in dorsal surface PTI and MF. Dorsal 
CA also showed no significant differences between groups in both tested shoe conditions. 
However, a significantly larger CA was recorded in the orthopaedic shoes in both study 
groups. 
Timing of the dorsal PP during the gait cycle showed no significant differences between 
the two tested shoes in both study groups as well as between groups in both shoe 
conditions. The frequency of occurrence of dorsal PP showed a two peaks pattern with an 
increase at initial contact/loading response then at pre-swing/initial swing phases. A 
significant difference in the time of dorsal PP between the two tested shoes was noted 
when combining all participants’ data as one group. More frequent peaks occurred later 
in the swing phase within the orthopaedic shoes. Shoe deformation with dorsiflexion of 
the foot during these phases of the gait cycle could be the reason for these two peaks. 
The own shoes showed no significant differences between groups in total planter PP, 
although, midfoot areas were significantly higher in diabetes groups and lateral areas 
under toes and metatarsal heads were significantly higher in the control group. 
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Orthopaedic shoes showed a significantly higher total plantar PP in the diabetes group 
compared to the control group. 
A significantly higher total in-shoe plantar PP within participants’ own shoes was noted 
in both study groups. However, this significant difference was apparent in one foot area 
in the diabetes group and the medial midfoot area had a significantly higher PP within the 
orthopaedic shoes in the control group. 
Although orthopaedic footwear significantly reduced in-shoe pressure, pressure 
measurement would be a crucial prerequisite to adjust shoe design as well as insole 
requirements in-order to better distribute dorsal and plantar pressures, thus achieving 
effective offloading essential for ulcer prevention. 
Blood perfusion changes under loading pressure have been studied in response to the 
iontophoresis of acetylcholine (ACh) an endothelium-dependent vasodilator and sodium 
nitroprusside (SNP) an endothelium-independent vasodilator. Negative correlations have 
been generally noted, however, no significant associations were detected between PP and 
changes in blood flow in response to ACh or SNP under any of the testing pressure 
conditions on dorsal or plantar surfaces in both study groups. 
Both study groups have shown a significant reduction in blood flow response to the 
iontophoresis of ACh and SNP from resting/no pressure condition, under own shoes as 
well as orthopaedic shoes’ PP values on the dorsal and plantar surfaces of the foot. 
Although own shoes’ dorsal PP was significantly higher than orthopaedic shoes’ PP in 
both study groups, the control group showed a significantly higher change in response 
from baseline under the orthopaedic shoes’ dorsal PP with ACh and SNP while diabetes 
group only recorded a significant change in response with SNP use. Comparing 
differences between groups in blood flow response under no pressure, own shoes’ PP and 
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orthopaedic shoes’ PP on the dorsum of the foot revealed the only significant difference 
to be in blood flux changes in response to the iontophoresis of ACh under no pressure. 
These findings indicate an impairment in ACh endothelium-dependent vasodilation 
response on the foot dorsum in the diabetes group that would play an important role in 
the predisposition of ulceration and the development of complications on the foot dorsum. 
The diabetes group showed significantly higher blood flux values on the plantar surface 
in response to ACh iontophoresis in resting /no pressure, under orthopaedic PP and own 
shoes PPs. However, no significant differences from the control group were detected in 
changes in response from baseline flux with the iontophoresis of ACh as well as SNP on 
the plantar surface under any of the three pressure conditions. Early sympathetic 
neuropathy could have impacted the plantar surface microvascular haemodynamics and 
resulted in the increased blood flux values recorded in the diabetes group. 
Although low PP values were recorded on the foot dorsum, a significant reduction in 
blood flow response was present on applying dorsal PP. Also, the dorsal foot surface was 
more sensitive to changes related to endothelial dysfunction in patients with diabetes. 
Therefore, dorsal pressure measurement and its impact investigation can offer a reliable, 
accessible tool for the assessment of diabetic foot and should be considered in the design 
and prescription of therapeutic footwear to reduce the risk of diabetic foot ulceration. 
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Tables for results of the study protocol application 
4.2 In-Shoe Foot Pressure Assessment 
4.2.1 Peak Pressure: Table 1-4 
4.2.2 Pressure Time Integral: Tables 5-8 
4.2.3 Contact Area: Tables 9-12 
4.2.4 Maximum Force: Tables 13-16 
4.2.5 Time for Peak Pressure: Tables 17-19  
4.3 Assessment of the Impact of Pressure on Endothelial Function 
4.3.1 Comparison of Flux Values Under the Three Tested Pressure Conditions Within 
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4.3.1.2 Blood Flow Changes in Diabetes Group: Tables 28-35 
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Table 1 Comparison between Orthopaedic Shoes and Own Shoes PP (KPa) in control group using: 
Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 21.21 12.94 4.17 50 
<0.001** 
Own Shoes 31.63 23.54 4.17 88.33 
DT Lat/M2 
Orthopaedic Shoes 32.33 14.49 5.83 81.67 
<0.001** 
Own Shoes 46.76 22.60 10.83 96.67 
DMH1/M3 
Orthopaedic Shoes 30.27 13.87 5.83 63.33 
<0.001** 
Own Shoes 55.51 27.94 9.17 133.33 
DMH2/M4 
Orthopaedic Shoes 21.48 12.40 4.17 61.67 
<0.001** 
Own Shoes 40.25 27.65 5.83 121.67 
DMH3/M5 
Orthopaedic Shoes 23.12 15.65 4.17 83.33 
<0.001** 
Own Shoes 32.75 19.70 4.17 86.67 
DMH4/M6 
Orthopaedic Shoes 28.94 14.76 4.17 75.83 
<0.001** 
Own Shoes 36.24 19.12 5.83 92.5 
DMH5/M7 
Orthopaedic Shoes 23.62 13.36 6.67 58.33 
<0.001** 
Own Shoes 33.44 20.73 5 78.33 
DM midfoot/M8 
Orthopaedic Shoes 36.76 16.04 10 77.5 
0.023* 
Own Shoes 42.14 21.78 8.33 103.33 
DL midfoot/M9 
Orthopaedic Shoes 24.34 14.04 8.33 64.17 
0.009* 
Own Shoes 30.27 21.80 5.83 87.5 
PT1/ M10 
Orthopaedic Shoes 222.23 53.07 130 360 
0.164 
Own Shoes 232.48 65.52 132.5 432.5 
PT2/M11 
Orthopaedic Shoes 150.72 36.81 57.5 255 
0.043* 
Own Shoes 161.80 50.74 75 352.5 
PT3/M12 
Orthopaedic Shoes 130.38 30.83 57.5 197.5 
0.004* 
Own Shoes 142.44 36.47 67.5 250 
PMH1/M13 
Orthopaedic Shoes 218.69 49.28 130 352.5 
0.007* 
Own Shoes 241.55 82.79 97.5 542.5 
PMH2/M14 
Orthopaedic Shoes 205.95 45.68 130 310 
<0.001** 
Own Shoes 232.69 64.53 117.5 432.5 
PMH3/M15 
Orthopaedic Shoes 182.22 41.35 100 287.5 
<0.001** 
Own Shoes 224.34 70.80 102.5 432.5 
PMH4/M16 
Orthopaedic Shoes 149.58 39.38 82.5 262.5 
<0.001** 
Own Shoes 188.60 63.30 92.5 337.5 
PMH5/M17 
Orthopaedic Shoes 130.98 48.43 42.5 320 
<0.001** 
Own Shoes 160.40 68.79 55 405 
PM midfoot/M18 
Orthopaedic Shoes 63.69 28.95 7.5 145 
0.002* 
Own Shoes 53.47 24.91 10 117.5 
PL midfoot/M19 
Orthopaedic Shoes 98.48 31.28 20 187.5 
0.310 
Own Shoes 104.19 56.27 17.5 310 
PM heel/M20 
Orthopaedic Shoes 233.94 48.77 147.5 377.5 
0.814 
Own Shoes 235.61 65.30 117.5 512.5 
PL heel/M21 
Orthopaedic Shoes 235.78 46.22 140 380 
0.660 
Own Shoes 238.86 66.11 130 435 
Whole Dorsal 
surface PP (KPa) 
Orthopaedic Shoes 49.22 14.05 20 83.33 
<0.001** 
Own Shoes 70.65 23.96 25.00 133.33 
Whole Plantar 
surface PP (KPa) 
Orthopaedic Shoes 275.25 44.05 190 380 
<0.001** 
Own Shoes 307.77 72.32 202.5 542.5 
p >0.05 Not Significant (NS); *p <0.05 Significant (S); **p <0.001 Highly Significant (HS) 
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Table 2 Comparison between Orthopaedic Shoes and Own Shoes PP (KPa) in diabetes group using: 
Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 21.59 14.49 1.67 64.17 
0.222 
Own Shoes 24.65 21.59 7.5 146.67 
DT Lat/M2 
Orthopaedic Shoes 28.62 13.72 10.83 64.17 
0.009* 
Own Shoes 33.33 12.78 9.17 61.67 
DMH1/M3 
Orthopaedic Shoes 37.57 14.40 12.5 64.17 
<0.001** 
Own Shoes 65.43 32.86 25.83 162.5 
DMH2/M4 
Orthopaedic Shoes 26.99 13.60 8.33 58.33 
0.004* 
Own Shoes 33.86 20.08 5.83 100 
DMH3/M5 
Orthopaedic Shoes 21.63 8.81 4.17 47.5 
<0.001** 
Own Shoes 27.34 16.11 4.17 62.5 
DMH4/M6 
Orthopaedic Shoes 25.77 9.62 5.83 45 
<0.001** 
Own Shoes 32.49 16.04 0 74.17 
DMH5/M7 
Orthopaedic Shoes 16.59 6.61 5.83 37.5 
<0.001** 
Own Shoes 27.31 15.19 7.5 56.67 
DM midfoot/M8 
Orthopaedic Shoes 41.01 13.46 12.5 66.67 
<0.001** 
Own Shoes 52.10 24.84 20 131.67 
DL midfoot/M9 
Orthopaedic Shoes 23.94 10.27 5.83 45 
<0.001** 
Own Shoes 31.37 12.89 9.17 50.83 
PT1/M10 
Orthopaedic Shoes 195.53 58.12 87.5 355 
0.040* 
Own Shoes 215.97 84.85 47.5 412.5 
PT2/M11 
Orthopaedic Shoes 130.37 43.61 55 212.5 
0.186 
Own Shoes 139.40 55.68 47.5 307.5 
PT3/M12 
Orthopaedic Shoes 97.06 33.20 40 197.5 
0.673 
Own Shoes 95.09 35.15 25 177.5 
PMH1/M13 
Orthopaedic Shoes 232.89 66.90 117.5 402.5 
0.067 
Own Shoes 253.56 95.54 115 555 
PMH2/M14 
Orthopaedic Shoes 221.41 44.68 150 347.5 
0.140 
Own Shoes 231.23 52.35 157.5 362.5 
PMH3/M15 
Orthopaedic Shoes 189.35 44.08 110 282.5 
0.207 
Own Shoes 197.22 47.24 112.5 302.5 
PMH4/M16 
Orthopaedic Shoes 162.25 55.02 72.5 332.5 
0.477 
Own Shoes 157.38 44.73 80 292.5 
PMH5/M17 
Orthopaedic Shoes 132.06 64.56 42.5 365 
0.250 
Own Shoes 141.39 53.94 37.5 265 
PM midfoot/M18 
Orthopaedic Shoes 74.26 33.14 32.5 230 
0.444 
Own Shoes 71.00 29.35 22.5 145 
PL midfoot/M19 
Orthopaedic Shoes 116.92 52.65 52.5 332.5 
0.195 
Own Shoes 125.81 47.81 47.5 295 
PM heel/M20 
Orthopaedic Shoes 249.26 40.56 172.5 345 
0.295 
Own Shoes 242.29 55.80 155 357.5 
PL heel/M21 
Orthopaedic Shoes 257.99 45.13 167.5 467.5 
0.162 
Own Shoes 246.94 68.15 150 542.5 
Whole Dorsal 
surface PP (KPa) 
Orthopaedic Shoes 47.80 12.10 16.67 66.67 
<0.001** 
Own Shoes 73.84 33.27 28.33 162.50 
Whole Plantar 
surface PP (KPa) 
Orthopaedic Shoes 290.32 49.57 195.00 467.50 
0.006* 
Own Shoes 316.64 85.54 180.00 555.00 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 3 Comparison between control group and diabetes group PP (KPa) in Own Shoes using: 
Independent Sample t-test. 
Foot Area  
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 31.63 23.54 4.17 88.33 
0.019* 
Diabetes 24.65 21.59 7.5 146.67 
DT Lat/M2 
Control 46.76 22.60 10.83 96.67 
<0.001** 
Diabetes 33.33 12.78 9.17 61.67 
DMH1/M3 
Control 55.51 27.94 9.17 133.33 
0.012* 
Diabetes 65.43 32.86 25.83 162.5 
DMH2/M4 
Control 40.25 27.65 5.83 121.67 
0.046* 
Diabetes 33.86 20.08 5.83 100 
DMH3/M5 
Control 32.75 19.70 4.17 86.67 
0.023* 
Diabetes 27.34 16.11 4.17 62.5 
DMH4/M6 
Control 36.24 19.12 5.83 92.5 
0.106 
Diabetes 32.49 16.04 0 74.17 
DMH5/M7 
Control 33.44 20.73 5 78.33 
0.011* 
Diabetes 27.31 15.19 7.5 56.67 
DM midfoot/M8 
Control 42.14 21.78 8.33 103.33 
<0.001** 
Diabetes 52.10 24.84 20 131.67 
DL midfoot/M9 
Control 30.27 21.80 5.83 87.5 
0.642 
Diabetes 31.37 12.89 9.17 50.83 
PT1/M10 
Control 232.48 65.52 132.5 432.5 
0.090 
Diabetes 215.97 84.85 47.5 412.5 
PT2/M11 
Control 161.80 50.74 75 352.5 
<0.001** 
Diabetes 139.40 55.68 47.5 307.5 
PT3/M12 
Control 142.44 36.47 67.5 250 
<0.001** 
Diabetes 95.09 35.15 25 177.5 
PMH1/M13 
Control 241.55 82.79 97.5 542.5 
0.298 
Diabetes 253.56 95.54 115 555 
PMH2/M14 
Control 232.69 64.53 117.5 432.5 
0.850 
Diabetes 231.23 52.35 157.5 362.5 
PMH3/M15 
Control 224.34 70.80 102.5 432.5 
<0.001** 
Diabetes 197.22 47.24 112.5 302.5 
PMH4/M16 
Control 188.60 63.30 92.5 337.5 
<0.001** 
Diabetes 157.38 44.73 80 292.5 
PMH5/M17 
Control 160.40 68.79 55 405 
0.019* 
Diabetes 141.39 53.94 37.5 265 
PM midfoot/M18 
Control 53.47 24.91 10 117.5 
<0.001** 
Diabetes 71.00 29.35 22.5 145 
PL midfoot/M19 
Control 104.19 56.27 17.5 310 
0.002* 
Diabetes 125.81 47.81 47.5 295 
PM heel/M20 
Control 235.61 65.30 117.5 512.5 
0.401 
Diabetes 242.29 55.80 155 357.5 
PL heel/M21 
Control 238.86 66.11 130 435 
0.354 
Diabetes 246.94 68.15 150 542.5 
Whole Dorsal 
surface PP (KPa) 
Control 70.65 23.96 25.00 133.33 
0.389 
Diabetes 73.84 33.27 28.33 162.50 
Whole Plantar 
surface PP (KPa) 
Control 307.77 72.32 202.5 542.5 
0.384 
Diabetes 316.64 85.54 180 555 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 4 Comparison between control group and diabetes group PP (KPa) in Orthopaedic Shoes 
using: Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 21.21 12.94 4.17 50 
0.832 
Diabetes 21.59 14.49 1.67 64.17 
DT Lat/M2 
Control 32.33 14.49 5.83 81.67 
0.044* 
Diabetes 28.62 13.72 10.83 64.17 
DMH1/M3 
Control 30.27 13.87 5.83 63.33 
<0.001** 
Diabetes 37.57 14.40 12.5 64.17 
DMH2/M4 
Control 21.48 12.40 4.17 61.67 
<0.001** 
Diabetes 26.99 13.60 8.33 58.33 
DMH3/M5 
Control 23.12 15.65 4.17 83.33 
0.379 
Diabetes 21.63 8.81 4.17 47.5 
DMH4/M6 
Control 28.94 14.76 4.17 75.83 
0.056 
Diabetes 25.77 9.62 5.83 45 
DMH5/M7 
Control 23.62 13.36 6.67 58.33 
<0.001** 
Diabetes 16.59 6.61 5.83 37.5 
DM midfoot/M8 
Control 36.76 16.04 10 77.5 
0.029* 
Diabetes 41.01 13.46 12.5 66.67 
DL midfoot/M9 
Control 24.34 14.04 8.33 64.17 
0.804 
Diabetes 23.94 10.27 5.83 45 
PT1/M10 
Control 222.23 53.07 130 360 
<0.001** 
Diabetes 195.53 58.12 87.5 355 
PT2/M11 
Control 150.72 36.81 57.5 255 
<0.001** 
Diabetes 130.37 43.61 55 212.5 
PT3/M12 
Control 130.38 30.83 57.5 197.5 
<0.001** 
Diabetes 97.06 33.20 40 197.5 
PMH1/M13 
Control 218.69 49.28 130 352.5 
0.060 
Diabetes 232.89 66.90 117.5 402.5 
PMH2/M14 
Control 205.95 45.68 130 310 
0.009* 
Diabetes 221.41 44.68 150 347.5 
PMH3/M15 
Control 182.22 41.35 100 287.5 
0.198 
Diabetes 189.35 44.08 110 282.5 
PMH4/M16 
Control 149.58 39.38 82.5 262.5 
0.039* 
Diabetes 162.25 55.02 72.5 332.5 
PMH5/M17 
Control 130.98 48.43 42.5 320 
0.883 
Diabetes 132.06 64.56 42.5 365 
PM midfoot/M18 
Control 63.69 28.95 7.5 145 
0.009* 
Diabetes 74.26 33.14 32.5 230 
PL midfoot/M19 
Control 98.48 31.28 20 187.5 
<0.001** 
Diabetes 116.92 52.65 52.5 332.5 
PM heel/M20 
Control 233.94 48.77 147.5 377.5 
0.011* 
Diabetes 249.26 40.56 172.5 345 
PL heel/M21 
Control 235.78 46.22 140 380 
<0.001** 
Diabetes 257.99 45.13 167.5 467.5 
Whole Dorsal 
surface PP (KPa) 
Control 49.22 14.05 20.00 83.33 
0.409 
Diabetes 47.80 12.10 16.67 66.67 
Whole Plantar 
surface PP (KPa) 
Control 275.25 44.05 190 380 
0.013* 
Diabetes 290.32 49.57 195 467.5 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
266 
Table 5 Comparison between Orthopaedic Shoes and Own Shoes in PTI (KPa.s) in control group 
using: Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 25.34 14.19 4.52 68.23 
0.108 
Own Shoes 29.75 28.12 3.75 132.15 
DT Lat/M2 
Orthopaedic Shoes 56.47 35.63 7.65 145.92 
0.047* 
Own Shoes 70.37 71.65 4.68 369.9 
DMH1/M3 
Orthopaedic Shoes 31.54 15.44 1.38 80.05 
<0.001** 
Own Shoes 78.10 73.32 10.95 303.02 
DMH2/M4 
Orthopaedic Shoes 25.95 13.70 6.73 72.52 
<0.001** 
Own Shoes 37.29 27.65 5.67 160.62 
DMH3/M5 
Orthopaedic Shoes 21.33 20.29 0.38 109.83 
<0.001** 
Own Shoes 34.20 34.31 3.95 199.38 
DMH4/M6 
Orthopaedic Shoes 38.32 23.69 4.65 113.15 
0.380 
Own Shoes 41.67 36.84 3.32 218.4 
DMH5/M7 
Orthopaedic Shoes 39.19 25.57 5.9 113.15 
0.094 
Own Shoes 47.76 52.84 1.75 296.82 
DM midfoot/M8 
Orthopaedic Shoes 79.39 43.87 14.38 207.78 
0.032* 
Own Shoes 95.59 74.50 17.95 321.2 
DL midfoot/M9 
Orthopaedic Shoes 49.33 29.72 9.73 149.63 
0.284 
Own Shoes 54.23 43.18 10.92 194.72 
PT1/ M10 
Orthopaedic Shoes 243.13 92.40 87.85 543.9 
<0.001** 
Own Shoes 204.12 99.87 57.35 629.05 
PT2/M11 
Orthopaedic Shoes 178.29 70.72 69 413.5 
0.021* 
Own Shoes 159.14 62.73 45.15 378.85 
PT3/M12 
Orthopaedic Shoes 176.18 58.33 66.05 356.6 
0.072 
Own Shoes 163.23 58.22 48.65 332.5 
PMH1/M13 
Orthopaedic Shoes 265.03 78.56 117.35 595.4 
0.176 
Own Shoes 248.59 114.75 97.1 661.05 
PMH2/M14 
Orthopaedic Shoes 280.88 76.78 113.05 449.25 
0.077 
Own Shoes 262.57 90.09 114 536.8 
PMH3/M15 
Orthopaedic Shoes 260.99 72.47 118.95 430.15 
0.282 
Own Shoes 250.50 85.09 114.25 487.6 
PMH4/M16 
Orthopaedic Shoes 219.05 77.01 93.1 388.65 
0.172 
Own Shoes 232.58 83.41 121.85 460.5 
PMH5/M17 
Orthopaedic Shoes 217.53 81.37 57.65 425.25 
0.364 
Own Shoes 227.73 99.77 64.3 592.4 
PM midfoot/M18 
Orthopaedic Shoes 92.31 49.77 11.7 238.9 
<0.001** 
Own Shoes 69.19 36.06 4.9 168.4 
PL midfoot/M19 
Orthopaedic Shoes 166.24 60.40 41.2 309.2 
0.235 
Own Shoes 156.37 73.62 23.3 410.4 
PM heel/M20 
Orthopaedic Shoes 323.13 79.97 180.25 517.55 
0.016* 
Own Shoes 295.24 105.71 123.15 706.4 
PL heel/M21 
Orthopaedic Shoes 331.87 81.71 182.3 514.85 
0.956 
Own Shoes 332.62 133.80 144.7 754.55 
Whole Dorsal 
surface PTI (KPa.s) 
Orthopaedic Shoes 100.29 34.64 27.28 207.78 
<0.001** 
Own Shoes 144.27 83.78 33.37 369.90 
Whole Plantar 
surface PTI (KPa.s) 
Orthopaedic Shoes 367.29 74.54 216.25 595.40 
0.507 
Own Shoes 375.74 125.98 161.65 754.55 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 6 Comparison between Orthopaedic Shoes and Own Shoes in PTI (KPa.s) in diabetes group 
using: Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 30.84 28.68 1.27 185.73 
0.015* 
Own Shoes 22.40 21.32 2.07 120.77 
DT Lat/M2 
Orthopaedic Shoes 39.41 20.49 12.08 120.87 
0.054 
Own Shoes 45.96 28.54 14.68 130.07 
DMH1/M3 
Orthopaedic Shoes 38.02 14.84 14.65 76.97 
<0.001** 
Own Shoes 72.23 55.12 12.2 230.27 
DMH2/M4 
Orthopaedic Shoes 29.48 18.65 4.47 88.82 
0.328 
Own Shoes 26.92 19.66 1.32 92.53 
DMH3/M5 
Orthopaedic Shoes 20.46 10.08 2.82 44.32 
0.868 
Own Shoes 20.17 14.64 1 60.08 
DMH4/M6 
Orthopaedic Shoes 30.70 16.83 5.15 82.93 
0.975 
Own Shoes 30.78 20.09 0 91.2 
DMH5/M7 
Orthopaedic Shoes 24.96 13.19 5.05 74.98 
0.002* 
Own Shoes 33.13 23.10 5.97 99.93 
DM midfoot/M8 
Orthopaedic Shoes 106.91 61.94 18.38 246.9 
<0.001** 
Own Shoes 145.62 101.63 25.67 521.12 
DL midfoot/M9 
Orthopaedic Shoes 53.75 27.90 8.68 131.08 
<0.001** 
Own Shoes 78.77 48.45 11.8 230.43 
PT1/M10 
Orthopaedic Shoes 205.24 65.81 94 371.05 
<0.001** 
Own Shoes 169.21 77.39 29.9 429.7 
PT2/M11 
Orthopaedic Shoes 145.71 62.01 38.4 382.3 
<0.001** 
Own Shoes 120.97 50.45 43.55 308.05 
PT3/M12 
Orthopaedic Shoes 127.62 46.62 60 279.7 
<0.001** 
Own Shoes 102.71 47.85 19.9 315.75 
PMH1/M13 
Orthopaedic Shoes 290.54 75.43 154.95 508.1 
0.601 
Own Shoes 282.86 132.58 105.4 759.25 
PMH2/M14 
Orthopaedic Shoes 301.52 79.00 171.5 587.05 
0.005* 
Own Shoes 266.92 98.35 126.65 596.85 
PMH3/M15 
Orthopaedic Shoes 267.12 74.99 134.5 509.9 
<0.001** 
Own Shoes 231.35 84.94 118.25 514.35 
PMH4/M16 
Orthopaedic Shoes 230.91 84.22 77.4 468.15 
0.004* 
Own Shoes 199.80 74.00 97.4 432.65 
PMH5/M17 
Orthopaedic Shoes 211.65 105.06 48.55 432.9 
0.775 
Own Shoes 207.51 107.11 46.1 475.35 
PM midfoot/M18 
Orthopaedic Shoes 112.17 49.88 43 362.25 
0.107 
Own Shoes 100.15 58.87 11.7 228.7 
PL midfoot/M19 
Orthopaedic Shoes 203.83 79.60 87.5 442.9 
0.187 
Own Shoes 189.39 80.65 59.9 406.2 
PM heel/M20 
Orthopaedic Shoes 363.90 92.11 190.25 640.7 
0.002* 
Own Shoes 315.50 134.88 120.95 903.25 
PL heel/M21 
Orthopaedic Shoes 394.16 131.60 212.55 1001.1 
<0.001** 
Own Shoes 319.65 122.06 125.95 759.35 
Whole Dorsal 
surface PTI (KPa.s) 
Orthopaedic Shoes 111.32 58.82 25.23 246.90 
<0.001** 
Own Shoes 154.45 100.09 25.67 521.12 
Whole Plantar 
surface PTI (KPa.s) 
Orthopaedic Shoes 408.69 126.84 231.00 1001.10 
0.044* 
Own Shoes 371.86 139.76 129.95 903.25 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 7 Comparison between control group and diabetes group in PTI (KPa.s) in Own Shoes using: 
Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 29.75 28.12 3.75 132.15 
0.026* 
Diabetes 22.40 21.32 2.07 120.77 
DT Lat/M2 
Control 70.37 71.65 4.68 369.9 
<0.001** 
Diabetes 45.96 28.54 14.68 130.07 
DMH1/M3 
Control 78.10 73.32 10.95 303.02 
0.492 
Diabetes 72.23 55.12 12.2 230.27 
DMH2/M4 
Control 37.29 27.65 5.67 160.62 
<0.001** 
Diabetes 26.92 19.66 1.32 92.53 
DMH3/M5 
Control 34.20 34.31 3.95 199.38 
<0.001** 
Diabetes 20.17 14.64 1 60.08 
DMH4/M6 
Control 41.67 36.84 3.32 218.4 
0.006* 
Diabetes 30.78 20.09 0 91.2 
DMH5/M7 
Control 47.76 52.84 1.75 296.82 
0.008* 
Diabetes 33.13 23.10 5.97 99.93 
DM midfoot/M8 
Control 95.59 74.50 17.95 321.2 
<0.001** 
Diabetes 145.62 101.63 25.67 521.12 
DL midfoot/M9 
Control 54.23 43.18 10.92 194.72 
<0.001** 
Diabetes 78.77 48.45 11.8 230.43 
PT1/M10 
Control 204.12 99.87 57.35 629.05 
0.003* 
Diabetes 169.21 77.39 29.9 429.7 
PT2/M11 
Control 159.14 62.73 45.15 378.85 
<0.001** 
Diabetes 120.97 50.45 43.55 308.05 
PT3/M12 
Control 163.23 58.22 48.65 332.5 
<0.001** 
Diabetes 102.71 47.85 19.9 315.75 
PMH1/M13 
Control 248.59 114.75 97.1 661.05 
0.033* 
Diabetes 282.86 132.58 105.4 759.25 
PMH2/M14 
Control 262.57 90.09 114 536.8 
0.722 
Diabetes 266.92 98.35 126.65 596.85 
PMH3/M15 
Control 250.50 85.09 114.25 487.6 
0.084 
Diabetes 231.35 84.94 118.25 514.35 
PMH4/M16 
Control 232.58 83.41 121.85 460.5 
0.002* 
Diabetes 199.80 74.00 97.4 432.65 
PMH5/M17 
Control 227.73 99.77 64.3 592.4 
0.132 
Diabetes 207.51 107.11 46.1 475.35 
PM midfoot/M18 
Control 69.19 36.06 4.9 168.4 
<0.001** 
Diabetes 100.15 58.87 11.7 228.7 
PL midfoot/M19 
Control 156.37 73.62 23.3 410.4 
<0.001** 
Diabetes 189.39 80.65 59.9 406.2 
PM heel/M20 
Control 295.24 105.71 123.15 706.4 
0.193 
Diabetes 315.50 134.88 120.95 903.25 
PL heel/M21 
Control 332.62 133.80 144.7 754.55 
0.438 
Diabetes 319.65 122.06 125.95 759.35 
Whole Dorsal surface 
PTI (KPa.s) 
Control 144.27 83.78 33.37 369.90 
0.392 
Diabetes 154.45 100.09 25.67 521.12 
Whole Plantar surface 
PTI (KPa.s) 
Control 375.74 125.98 161.65 754.55 
0.821 
Diabetes 371.86 139.76 129.95 903.25 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 8 Comparison between control group and diabetes group in PTI (KPa.s) in Orthopaedic Shoes 
using: Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 25.34 14.19 4.52 68.23 
0.054 
Diabetes 30.84 28.68 1.27 185.73 
DT Lat/M2 
Control 56.47 35.63 7.65 145.92 
<0.001** 
Diabetes 39.41 20.49 12.08 120.87 
DMH1/M3 
Control 31.54 15.44 1.38 80.05 
<0.001** 
Diabetes 38.02 14.84 14.65 76.97 
DMH2/M4 
Control 25.95 13.70 6.73 72.52 
0.092 
Diabetes 29.48 18.65 4.47 88.82 
DMH3/M5 
Control 21.33 20.29 0.38 109.83 
0.682 
Diabetes 20.46 10.08 2.82 44.32 
DMH4/M6 
Control 38.32 23.69 4.65 113.15 
0.005* 
Diabetes 30.70 16.83 5.15 82.93 
DMH5/M7 
Control 39.19 25.57 5.9 113.15 
<0.001** 
Diabetes 24.96 13.19 5.05 74.98 
DM midfoot/M8 
Control 79.39 43.87 14.38 207.78 
<0.001** 
Diabetes 106.91 61.94 18.38 246.9 
DL midfoot/M9 
Control 49.33 29.72 9.73 149.63 
0.241 
Diabetes 53.75 27.90 8.68 131.08 
PT1/M10 
Control 243.13 92.40 87.85 543.9 
<0.001** 
Diabetes 205.24 65.81 94 371.05 
PT2/M11 
Control 178.29 70.72 69 413.5 
<0.001** 
Diabetes 145.71 62.01 38.4 382.3 
PT3/M12 
Control 176.18 58.33 66.05 356.6 
<0.001** 
Diabetes 127.62 46.62 60 279.7 
PMH1/M13 
Control 265.03 78.56 117.35 595.4 
0.011* 
Diabetes 290.54 75.43 154.95 508.1 
PMH2/M14 
Control 280.88 76.78 113.05 449.25 
0.042* 
Diabetes 301.52 79.00 171.5 587.05 
PMH3/M15 
Control 260.99 72.47 118.95 430.15 
0.521 
Diabetes 267.12 74.99 134.5 509.9 
PMH4/M16 
Control 219.05 77.01 93.1 388.65 
0.256 
Diabetes 230.91 84.22 77.4 468.15 
PMH5/M17 
Control 217.53 81.37 57.65 425.25 
0.626 
Diabetes 211.65 105.06 48.55 432.9 
PM midfoot/M18 
Control 92.31 49.77 11.7 238.9 
0.002* 
Diabetes 112.17 49.88 43 362.25 
PL midfoot/M19 
Control 166.24 60.40 41.2 309.2 
<0.001** 
Diabetes 203.83 79.60 87.5 442.9 
PM heel/M20 
Control 323.13 79.97 180.25 517.55 
<0.001** 
Diabetes 363.90 92.11 190.25 640.7 
PL heel/M21 
Control 331.87 81.71 182.3 514.85 
<0.001** 
Diabetes 394.16 131.60 212.55 1001.1 
Whole Dorsal surface 
PTI (KPa.s) 
Control 100.29 34.64 27.28 207.78 
0.072 
Diabetes 111.32 58.82 25.23 246.90 
Whole Plantar 
surface PTI (KPa.s) 
Control 367.29 74.54 216.25 595.40 
0.002* 
Diabetes 408.69 126.84 231.00 1001.10 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 9 Comparison between Orthopaedic Shoes and Own Shoes in CA (cm2) in control group using: 
Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 7.58 0.97 5.09 8.50 
0.892 
Own Shoes 7.59 0.95 5.58 8.50 
DT Lat/M2 
Orthopaedic Shoes 7.69 0.78 6.82 8.62 
0.244 
Own Shoes 7.80 0.77 6.82 8.62 
DMH1/M3 
Orthopaedic Shoes 12.33 2.21 2.78 14.53 
0.683 
Own Shoes 12.44 1.79 8.41 14.53 
DMH2/M4 
Orthopaedic Shoes 11.62 2.24 5.27 14.00 
0.612 
Own Shoes 11.49 1.86 7.09 14.00 
DMH3/M5 
Orthopaedic Shoes 5.55 1.17 1.34 6.96 
0.729 
Own Shoes 5.59 1.07 2.72 6.96 
DMH4/M6 
Orthopaedic Shoes 5.83 1.23 1.47 7.65 
0.223 
Own Shoes 5.63 1.36 0.21 7.65 
DMH5/M7 
Orthopaedic Shoes 6.00 0.95 2.80 6.96 
0.222 
Own Shoes 5.85 1.04 2.79 6.96 
DM midfoot/M8 
Orthopaedic Shoes 18.03 3.54 8.37 21.39 
0.002* 
Own Shoes 16.75 3.19 8.48 21.39 
DL midfoot/M9 
Orthopaedic Shoes 21.99 3.39 14.28 28.17 
<0.001** 
Own Shoes 19.08 5.29 7.06 27.96 
PT1/ M10 
Orthopaedic Shoes 7.55 0.95 6.20 9.58 
0.734 
Own Shoes 7.59 0.93 6.24 9.58 
PT2/M11 
Orthopaedic Shoes 8.90 1.27 7.02 11.22 
0.673 
Own Shoes 8.84 1.25 7.02 11.22 
PT3/M12 
Orthopaedic Shoes 9.54 1.51 6.62 12.05 
0.695 
Own Shoes 9.61 1.40 7.89 12.05 
PMH1/M13 
Orthopaedic Shoes 12.38 1.62 9.49 15.49 
0.650 
Own Shoes 12.47 1.62 9.95 15.49 
PMH2/M14 
Orthopaedic Shoes 12.48 1.73 9.71 15.57 
0.910 
Own Shoes 12.50 1.72 9.71 15.57 
PMH3/M15 
Orthopaedic Shoes 6.22 0.71 5.13 7.53 
1.000 
Own Shoes 6.22 0.71 5.13 7.53 
PMH4/M16 
Orthopaedic Shoes 6.33 0.78 5.19 7.67 
1.000 
Own Shoes 6.33 0.78 5.19 7.67 
PMH5/M17 
Orthopaedic Shoes 6.43 0.96 5.12 8.52 
1.000 
Own Shoes 6.43 0.96 5.12 8.52 
PM midfoot/M18 
Orthopaedic Shoes 13.62 3.75 5.13 22.97 
0.325 
Own Shoes 14.20 5.71 1.28 21.00 
PL midfoot/M19 
Orthopaedic Shoes 25.08 3.62 19.04 30.96 
0.403 
Own Shoes 24.67 4.34 12.69 30.96 
PM heel/M20 
Orthopaedic Shoes 16.87 2.10 12.72 21.19 
0.927 
Own Shoes 16.85 2.25 12.72 21.19 
PL heel/M21 
Orthopaedic Shoes 23.28 3.02 19.05 28.81 
0.910 
Own Shoes 23.32 3.14 17.79 28.81 
Whole Dorsal 
surface CA (cm2) 
Orthopaedic Shoes 96.61 12.35 61.56 114.94 
0.005* 
Own Shoes 92.23 12.84 58.65 111.38 
Whole Plantar 
surface CA (cm2) 
Orthopaedic Shoes 148.68 19.84 114.47 189.49 
0.890 
Own Shoes 149.03 21.31 104.26 185.60 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 10 Comparison between Orthopaedic Shoes and Own Shoes in CA (cm2) in diabetes group 
using: Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 7.27 1.07 3.41 8.50 
0.979 
Own Shoes 7.26 1.10 4.09 8.50 
DT Lat/M2 
Orthopaedic Shoes 7.58 0.81 5.16 8.52 
0.822 
Own Shoes 7.55 1.01 5.53 8.52 
DMH1/M3 
Orthopaedic Shoes 12.39 1.55 9.25 14.53 
0.242 
Own Shoes 12.64 1.61 9.78 14.53 
DMH2/M4 
Orthopaedic Shoes 11.62 1.57 5.31 14.00 
0.009* 
Own Shoes 10.92 2.24 6.95 14.00 
DMH3/M5 
Orthopaedic Shoes 5.43 0.87 2.70 6.89 
0.520 
Own Shoes 5.33 1.28 1.89 6.96 
DMH4/M6 
Orthopaedic Shoes 5.36 1.13 3.47 6.82 
0.723 
Own Shoes 5.42 1.57 0.00 6.96 
DMH5/M7 
Orthopaedic Shoes 5.70 0.91 3.21 6.96 
0.029* 
Own Shoes 5.40 1.09 3.21 6.96 
DM midfoot/M8 
Orthopaedic Shoes 18.20 2.24 14.11 21.39 
0.185 
Own Shoes 17.67 3.41 9.71 21.39 
DL midfoot/M9 
Orthopaedic Shoes 21.68 3.05 11.30 27.96 
<0.001** 
Own Shoes 17.88 5.13 7.15 27.96 
PT1/M10 
Orthopaedic Shoes 7.63 1.04 6.20 9.58 
0.975 
Own Shoes 7.62 0.99 6.24 9.58 
PT2/M11 
Orthopaedic Shoes 8.88 1.33 6.90 11.22 
0.084 
Own Shoes 8.60 1.03 7.13 10.26 
PT3/M12 
Orthopaedic Shoes 9.78 1.61 6.67 12.05 
0.781 
Own Shoes 9.72 1.65 7.34 12.05 
PMH1/M13 
Orthopaedic Shoes 12.61 1.79 10.25 15.49 
0.758 
Own Shoes 12.69 1.82 10.25 15.49 
PMH2/M14 
Orthopaedic Shoes 12.82 1.78 10.27 15.57 
0.746 
Own Shoes 12.90 1.80 10.27 15.57 
PMH3/M15 
Orthopaedic Shoes 6.22 0.78 5.13 7.53 
0.185 
Own Shoes 6.40 1.09 5.13 9.51 
PMH4/M16 
Orthopaedic Shoes 6.34 0.89 5.19 7.67 
0.725 
Own Shoes 6.38 0.90 5.19 7.67 
PMH5/M17 
Orthopaedic Shoes 6.35 0.97 5.12 8.52 
0.534 
Own Shoes 6.44 1.22 5.12 10.20 
PM midfoot/M18 
Orthopaedic Shoes 14.21 2.98 5.18 19.09 
<0.001** 
Own Shoes 16.22 4.13 5.18 22.97 
PL midfoot/M19 
Orthopaedic Shoes 25.37 3.60 20.30 30.96 
0.579 
Own Shoes 25.64 3.54 20.30 30.96 
PM heel/M20 
Orthopaedic Shoes 17.16 2.34 13.98 21.19 
0.666 
Own Shoes 17.30 2.38 13.98 21.19 
PL heel/M21 
Orthopaedic Shoes 23.06 3.23 19.05 28.81 
0.318 
Own Shoes 23.51 3.34 19.05 28.81 
Whole Dorsal 
surface CA (cm2) 
Orthopaedic Shoes 95.21 10.30 76.71 111.66 
0.005* 
Own Shoes 90.08 15.49 59.88 114.55 
Whole Plantar 
surface CA (cm2) 
Orthopaedic Shoes 150.44 19.54 121.99 185.61 
0.270 
Own Shoes 153.41 20.03 118.29 189.49 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 11 Comparison between control group and diabetes group in CA (cm2) in Own Shoes Using: 
Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 7.59 0.95 5.58 8.50 
0.013* 
Diabetes 7.26 1.10 4.09 8.50 
DT Lat/M2 
Control 7.80 0.77 6.82 8.62 
0.029* 
Diabetes 7.55 1.01 5.53 8.52 
DMH1/M3 
Control 12.44 1.79 8.41 14.53 
0.358 
Diabetes 12.64 1.61 9.78 14.53 
DMH2/M4 
Control 11.49 1.86 7.09 14.00 
0.033* 
Diabetes 10.92 2.24 6.95 14.00 
DMH3/M5 
Control 5.59 1.07 2.72 6.96 
0.088 
Diabetes 5.33 1.28 1.89 6.96 
DMH4/M6 
Control 5.63 1.36 0.21 7.65 
0.266 
Diabetes 5.42 1.57 0.00 6.96 
DMH5/M7 
Control 5.85 1.04 2.79 6.96 
<0.001** 
Diabetes 5.40 1.09 3.21 6.96 
DM midfoot/M8 
Control 16.75 3.19 8.48 21.39 
0.033* 
Diabetes 17.67 3.41 9.71 21.39 
DL midfoot/M9 
Control 19.08 5.29 7.06 27.96 
0.078 
Diabetes 17.88 5.13 7.15 27.96 
PT1/M10 
Control 7.59 0.93 6.24 9.58 
0.793 
Diabetes 7.62 0.99 6.24 9.58 
PT2/M11 
Control 8.84 1.25 7.02 11.22 
0.112 
Diabetes 8.60 1.03 7.13 10.26 
PT3/M12 
Control 9.61 1.40 7.89 12.05 
0.584 
Diabetes 9.72 1.65 7.34 12.05 
PMH1/M13 
Control 12.47 1.62 9.95 15.49 
0.332 
Diabetes 12.69 1.82 10.25 15.49 
PMH2/M14 
Control 12.50 1.72 9.71 15.57 
0.080 
Diabetes 12.90 1.80 10.27 15.57 
PMH3/M15 
Control 6.22 0.71 5.13 7.53 
0.130 
Diabetes 6.40 1.09 5.13 9.51 
PMH4/M16 
Control 6.33 0.78 5.19 7.67 
0.601 
Diabetes 6.38 0.90 5.19 7.67 
PMH5/M17 
Control 6.43 0.96 5.12 8.52 
0.910 
Diabetes 6.44 1.22 5.12 10.20 
PM midfoot/M18 
Control 14.20 5.71 1.28 21.00 
0.002* 
Diabetes 16.22 4.13 5.18 22.97 
PL midfoot/M19 
Control 24.67 4.34 12.69 30.96 
0.063 
Diabetes 25.64 3.54 20.30 30.96 
PM heel/M20 
Control 16.85 2.25 12.72 21.19 
0.132 
Diabetes 17.30 2.38 13.98 21.19 
PL heel/M21 
Control 23.32 3.14 17.79 28.81 
0.665 
Diabetes 23.51 3.34 19.05 28.81 
Whole Dorsal 
surface CA (cm2) 
Control 92.23 12.84 58.65 111.38 
0.241 
Diabetes 90.08 15.49 59.88 114.55 
Whole Plantar 
surface CA (cm2) 
Control 149.03 21.31 104.26 185.60 
0.105 
Diabetes 153.41 20.03 118.29 189.49 
p >0.05 NS; *p <0.05 S; **p <0.001 HS  
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Table 12 Comparison between control group and diabetes group in CA (cm2) in Orthopaedic Shoes 
using: Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 7.58 0.97 5.09 8.50 
0.020* 
Diabetes 7.27 1.07 3.41 8.50 
DT Lat/M2 
Control 7.69 0.78 6.82 8.62 
0.280 
Diabetes 7.58 0.81 5.16 8.52 
DMH1/M3 
Control 12.33 2.21 2.78 14.53 
0.831 
Diabetes 12.39 1.55 9.25 14.53 
DMH2/M4 
Control 11.62 2.24 5.27 14.00 
0.995 
Diabetes 11.62 1.57 5.31 14.00 
DMH3/M5 
Control 5.55 1.17 1.34 6.96 
0.392 
Diabetes 5.43 0.87 2.70 6.89 
DMH4/M6 
Control 5.83 1.23 1.47 7.65 
0.002* 
Diabetes 5.36 1.13 3.47 6.82 
DMH5/M7 
Control 6.00 0.95 2.80 6.96 
0.013* 
Diabetes 5.70 0.91 3.21 6.96 
DM midfoot/M8 
Control 18.03 3.54 8.37 21.39 
0.668 
Diabetes 18.20 2.24 14.11 21.39 
DL midfoot/M9 
Control 21.99 3.39 14.28 28.17 
0.464 
Diabetes 21.68 3.05 11.30 27.96 
PT1/M10 
Control 7.55 0.95 6.20 9.58 
0.553 
Diabetes 7.63 1.04 6.20 9.58 
PT2/M11 
Control 8.90 1.27 7.02 11.22 
0.884 
Diabetes 8.88 1.33 6.90 11.22 
PT3/M12 
Control 9.54 1.51 6.62 12.05 
0.235 
Diabetes 9.78 1.61 6.67 12.05 
PMH1/M13 
Control 12.38 1.62 9.49 15.49 
0.297 
Diabetes 12.61 1.79 10.25 15.49 
PMH2/M14 
Control 12.48 1.73 9.71 15.57 
0.130 
Diabetes 12.82 1.78 10.27 15.57 
PMH3/M15 
Control 6.22 0.71 5.13 7.53 
0.949 
Diabetes 6.22 0.78 5.13 7.53 
PMH4/M16 
Control 6.33 0.78 5.19 7.67 
0.897 
Diabetes 6.34 0.89 5.19 7.67 
PMH5/M17 
Control 6.43 0.96 5.12 8.52 
0.535 
Diabetes 6.35 0.97 5.12 8.52 
PM midfoot/M18 
Control 13.62 3.75 5.13 22.97 
0.180 
Diabetes 14.21 2.98 5.18 19.09 
PL midfoot/M19 
Control 25.08 3.62 19.04 30.96 
0.538 
Diabetes 25.37 3.60 20.30 30.96 
PM heel/M20 
Control 16.87 2.10 12.72 21.19 
0.314 
Diabetes 17.16 2.34 13.98 21.19 
PL heel/M21 
Control 23.28 3.02 19.05 28.81 
0.582 
Diabetes 23.06 3.23 19.05 28.81 
Whole Dorsal 
surface CA (cm2) 
Control 96.61 12.35 61.56 114.94 
0.349 
Diabetes 95.21 10.30 76.71 111.66 
Whole Plantar 
surface CA (cm2) 
Control 148.68 19.84 114.47 189.49 
0.492 
Diabetes 150.44 19.54 121.99 185.61 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 13 Comparison between Orthopaedic Shoes and Own Shoes in MF (N) in control group using: 
Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 7.92 5.27 1.28 23.62 
<0.001** 
Own Shoes 10.70 8.13 1.14 33.16 
DT Lat/M2 
Orthopaedic Shoes 11.42 4.32 3.12 21.49 
<0.001** 
Own Shoes 17.63 7.95 5.91 35.54 
DMH1/M3 
Orthopaedic Shoes 16.81 9.21 2.55 36.21 
<0.001** 
Own Shoes 27.83 16.93 3.81 74.03 
DMH2/M4 
Orthopaedic Shoes 11.29 6.67 1.58 30.25 
<0.001** 
Own Shoes 21.39 17.12 1.87 72.32 
DMH3/M5 
Orthopaedic Shoes 5.58 3.22 0.99 14.22 
<0.001** 
Own Shoes 9.57 6.69 1.3 30.53 
DMH4/M6 
Orthopaedic Shoes 6.91 3.59 1.57 17.75 
<0.001** 
Own Shoes 10.21 6.10 0.08 30.88 
DMH5/M7 
Orthopaedic Shoes 6.09 2.62 2.22 14.62 
<0.001** 
Own Shoes 9.10 5.73 0.69 21.92 
DM midfoot/M8 
Orthopaedic Shoes 21.31 10.39 5.02 52.67 
0.453 
Own Shoes 22.51 15.25 2.93 61.74 
DL midfoot/M9 
Orthopaedic Shoes 15.51 10.04 5.59 48.55 
0.615 
Own Shoes 16.20 11.94 1.66 56.38 
PT1/ M10 
Orthopaedic Shoes 108.60 27.27 52.61 180.06 
0.744 
Own Shoes 109.84 33.99 42.97 189.56 
PT2/M11 
Orthopaedic Shoes 74.76 21.16 39.52 118.67 
0.416 
Own Shoes 76.88 21.00 37.84 127.53 
PT3/M12 
Orthopaedic Shoes 69.21 24.44 26.57 110.9 
0.046* 
Own Shoes 74.99 22.45 32.08 118.98 
PMH1/M13 
Orthopaedic Shoes 180.20 43.99 103.96 289.25 
0.097 
Own Shoes 170.14 53.79 72.63 307.5 
PMH2/M14 
Orthopaedic Shoes 166.03 39.97 94.94 257.67 
0.218 
Own Shoes 172.31 42.63 85 259.19 
PMH3/M15 
Orthopaedic Shoes 80.21 20.76 35.64 139.36 
<0.001** 
Own Shoes 92.86 28.12 49.23 174.92 
PMH4/M16 
Orthopaedic Shoes 69.18 19.95 27.69 119.79 
<0.001** 
Own Shoes 80.97 23.25 45.31 153.02 
PMH5/M17 
Orthopaedic Shoes 60.06 21.43 14.38 142.77 
<0.001** 
Own Shoes 72.76 27.88 22.73 148.32 
PM midfoot/M18 
Orthopaedic Shoes 23.70 19.47 2.14 100.31 
<0.001** 
Own Shoes 36.04 28.31 1.28 123.45 
PL midfoot/M19 
Orthopaedic Shoes 114.75 48.81 15.87 283.27 
0.005* 
Own Shoes 134.94 66.38 7.85 285 
PM heel/M20 
Orthopaedic Shoes 241.47 53.17 125.11 388.12 
0.108 
Own Shoes 229.63 65.40 117.35 461.52 
PL heel/M21 
Orthopaedic Shoes 350.80 63.08 192.61 497.81 
0.002* 
Own Shoes 319.24 97.03 101.32 539.92 
Whole Dorsal 
surface MF (N) 
Orthopaedic Shoes 25.41 9.29 8.85 52.67 
<0.001** 
Own Shoes 34.74 16.51 7.56 74.03 
Whole Plantar 
surface MF (N) 
Orthopaedic Shoes 350.85 63.10 192.61 497.81 
0.026* 
Own Shoes 331.07 79.48 164.54 539.92 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 14 Comparison between Orthopaedic Shoes and Own Shoes in MF (N) in diabetes group using: 
Independent Sample t-test. 
Foot Area 
/Mask no. 
Tested Condition Mean SD Min. Max. p 
DT Med/M1 
Orthopaedic Shoes 6.88 3.90 0.57 15.99 
0.729 
Own Shoes 7.12 5.93 1.23 44.49 
DT Lat/M2 
Orthopaedic Shoes 11.13 5.41 4.12 24.47 
0.592 
Own Shoes 11.50 4.51 4.78 23.75 
DMH1/M3 
Orthopaedic Shoes 20.59 9.66 4.02 42.32 
<0.001** 
Own Shoes 32.32 20.74 8.63 100.18 
DMH2/M4 
Orthopaedic Shoes 13.59 9.20 1.6 42.82 
0.032* 
Own Shoes 16.24 8.83 2.78 34.56 
DMH3/M5 
Orthopaedic Shoes 6.31 3.44 1.22 20.28 
0.004* 
Own Shoes 8.08 5.23 0.58 24.51 
DMH4/M6 
Orthopaedic Shoes 6.48 2.86 1.06 14.96 
<0.001** 
Own Shoes 9.35 5.79 0 25.24 
DMH5/M7 
Orthopaedic Shoes 4.19 1.74 1.34 10.11 
<0.001** 
Own Shoes 7.35 3.92 1.39 15.66 
DM midfoot/M8 
Orthopaedic Shoes 24.90 9.26 7.51 43.38 
0.009* 
Own Shoes 29.36 15.08 7.19 58.41 
DL midfoot/M9 
Orthopaedic Shoes 13.19 5.81 4.36 28.49 
0.035* 
Own Shoes 15.42 9.20 2.16 39.23 
PT1/M10 
Orthopaedic Shoes 94.51 31.23 37.12 186.84 
0.604 
Own Shoes 92.08 37.33 26.64 195.56 
PT2/M11 
Orthopaedic Shoes 58.00 23.42 23.11 110.64 
0.660 
Own Shoes 59.46 25.07 22.75 132.23 
PT3/M12 
Orthopaedic Shoes 48.03 20.13 20.81 120.07 
0.678 
Own Shoes 49.18 20.68 16.38 112.98 
PMH1/M13 
Orthopaedic Shoes 194.42 43.06 94.68 304.47 
0.657 
Own Shoes 191.45 54.44 106.65 382.53 
PMH2/M14 
Orthopaedic Shoes 186.22 29.88 135.57 262.59 
0.044* 
Own Shoes 178.32 27.27 141.53 262.95 
PMH3/M15 
Orthopaedic Shoes 85.65 21.34 38.11 136.68 
0.974 
Own Shoes 85.55 21.14 43.93 135.31 
PMH4/M16 
Orthopaedic Shoes 73.24 25.16 16.3 137.94 
0.528 
Own Shoes 71.30 19.67 31.93 120.45 
PMH5/M17 
Orthopaedic Shoes 58.02 27.66 13.2 131.54 
0.457 
Own Shoes 60.72 25.55 13.43 113.71 
PM midfoot/M18 
Orthopaedic Shoes 25.29 15.28 7.62 70.6 
<0.001** 
Own Shoes 44.72 29.69 6.7 122.97 
PL midfoot/M19 
Orthopaedic Shoes 133.08 52.67 55.9 291.12 
0.004* 
Own Shoes 155.01 58.54 62.07 313.21 
PM heel/M20 
Orthopaedic Shoes 257.44 62.26 163.98 432.28 
0.433 
Own Shoes 251.03 57.67 145.93 384.78 
PL heel/M21 
Orthopaedic Shoes 376.68 72.44 271.43 581.68 
0.056 
Own Shoes 356.33 82.76 211.87 639.14 
Whole Dorsal 
surface MF (N) 
Orthopaedic Shoes 27.41 9.44 7.51 43.38 
<0.001** 
Own Shoes 38.24 19.43 13.75 100.18 
Whole Plantar 
surface MF (N) 
Orthopaedic Shoes 376.86 72.30 271.43 581.68 
0.060 
Own Shoes 356.89 82.63 211.87 639.14 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 15 Comparison between control group and diabetes group in MF (N) in Own Shoes using: 
Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 10.70 8.13 1.14 33.16 
<0.001** 
Diabetes 7.12 5.93 1.23 44.49 
DT Lat/M2 
Control 17.63 7.95 5.91 35.54 
<0.001** 
Diabetes 11.50 4.51 4.78 23.75 
DMH1/M3 
Control 27.83 16.93 3.81 74.03 
0.066 
Diabetes 32.32 20.74 8.63 100.18 
DMH2/M4 
Control 21.39 17.12 1.87 72.32 
0.005* 
Diabetes 16.24 8.83 2.78 34.56 
DMH3/M5 
Control 9.57 6.69 1.3 30.53 
0.059 
Diabetes 8.08 5.23 0.58 24.51 
DMH4/M6 
Control 10.21 6.10 0.08 30.88 
0.271 
Diabetes 9.35 5.79 0 25.24 
DMH5/M7 
Control 9.10 5.73 0.69 21.92 
0.008* 
Diabetes 7.35 3.92 1.39 15.66 
DM midfoot/M8 
Control 22.51 15.25 2.93 61.74 
<0.001** 
Diabetes 29.36 15.08 7.19 58.41 
DL midfoot/M9 
Control 16.20 11.94 1.66 56.38 
0.578 
Diabetes 15.42 9.20 2.16 39.23 
PT1/M10 
Control 109.84 33.99 42.97 189.56 
<0.001** 
Diabetes 92.08 37.33 26.64 195.56 
PT2/M11 
Control 76.88 21.00 37.84 127.53 
<0.001** 
Diabetes 59.46 25.07 22.75 132.23 
PT3/M12 
Control 74.99 22.45 32.08 118.98 
<0.001** 
Diabetes 49.18 20.68 16.38 112.98 
PMH1/M13 
Control 170.14 53.79 72.63 307.5 
0.003* 
Diabetes 191.45 54.44 106.65 382.53 
PMH2/M14 
Control 172.31 42.63 85 259.19 
0.206 
Diabetes 178.32 27.27 141.53 262.95 
PMH3/M15 
Control 92.86 28.12 49.23 174.92 
0.027* 
Diabetes 85.55 21.14 43.93 135.31 
PMH4/M16 
Control 80.97 23.25 45.31 153.02 
<0.001** 
Diabetes 71.30 19.67 31.93 120.45 
PMH5/M17 
Control 72.76 27.88 22.73 148.32 
<0.001** 
Diabetes 60.72 25.55 13.43 113.71 
PM midfoot/M18 
Control 36.04 28.31 1.28 123.45 
0.022* 
Diabetes 44.72 29.69 6.7 122.97 
PL midfoot/M19 
Control 134.94 66.38 7.85 285 
0.015* 
Diabetes 155.01 58.54 62.07 313.21 
PM heel/M20 
Control 229.63 65.40 117.35 461.52 
0.008* 
Diabetes 251.03 57.67 145.93 384.78 
PL heel/M21 
Control 319.24 97.03 101.32 539.92 
0.002* 
Diabetes 356.33 82.76 211.87 639.14 
Whole Dorsal 
surface MF (N) 
Control 34.74 16.51 7.56 74.03 
0.134 
Diabetes 38.24 19.43 13.75 100.18 
Whole Plantar 
surface MF (N) 
Control 331.07 79.48 164.54 539.92 
0.015* 
Diabetes 356.89 82.63 211.87 639.14 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 16 Comparison between control group and diabetes group in MF (N) in Orthopaedic Shoes 
using: Independent Sample t-test. 
Foot Area 
/Mask no 
Group Mean SD Min. Max. p 
DT Med/M1 
Control 7.92 5.27 1.28 23.62 
0.090 
Diabetes 6.88 3.90 0.57 15.99 
DT Lat/M2 
Control 11.42 4.32 3.12 21.49 
0.650 
Diabetes 11.13 5.41 4.12 24.47 
DMH1/M3 
Control 16.81 9.21 2.55 36.21 
0.002* 
Diabetes 20.59 9.66 4.02 42.32 
DMH2/M4 
Control 11.29 6.67 1.58 30.25 
0.026* 
Diabetes 13.59 9.20 1.6 42.82 
DMH3/M5 
Control 5.58 3.22 0.99 14.22 
0.091 
Diabetes 6.31 3.44 1.22 20.28 
DMH4/M6 
Control 6.91 3.59 1.57 17.75 
0.314 
Diabetes 6.48 2.86 1.06 14.96 
DMH5/M7 
Control 6.09 2.62 2.22 14.62 <0.001*
* Diabetes 4.19 1.74 1.34 10.11 
DM midfoot/M8 
Control 21.31 10.39 5.02 52.67 
0.006* 
Diabetes 24.90 9.26 7.51 43.38 
DL midfoot/M9 
Control 15.51 10.04 5.59 48.55 
0.035* 
Diabetes 13.19 5.81 4.36 28.49 
PT1/M10 
Control 108.60 27.27 52.61 180.06 <0.001*
* Diabetes 94.51 31.23 37.12 186.84 
PT2/M11 
Control 74.76 21.16 39.52 118.67 <0.001*
* Diabetes 58.00 23.42 23.11 110.64 
PT3/M12 
Control 69.21 24.44 26.57 110.9 <0.001*
* Diabetes 48.03 20.13 20.81 120.07 
PMH1/M13 
Control 180.20 43.99 103.96 289.25 
0.013* 
Diabetes 194.42 43.06 94.68 304.47 
PMH2/M14 
Control 166.03 39.97 94.94 257.67 <0.001*
* Diabetes 186.22 29.88 135.57 262.59 
PMH3/M15 
Control 80.21 20.76 35.64 139.36 
0.047* 
Diabetes 85.65 21.34 38.11 136.68 
PMH4/M16 
Control 69.18 19.95 27.69 119.79 
0.164 
Diabetes 73.24 25.16 16.3 137.94 
PMH5/M17 
Control 60.06 21.43 14.38 142.77 
0.520 
Diabetes 58.02 27.66 13.2 131.54 
PM midfoot/M18 
Control 23.70 19.47 2.14 100.31 
0.489 
Diabetes 25.29 15.28 7.62 70.6 
PL midfoot/M19 
Control 114.75 48.81 15.87 283.27 
0.006* 
Diabetes 133.08 52.67 55.9 291.12 
PM heel/M20 
Control 241.47 53.17 125.11 388.12 
0.033* 
Diabetes 257.44 62.26 163.98 432.28 
PL heel/M21 
Control 350.80 63.08 192.61 497.81 
0.003* 
Diabetes 376.68 72.44 271.43 581.68 
Whole Dorsal 
surface MF (N) 
Control 25.41 9.29 8.85 52.67 
0.100 
Diabetes 27.41 9.44 7.51 43.38 
Whole Plantar 
surface MF (N) 
Control 350.85 63.10 192.61 497.81 
0.003* 
Diabetes 376.86 72.30 271.43 581.68 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 17 Comparison between Orthopaedic shoes and Own shoes according to time of Dorsal PP 
(% of Gait) in study groups using: Independent Sample t-test. 
Group Tested condition Mean SD Min. Max. p 
Control 
Orthopaedic shoes 42.57 24.66 1.6 89.4 
0.095 
Own shoes 45.20 19.07 1.7 82.6 
Diabetes 
Orthopaedic shoes 45.05 25.71 0 98.7 
0.266 
Own shoes 47.18 22.18 2 77.8 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
 
Table 18 Comparison between control group and diabetes group according to time of Dorsal PP  
(% of Gait) in tested shoe conditions using: Independent Sample t-test. 
Tested condition Group Mean SD Min. Max. p 
Orthopaedic 
shoes 
Control 42.57 24.66 1.6 89.4 
0.189 
Diabetes 45.05 25.71 0 98.7 
Own shoes 
Control 45.20 19.07 1.7 82.6 
0.203 
Diabetes 47.18 22.18 2 77.8 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
 
Table 19 Comparison between all Orthopaedic shoes and Own shoes time of Dorsal PP (% of Gait) 
using: Independent Sample t-test. 
Tested condition Mean SD Min. Max. P 
Orthopaedic 
shoes 
43.66 25.14 0 98.7 
0.047* 
Own shoes 46.08 20.52 1.7 82.6 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 20 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of ACh on the dorsal surface in control group using: One Way analysis of 
variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 20.82 6.40a 6.25a 
<0.001** 
SD 13.74 2.83 1.67 
100µA/60 seconds 
Mean 28.50 6.72a 6.31a 
<0.001** 
SD 19.25 2.76 1.67 
100µA/60 seconds 
Mean 40.86 7.22a 6.50a 
<0.001** 
SD 21.37 2.99 1.76 
100µA/60 seconds 
Mean 52.47 7.57a 6.75a 
<0.001** 
SD 21.78 3.45 1.86 
100µA/60 seconds 
Mean 64.61 7.74a 6.73a 
<0.001** 
SD 28.92 3.70 2.16 
100µA/60 seconds 
Mean 75.30 8.29a 6.87a 
<0.001** 
SD 34.93 4.61 2.30 
100µA/60 seconds 
Mean 83.72 8.49a 7.02a 
<0.001** 
SD 37.64 5.26 2.29 
100µA/60 seconds 
Mean 97.32 8.85a 7.14a 
<0.001** 
SD 43.88 5.50 2.28 
100µA/60 seconds 
Mean 113.61 9.13a 7.45a 
<0.001** 
SD 45.04 6.26 2.27 
100µA/60 seconds 
Mean 124.31 9.32a 7.68a 
<0.001** 
SD 50.19 6.17 2.48 
100µA/60 seconds 
Mean 129.34 10.11a 7.53a 
<0.001** 
SD 46.54 6.38 2.50 
100µA/60 seconds 
Mean 129.06 10.65a 7.92a 
<0.001** 
SD 47.85 6.89 2.71 
100µA/60 seconds 
Mean 128.14 10.41a 7.82a 
<0.001** 
SD 49.16 6.54 2.75 
100µA/60 seconds 
Mean 130.24 10.20a 7.92a 
<0.001** 
SD 51.97 6.45 2.71 
100µA/60 seconds 
Mean 132.43 11.14a 8.40a 
<0.001** 
SD 54.08 8.43 3.02 
Peak of Max 
response 
Mean 142.99 18.27a 14.90a 
<0.001** 
SD 39.56 8.19 3.64 
Change in 
response % 
Mean 756.05 192.00a 149.65ab 
<0.001** 
SD 467.04 80.08 66.86 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 21 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of SNP on the dorsal surface in control group using: One Way analysis of 
variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 24.64 7.37a 6.21a 
<0.001** 
SD 12.18 4.41 2.39 
100µA/60 seconds 
Mean 28.63 7.86a 6.43a 
<0.001** 
SD 13.96 4.54 2.42 
100µA/60 seconds 
Mean 44.27 11.67a 6.64a 
<0.001** 
SD 26.18 18.53 2.54 
100µA/60 seconds 
Mean 59.95 12.71a 6.57a 
<0.001** 
SD 34.65 21.98 2.56 
100µA/60 seconds 
Mean 73.97 12.10a 6.52a 
<0.001** 
SD 43.86 16.70 2.42 
100µA/60 seconds 
Mean 86.76 13.52a 6.65a 
<0.001** 
SD 46.12 22.75 2.37 
100µA/60 seconds 
Mean 96.52 15.41a 6.57a 
<0.001** 
SD 49.37 29.93 2.41 
100µA/60 seconds 
Mean 103.14 13.95a 6.87a 
<0.001** 
SD 46.97 22.85 2.85 
100µA/60 seconds 
Mean 111.09 12.49a 6.83a 
<0.001** 
SD 47.18 16.40 2.73 
100µA/60 seconds 
Mean 116.28 12.56a 7.30a 
<0.001** 
SD 48.95 15.53 2.99 
100µA/60 seconds 
Mean 119.73 12.06a 7.39a 
<0.001** 
SD 47.11 13.06 3.20 
100µA/60 seconds 
Mean 124.47 12.98a 7.45a 
<0.001** 
SD 51.82 16.86 3.13 
100µA/60 seconds 
Mean 119.07 13.47a 7.22a 
<0.001** 
SD 43.26 18.23 2.93 
100µA/60 seconds 
Mean 123.62 14.69a 7.54a 
<0.001** 
SD 43.66 23.67 3.36 
100µA/60 seconds 
Mean 123.51 15.48a 7.45a 
<0.001** 
SD 45.73 26.16 3.53 
Peak of Max 
response 
Mean 141.32 23.91a 14.66a 
<0.001** 
SD 56.41 27.79 5.84 
Change in 
response % 
Mean 517.86 199.67a 139.22ab 
<0.001** 
SD 247.75 124.29 51.86 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
  
281 
 
 
Table 22 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of ACh on the plantar surface in control group using: One Way analysis of 
variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 45.22 3.66a 3.59a 
<0.001** 
SD 32.22 1.54 1.01 
100µA/60 seconds 
Mean 44.78 3.91a 3.69a 
<0.001** 
SD 31.79 1.84 1.21 
100µA/60 seconds 
Mean 59.97 4.04a 3.63a 
<0.001** 
SD 39.06 1.98 1.23 
100µA/60 seconds 
Mean 87.74 4.11a 3.67a 
<0.001** 
SD 74.46 2.06 1.39 
100µA/60 seconds 
Mean 105.96 4.05a 3.59a 
<0.001** 
SD 104.81 2.00 1.23 
100µA/60 seconds 
Mean 130.41 4.01a 3.67a 
<0.001** 
SD 129.36 2.00 1.48 
100µA/60 seconds 
Mean 143.90 4.06a 3.96a 
<0.001** 
SD 134.62 1.96 2.12 
100µA/60 seconds 
Mean 153.66 4.24a 3.68a 
<0.001** 
SD 137.10 2.06 1.74 
100µA/60 seconds 
Mean 164.49 4.42a 3.87a 
<0.001** 
SD 138.38 2.10 2.12 
100µA/60 seconds 
Mean 183.41 4.44a 3.84a 
<0.001** 
SD 138.92 2.74 2.02 
100µA/60 seconds 
Mean 193.87 4.52a 3.80a 
<0.001** 
SD 144.86 2.88 2.15 
100µA/60 seconds 
Mean 202.97 4.51a 3.94a 
<0.001** 
SD 149.53 2.82 2.37 
100µA/60 seconds 
Mean 212.48 4.63a 3.97a 
<0.001** 
SD 150.96 2.83 2.33 
100µA/60 seconds 
Mean 219.14 4.58a 3.99a 
<0.001** 
SD 164.21 2.71 2.47 
100µA/60 seconds 
Mean 218.60 4.40a 3.89a 
<0.001** 
SD 168.44 2.29 2.29 
Peak of Max 
response 
Mean 223.44 8.98a 8.13a 
<0.001** 
SD 140.95 4.19 3.48 
Change in 
response % 
Mean 491.46 146.20a 125.83a 
<0.001** 
SD 355.82 63.87 70.15 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 23 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of SNP on the plantar surface in control group using: One Way analysis of 
variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 50.13 3.59a 3.50a 
<0.001** 
SD 61.57 1.33 0.81 
100µA/60 seconds 
Mean 48.54 3.62a 3.46a 
<0.001** 
SD 60.26 1.32 0.95 
100µA/60 seconds 
Mean 61.47 3.89a 3.63a 
<0.001** 
SD 78.54 1.79 1.19 
100µA/60 seconds 
Mean 84.66 4.05a 3.54a 
<0.001** 
SD 83.00 1.90 1.01 
100µA/60 seconds 
Mean 115.46 4.09a 3.56a 
<0.001** 
SD 88.61 1.85 0.99 
100µA/60 seconds 
Mean 143.24 4.01a 3.63a 
<0.001** 
SD 121.10 1.74 1.05 
100µA/60 seconds 
Mean 156.12 4.16a 3.59a 
<0.001** 
SD 127.75 1.97 0.89 
100µA/60 seconds 
Mean 163.81 4.43a 3.74a 
<0.001** 
SD 134.38 2.34 1.14 
100µA/60 seconds 
Mean 161.89 4.36a 3.68a 
<0.001** 
SD 136.93 2.12 1.01 
100µA/60 seconds 
Mean 163.39 4.15a 3.68a 
<0.001** 
SD 135.21 1.89 0.90 
100µA/60 seconds 
Mean 162.08 4.25a 3.62a 
<0.001** 
SD 131.46 2.18 0.93 
100µA/60 seconds 
Mean 162.21 4.20a 3.51a 
<0.001** 
SD 129.28 1.84 0.78 
100µA/60 seconds 
Mean 166.83 4.19a 3.88a 
<0.001** 
SD 125.40 1.74 1.52 
100µA/60 seconds 
Mean 155.81 4.22a 3.93a 
<0.001** 
SD 119.80 1.72 1.66 
100µA/60 seconds 
Mean 161.27 4.22a 4.10a 
<0.001** 
SD 120.01 1.81 1.99 
Peak of Max 
response 
Mean 203.12 8.00a 7.84a 
<0.001** 
SD 138.22 3.59 3.97 
Change in 
response % 
Mean 645.00 128.37a 118.30a 
<0.001** 
SD 722.90 86.96 59.06 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 24 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of ACh on the dorsal surface in control group using: One Way analysis of variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 21.67 6.83a 6.56a 
<0.001** 
SD 13.98 2.93 1.67 
100µA/60 seconds 
Mean 29.31 7.19a 6.68a 
<0.001** 
SD 18.89 2.96 1.71 
100µA/60 seconds 
Mean 41.99 7.71a 6.97a 
<0.001** 
SD 21.43 3.22 1.88 
100µA/60 seconds 
Mean 53.93 8.06a 7.21a 
<0.001** 
SD 21.97 3.65 1.99 
100µA/60 seconds 
Mean 67.18 8.20a 7.17a 
<0.001** 
SD 28.24 3.81 2.31 
100µA/60 seconds 
Mean 77.18 8.75a 7.32a 
<0.001** 
SD 34.39 4.79 2.39 
100µA/60 seconds 
Mean 85.52 8.94a 7.43a 
<0.001** 
SD 37.75 5.47 2.32 
100µA/60 seconds 
Mean 100.07 9.30a 7.54a 
<0.001** 
SD 43.25 5.65 2.37 
100µA/60 seconds 
Mean 116.98 9.59a 7.86a 
<0.001** 
SD 44.96 6.36 2.25 
100µA/60 seconds 
Mean 125.59 9.75a 8.06a 
<0.001** 
SD 50.01 6.28 2.55 
100µA/60 seconds 
Mean 130.94 10.53a 7.97a 
<0.001** 
SD 46.43 6.47 2.54 
100µA/60 seconds 
Mean 130.67 11.03a 8.32a 
<0.001** 
SD 47.55 6.95 2.71 
100µA/60 seconds 
Mean 129.83 10.79a 8.20a 
<0.001** 
SD 48.93 6.65 2.79 
100µA/60 seconds 
Mean 131.99 10.62a 8.35a 
<0.001** 
SD 51.59 6.62 2.82 
100µA/60 seconds 
Mean 133.99 11.34a 8.73a 
<0.001** 
SD 53.84 8.14 3.02 
Peak of Max 
response 
Mean 142.99 18.27a 14.90a 
<0.001** 
SD 39.56 8.19 3.64 
Change in 
response % 
Mean 711.29 172.88a 136.28ab 
<0.001** 
SD 431.85 75.75 61.02 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 25 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of SNP on the dorsal surface in control group using: One Way analysis of variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 25.30 7.96a 6.57a 
<0.001** 
SD 12.54 4.49 2.50 
100µA/60 seconds 
Mean 29.56 8.42a 6.85a 
<0.001** 
SD 14.31 4.68 2.53 
100µA/60 seconds 
Mean 45.66 12.01a 7.03a 
<0.001** 
SD 27.78 17.55 2.65 
100µA/60 seconds 
Mean 61.62 13.08a 6.93a 
<0.001** 
SD 35.86 21.45 2.71 
100µA/60 seconds 
Mean 75.58 12.54a 6.96a 
<0.001** 
SD 44.35 16.60 2.57 
100µA/60 seconds 
Mean 88.54 14.05a 7.07a 
<0.001** 
SD 46.62 22.93 2.55 
100µA/60 seconds 
Mean 98.11 15.71a 7.02a 
<0.001** 
SD 49.84 29.33 2.63 
100µA/60 seconds 
Mean 104.67 14.44a 7.30a 
<0.001** 
SD 47.73 22.99 3.05 
100µA/60 seconds 
Mean 112.80 13.02a 7.31a 
<0.001** 
SD 48.05 16.52 2.93 
100µA/60 seconds 
Mean 117.98 13.12a 7.72a 
<0.001** 
SD 49.24 15.97 3.23 
100µA/60 seconds 
Mean 121.38 12.45a 7.81a 
<0.001** 
SD 47.80 13.02 3.37 
100µA/60 seconds 
Mean 125.73 13.51a 7.85a 
<0.001** 
SD 51.96 17.47 3.32 
100µA/60 seconds 
Mean 121.68 13.93a 7.67a 
<0.001** 
SD 44.66 18.48 3.17 
100µA/60 seconds 
Mean 125.07 15.28a 7.93a 
<0.001** 
SD 44.94 24.23 3.51 
100µA/60 seconds 
Mean 125.04 15.95a 7.85a 
<0.001** 
SD 46.76 26.15 3.67 
Peak of Max 
response 
Mean 141.32 23.91a 14.66a 
<0.001** 
SD 56.41 27.79 5.84 
Change in 
response % 
Mean 502.76 174.99a 124.89ab 
<0.001** 
SD 244.33 119.05 43.93 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 26 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of ACh on the plantar surface in control group using: One Way analysis of variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 47.27 3.91a 3.73a 
<0.001** 
SD 33.03 1.78 1.06 
100µA/60 seconds 
Mean 46.89 4.16a 3.81a 
<0.001** 
SD 32.85 1.97 1.28 
100µA/60 seconds 
Mean 61.91 4.29a 3.85a 
<0.001** 
SD 39.58 2.17 1.35 
100µA/60 seconds 
Mean 90.50 4.44a 3.92a 
<0.001** 
SD 75.48 2.31 1.60 
100µA/60 seconds 
Mean 107.88 4.40a 3.79a 
<0.001** 
SD 102.87 2.36 1.33 
100µA/60 seconds 
Mean 132.11 4.28a 3.95a 
<0.001** 
SD 129.60 2.27 1.65 
100µA/60 seconds 
Mean 145.65 4.38a 4.19a 
<0.001** 
SD 135.60 2.23 2.21 
100µA/60 seconds 
Mean 156.41 4.62a 3.91a 
<0.001** 
SD 138.34 2.39 1.86 
100µA/60 seconds 
Mean 170.08 4.70a 4.14a 
<0.001** 
SD 137.31 2.31 2.18 
100µA/60 seconds 
Mean 186.34 4.75a 4.05a 
<0.001** 
SD 139.27 2.91 2.05 
100µA/60 seconds 
Mean 196.50 4.78a 4.05a 
<0.001** 
SD 145.32 3.02 2.19 
100µA/60 seconds 
Mean 204.87 4.78a 4.17a 
<0.001** 
SD 149.94 2.96 2.41 
100µA/60 seconds 
Mean 213.75 4.90a 4.20a 
<0.001** 
SD 151.28 2.93 2.35 
100µA/60 seconds 
Mean 219.48 4.84a 4.19a 
<0.001** 
SD 163.68 2.83 2.50 
100µA/60 seconds 
Mean 218.87 4.69a 4.12a 
<0.001** 
SD 167.36 2.50 2.32 
Peak of Max 
response 
Mean 223.44 8.98a 8.13a 
<0.001** 
SD 140.95 4.19 3.48 
Change in 
response % 
Mean 460.66 130.92a 116.36a 
<0.001** 
SD 344.35 53.81 64.56 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 27 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of SNP on the plantar surface in control group using: One Way analysis of variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 51.45 3.77a 3.76a 
<0.001** 
SD 62.29 1.40 1.20 
100µA/60 seconds 
Mean 49.90 3.83a 3.73a 
<0.001** 
SD 60.77 1.41 1.36 
100µA/60 seconds 
Mean 62.61 4.10a 3.91a 
<0.001** 
SD 77.32 1.88 1.55 
100µA/60 seconds 
Mean 85.68 4.24a 3.82a 
<0.001** 
SD 80.51 1.95 1.42 
100µA/60 seconds 
Mean 116.59 4.32a 3.82a 
<0.001** 
SD 88.32 1.98 1.39 
100µA/60 seconds 
Mean 144.77 4.26a 3.93a 
<0.001** 
SD 120.54 1.85 1.41 
100µA/60 seconds 
Mean 157.35 4.41a 3.90a 
<0.001** 
SD 127.90 2.04 1.28 
100µA/60 seconds 
Mean 163.84 4.63a 4.03a 
<0.001** 
SD 135.86 2.35 1.49 
100µA/60 seconds 
Mean 163.93 4.58a 3.96a 
<0.001** 
SD 138.32 2.19 1.38 
100µA/60 seconds 
Mean 165.48 4.41a 3.97a 
<0.001** 
SD 135.62 2.00 1.34 
100µA/60 seconds 
Mean 164.05 4.49a 3.92a 
<0.001** 
SD 132.88 2.27 1.33 
100µA/60 seconds 
Mean 163.78 4.44a 3.81a 
<0.001** 
SD 130.22 1.98 1.24 
100µA/60 seconds 
Mean 167.77 4.42a 4.14a 
<0.001** 
SD 126.48 1.86 1.77 
100µA/60 seconds 
Mean 157.93 4.44a 4.18a 
<0.001** 
SD 120.67 1.86 1.86 
100µA/60 seconds 
Mean 162.24 4.46a 4.39a 
<0.001** 
SD 121.12 1.92 2.08 
Peak of Max 
response 
Mean 203.12 8.00a 7.84a 
<0.001** 
SD 138.22 3.59 3.97 
Change in 
response % 
Mean 604.93 117.79a 103.58a 
<0.001** 
SD 685.26 82.24 42.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 28 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of ACh on the dorsal surface in diabetes group using: One Way analysis of 
variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 29.19 8.73a 6.19a 
<0.001** 
SD 16.90 3.37 1.90 
100µA/60 seconds 
Mean 38.33 8.76a 6.67a 
<0.001** 
SD 23.74 3.25 2.12 
100µA/60 seconds 
Mean 57.91 9.05a 6.35a 
<0.001** 
SD 38.24 2.97 2.29 
100µA/60 seconds 
Mean 66.30 9.32a 6.73a 
<0.001** 
SD 41.27 3.04 2.33 
100µA/60 seconds 
Mean 78.09 9.79a 6.94a 
<0.001** 
SD 46.20 3.42 2.33 
100µA/60 seconds 
Mean 87.43 9.77a 6.87a 
<0.001** 
SD 49.41 3.56 2.30 
100µA/60 seconds 
Mean 95.35 10.41a 7.07a 
<0.001** 
SD 51.98 4.10 2.64 
100µA/60 seconds 
Mean 100.72 10.81a 7.07a 
<0.001** 
SD 55.12 4.52 2.60 
100µA/60 seconds 
Mean 106.39 10.83a 7.39a 
<0.001** 
SD 55.74 4.33 2.67 
100µA/60 seconds 
Mean 102.57 11.05a 7.55a 
<0.001** 
SD 49.67 4.35 3.02 
100µA/60 seconds 
Mean 110.01 12.34a 7.53a 
<0.001** 
SD 56.77 5.29 3.06 
100µA/60 seconds 
Mean 110.50 11.76a 7.32a 
<0.001** 
SD 66.23 5.43 2.81 
100µA/60 seconds 
Mean 110.34 11.30a 7.57a 
<0.001** 
SD 77.66 3.87 3.09 
100µA/60 seconds 
Mean 107.41 11.89a 7.79a 
<0.001** 
SD 78.45 4.88 2.95 
100µA/60 seconds 
Mean 107.33 11.84a 7.83a 
<0.001** 
SD 75.96 4.81 2.98 
Peak of Max 
response 
Mean 141.10 20.40a 14.52a 
<0.001** 
SD 85.93 8.03 5.34 
Change in 
response % 
Mean 450.48 144.70a 136.01a 
<0.001** 
SD 319.52 77.64 55.09 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 29 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of SNP on the dorsal surface in diabetes group using: One Way analysis of 
variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 23.67 7.51a 7.29a 
<0.001** 
SD 11.36 2.81 3.37 
100µA/60 seconds 
Mean 22.95 8.29a 7.37a 
<0.001** 
SD 9.62 4.25 3.32 
100µA/60 seconds 
Mean 36.07 8.32a 7.37a 
<0.001** 
SD 16.59 4.25 3.10 
100µA/60 seconds 
Mean 63.04 8.83a 7.98a 
<0.001** 
SD 39.50 4.34 3.51 
100µA/60 seconds 
Mean 89.81 9.15a 8.35a 
<0.001** 
SD 72.49 4.32 4.13 
100µA/60 seconds 
Mean 113.62 9.31a 8.76a 
<0.001** 
SD 101.29 4.20 4.70 
100µA/60 seconds 
Mean 123.03 9.19a 9.03a 
<0.001** 
SD 101.49 4.46 5.03 
100µA/60 seconds 
Mean 129.67 9.21a 9.15a 
<0.001** 
SD 100.12 4.77 5.24 
100µA/60 seconds 
Mean 128.03 9.09a 8.99a 
<0.001** 
SD 85.26 4.53 4.79 
100µA/60 seconds 
Mean 134.79 8.99a 8.71a 
<0.001** 
SD 84.67 5.04 4.34 
100µA/60 seconds 
Mean 137.69 9.35a 8.82a 
<0.001** 
SD 82.57 5.27 4.06 
100µA/60 seconds 
Mean 138.11 9.61a 9.23a 
<0.001** 
SD 83.54 5.53 4.43 
100µA/60 seconds 
Mean 137.27 9.89a 9.55a 
<0.001** 
SD 82.40 5.87 4.88 
100µA/60 seconds 
Mean 135.26 10.29a 9.12a 
<0.001** 
SD 76.21 6.23 4.32 
100µA/60 seconds 
Mean 133.67 10.59a 9.00a 
<0.001** 
SD 77.87 6.55 4.07 
Peak of Max 
response 
Mean 164.80 18.56a 18.63a 
<0.001** 
SD 97.46 9.48 7.96 
Change in 
response % 
Mean 673.14 145.36a 171.43ab 
<0.001** 
SD 469.64 55.33 84.82 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 30 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of ACh on the plantar surface in diabetes group using: One Way analysis 
of variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 71.80 5.14a 5.19a 
<0.001** 
SD 43.65 1.84 1.95 
100µA/60 seconds 
Mean 84.01 5.49a 5.47a 
<0.001** 
SD 47.37 2.13 2.07 
100µA/60 seconds 
Mean 117.98 5.49a 5.63a 
<0.001** 
SD 68.15 2.23 2.23 
100µA/60 seconds 
Mean 165.60 5.52a 5.67a 
<0.001** 
SD 99.90 2.04 2.32 
100µA/60 seconds 
Mean 188.11 5.56a 5.72a 
<0.001** 
SD 113.00 2.26 2.32 
100µA/60 seconds 
Mean 203.95 5.67a 5.54a 
<0.001** 
SD 128.43 2.48 2.07 
100µA/60 seconds 
Mean 215.81 5.67a 5.77a 
<0.001** 
SD 133.14 2.42 2.38 
100µA/60 seconds 
Mean 222.55 6.01a 5.55a 
<0.001** 
SD 133.47 2.40 2.12 
100µA/60 seconds 
Mean 238.69 5.79a 5.78a 
<0.001** 
SD 142.22 2.34 2.39 
100µA/60 seconds 
Mean 246.98 6.03a 5.75a 
<0.001** 
SD 152.56 2.86 2.37 
100µA/60 seconds 
Mean 253.88 5.96a 5.98a 
<0.001** 
SD 161.37 2.94 2.59 
100µA/60 seconds 
Mean 248.19 5.85a 6.09a 
<0.001** 
SD 161.78 3.03 2.72 
100µA/60 seconds 
Mean 258.02 5.89a 6.01a 
<0.001** 
SD 160.39 2.98 2.60 
100µA/60 seconds 
Mean 260.47 5.91a 5.85a 
<0.001** 
SD 151.49 2.87 2.51 
100µA/60 seconds 
Mean 260.48 5.75a 5.73a 
<0.001** 
SD 156.91 2.81 2.39 
Peak of Max 
response 
Mean 314.91 11.48a 11.54a 
<0.001** 
SD 167.14 4.50 4.20 
Change in 
response % 
Mean 543.54 124.02a 130.29a 
0.002* 
SD 585.51 53.23 60.42 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 31 Comparison between the three tested pressure conditions application on flux median (PU) 
during the iontophoresis of SNP on the plantar surface in diabetes group using: One Way analysis of 
variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 67.52 5.45a 4.65a 
<0.001** 
SD 45.70 4.00 1.93 
100µA/60 seconds 
Mean 76.53 5.80a 4.74a 
<0.001** 
SD 54.62 4.50 1.87 
100µA/60 seconds 
Mean 90.69 5.95a 4.67a 
<0.001** 
SD 66.88 5.67 1.85 
100µA/60 seconds 
Mean 121.96 5.41a 4.80a 
<0.001** 
SD 81.69 4.08 2.29 
100µA/60 seconds 
Mean 157.38 5.99a 4.87a 
<0.001** 
SD 98.94 5.52 2.07 
100µA/60 seconds 
Mean 177.60 5.65a 4.69a 
<0.001** 
SD 99.63 4.30 1.85 
100µA/60 seconds 
Mean 193.88 5.97a 4.41a 
<0.001** 
SD 109.66 5.60 1.57 
100µA/60 seconds 
Mean 192.97 7.23a 4.41a 
<0.001** 
SD 110.96 10.15 1.69 
100µA/60 seconds 
Mean 196.31 7.39a 4.20a 
<0.001** 
SD 113.92 11.03 1.70 
100µA/60 seconds 
Mean 190.29 7.73a 4.50a 
<0.001** 
SD 117.53 11.82 2.02 
100µA/60 seconds 
Mean 189.45 6.81a 4.39a 
<0.001** 
SD 117.53 9.22 1.90 
100µA/60 seconds 
Mean 186.15 6.91a 4.37a 
<0.001** 
SD 109.22 9.54 1.86 
100µA/60 seconds 
Mean 184.92 6.58a 4.43a 
<0.001** 
SD 101.43 9.17 2.00 
100µA/60 seconds 
Mean 187.89 6.70a 4.63a 
<0.001** 
SD 90.25 7.99 2.19 
100µA/60 seconds 
Mean 181.20 7.17a 4.39a 
<0.001** 
SD 81.34 10.18 1.77 
Peak of Max 
response 
Mean 247.69 14.86a 9.55a 
<0.001** 
SD 112.18 19.78 3.68 
Change in 
response % 
Mean 332.47 141.91a 111.26ab 
<0.001** 
SD 146.04 88.61 47.50 
 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 32 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of ACh on the dorsal surface in diabetes group using: One Way analysis of variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 29.94 9.02a 6.45a 
<0.001** 
SD 17.17 3.29 1.94 
100µA/60 seconds 
Mean 39.73 9.14a 6.94a 
<0.001** 
SD 24.75 3.30 2.21 
100µA/60 seconds 
Mean 59.58 9.40a 6.74a 
<0.001** 
SD 39.07 3.09 2.34 
100µA/60 seconds 
Mean 68.04 9.68a 7.16a 
<0.001** 
SD 42.22 3.21 2.55 
100µA/60 seconds 
Mean 80.00 10.17a 7.35a 
<0.001** 
SD 47.10 3.60 2.62 
100µA/60 seconds 
Mean 89.33 10.15a 7.29a 
<0.001** 
SD 50.18 3.71 2.61 
100µA/60 seconds 
Mean 97.13 10.74a 7.53a 
<0.001** 
SD 53.29 4.27 2.93 
100µA/60 seconds 
Mean 102.41 11.25a 7.50a 
<0.001** 
SD 56.19 4.78 2.92 
100µA/60 seconds 
Mean 108.02 11.26a 7.85a 
<0.001** 
SD 56.37 4.50 3.02 
100µA/60 seconds 
Mean 105.26 11.43a 7.96a 
<0.001** 
SD 51.32 4.47 3.32 
100µA/60 seconds 
Mean 111.96 12.68a 7.98a 
<0.001** 
SD 58.03 5.46 3.42 
100µA/60 seconds 
Mean 112.27 12.12a 7.76a 
<0.001** 
SD 67.68 5.51 3.08 
100µA/60 seconds 
Mean 112.81 11.67a 7.99a 
<0.001** 
SD 80.23 4.03 3.48 
100µA/60 seconds 
Mean 109.59 12.23a 8.24a 
<0.001** 
SD 80.03 5.03 3.26 
100µA/60 seconds 
Mean 108.66 12.18a 8.25a 
<0.001** 
SD 77.55 4.96 3.26 
Peak of Max 
response 
Mean 141.10 20.40a 14.52a 
<0.001** 
SD 85.93 8.03 5.34 
Change in 
response % 
Mean 433.65 133.73a 125.65a 
<0.001** 
SD 308.32 69.18 47.70 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 33 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of SNP on the dorsal surface in diabetes group using: One Way analysis of variance. 
Iontophoresis 
Dorsum No 
pressure 
Dorsum 
Ortho 
pressure 
Dorsum Own 
pressure 
p 
0µA/60 seconds 
Mean 24.44 8.05a 7.71a 
<0.001** 
SD 11.41 3.09 3.60 
100µA/60 seconds 
Mean 23.86 8.71a 7.81a 
<0.001** 
SD 9.61 4.35 3.52 
100µA/60 seconds 
Mean 37.58 8.76a 7.96a 
<0.001** 
SD 17.74 4.41 3.34 
100µA/60 seconds 
Mean 64.83 9.28a 8.43a 
<0.001** 
SD 40.74 4.62 3.73 
100µA/60 seconds 
Mean 92.24 9.73a 8.81a 
<0.001** 
SD 73.75 4.66 4.25 
100µA/60 seconds 
Mean 115.11 9.84a 9.19a 
<0.001** 
SD 100.12 4.48 4.74 
100µA/60 seconds 
Mean 125.05 9.67a 9.51a 
<0.001** 
SD 102.17 4.79 5.03 
100µA/60 seconds 
Mean 131.76 9.68a 9.63a 
<0.001** 
SD 100.13 5.09 5.40 
100µA/60 seconds 
Mean 131.05 9.61a 9.35a 
<0.001** 
SD 87.20 4.90 4.84 
100µA/60 seconds 
Mean 137.56 9.52a 9.23a 
<0.001** 
SD 87.12 5.46 4.55 
100µA/60 seconds 
Mean 140.41 9.84a 9.36a 
<0.001** 
SD 84.96 5.59 4.20 
100µA/60 seconds 
Mean 141.00 10.04a 9.73a 
<0.001** 
SD 85.89 5.88 4.59 
100µA/60 seconds 
Mean 139.51 10.34a 10.02a 
<0.001** 
SD 84.40 6.23 5.00 
100µA/60 seconds 
Mean 137.54 10.68a 9.76a 
<0.001** 
SD 78.24 6.56 4.50 
100µA/60 seconds 
Mean 136.17 10.95a 9.59a 
<0.001** 
SD 79.59 6.83 4.33 
Peak of Max 
response 
Mean 164.80 18.56a 18.63a 
<0.001** 
SD 97.46 9.48 7.96 
Change in 
response % 
Mean 643.82 127.73a 156.10ab 
<0.001** 
SD 448.18 45.14 76.46 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 34 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of ACh on the plantar surface in diabetes group using: One Way analysis of variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 74.37 5.39a 5.49a 
<0.001** 
SD 44.50 1.90 2.05 
100µA/60 seconds 
Mean 86.94 5.74a 5.73a 
<0.001** 
SD 47.26 2.14 2.19 
100µA/60 seconds 
Mean 119.68 5.75a 5.94a 
<0.001** 
SD 67.90 2.22 2.31 
100µA/60 seconds 
Mean 169.98 5.85a 5.98a 
<0.001** 
SD 102.49 2.06 2.44 
100µA/60 seconds 
Mean 192.55 5.86a 5.99a 
<0.001** 
SD 115.84 2.29 2.38 
100µA/60 seconds 
Mean 208.65 5.99a 5.85a 
<0.001** 
SD 131.41 2.50 2.18 
100µA/60 seconds 
Mean 220.53 5.97a 6.04a 
<0.001** 
SD 136.63 2.42 2.49 
100µA/60 seconds 
Mean 227.05 6.42a 5.93a 
<0.001** 
SD 136.34 2.55 2.41 
100µA/60 seconds 
Mean 242.06 6.14a 6.08a 
<0.001** 
SD 144.28 2.46 2.52 
100µA/60 seconds 
Mean 251.27 6.25a 6.07a 
<0.001** 
SD 155.84 2.86 2.52 
100µA/60 seconds 
Mean 257.97 6.25a 6.42a 
<0.001** 
SD 163.25 2.97 2.72 
100µA/60 seconds 
Mean 252.36 6.08a 6.43a 
<0.001** 
SD 164.45 2.98 2.74 
100µA/60 seconds 
Mean 262.03 6.17a 6.34a 
<0.001** 
SD 162.67 2.94 2.65 
100µA/60 seconds 
Mean 264.38 6.17a 6.24a 
<0.001** 
SD 154.87 2.86 2.68 
100µA/60 seconds 
Mean 264.65 6.07a 6.09a 
<0.001** 
SD 159.12 2.84 2.63 
Peak of Max 
response 
Mean 314.91 11.48a 11.54a 
<0.001** 
SD 167.14 4.50 4.20 
Change in 
response % 
Mean 516.13 112.01a 116.65a 
0.002* 
SD 563.94 42.00 49.22 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 35 Comparison between the three tested pressure conditions flux mean (PU) during the 
iontophoresis of SNP on the plantar surface in diabetes group using: One Way analysis of variance. 
Iontophoresis 
Plantar No 
pressure 
Plantar 
Ortho 
pressure 
Plantar Own 
pressure 
p 
0µA/60 seconds 
Mean 70.39 5.93a 4.92a 
<0.001** 
SD 46.32 4.98 1.91 
100µA/60 seconds 
Mean 78.38 6.45a 5.03a 
<0.001** 
SD 55.31 5.73 1.98 
100µA/60 seconds 
Mean 94.01 6.64a 5.01a 
<0.001** 
SD 68.55 6.95 1.94 
100µA/60 seconds 
Mean 124.09 6.09a 5.02a 
<0.001** 
SD 81.68 5.36 2.25 
100µA/60 seconds 
Mean 159.19 6.62a 5.22a 
<0.001** 
SD 98.88 6.82 2.19 
100µA/60 seconds 
Mean 180.58 6.26a 5.01a 
<0.001** 
SD 101.00 5.60 1.97 
100µA/60 seconds 
Mean 195.09 6.62a 4.81a 
<0.001** 
SD 109.55 6.84 1.68 
100µA/60 seconds 
Mean 195.65 7.63a 4.76a 
<0.001** 
SD 111.51 10.55 1.86 
100µA/60 seconds 
Mean 199.05 7.80a 4.51a 
<0.001** 
SD 114.48 11.34 1.93 
100µA/60 seconds 
Mean 193.60 8.03a 4.79a 
<0.001** 
SD 118.05 11.92 2.13 
100µA/60 seconds 
Mean 192.41 7.38a 4.69a 
<0.001** 
SD 117.58 10.26 2.03 
100µA/60 seconds 
Mean 189.99 7.48a 4.72a 
<0.001** 
SD 110.35 10.20 1.97 
100µA/60 seconds 
Mean 188.82 7.13a 4.72a 
<0.001** 
SD 102.20 10.14 2.17 
100µA/60 seconds 
Mean 190.06 7.30a 4.85a 
<0.001** 
SD 91.38 9.12 2.19 
100µA/60 seconds 
Mean 183.48 7.59a 4.67a 
<0.001** 
SD 82.20 10.72 1.92 
Peak of Max 
response 
Mean 247.69 14.86a 9.55a 
<0.001** 
SD 112.18 19.78 3.68 
Change in 
response % 
Mean 310.31 124.58a 96.93ab 
<0.001** 
SD 139.64 67.91 38.99 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
Post Hoc: a: significant difference with no pressure; b: significant difference with Ortho pressure 
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Table 36 Comparison between control group and diabetes group median of flux (PU) on the dorsum 
of the foot with no pressure applied during the iontophoresis of ACh using: Independent Sample t-
test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 20.82 13.74 8.8 69 
0.115 
Diabetes 29.19 16.90 11.2 60.7 
100µA/60 seconds 
Control 28.50 19.25 12.1 83.5 
0.185 
Diabetes 38.33 23.74 11.4 78.6 
100µA/60 seconds 
Control 40.86 21.37 14.8 96.7 
0.103 
Diabetes 57.91 38.24 14.1 153.5 
100µA/60 seconds 
Control 52.47 21.78 11.9 95.5 
0.208 
Diabetes 66.30 41.27 13.3 162.5 
100µA/60 seconds 
Control 64.61 28.92 22.9 142.8 
0.297 
Diabetes 78.09 46.20 15.6 167.8 
100µA/60 seconds 
Control 75.30 34.93 22.7 167.5 
0.400 
Diabetes 87.43 49.41 19.4 169.4 
100µA/60 seconds 
Control 83.72 37.64 31.3 188.1 
0.448 
Diabetes 95.35 51.98 22.5 176.7 
100µA/60 seconds 
Control 97.32 43.88 47.9 201 
0.840 
Diabetes 100.72 55.12 22.1 182.2 
100µA/60 seconds 
Control 113.61 45.04 53.6 225.8 
0.675 
Diabetes 106.39 55.74 25.7 186.5 
100µA/60 seconds 
Control 124.31 50.19 55.7 222.2 
0.212 
Diabetes 102.57 49.67 27.1 178.1 
100µA/60 seconds 
Control 129.34 46.54 55.4 226.3 
0.276 
Diabetes 110.01 56.77 30.1 198.3 
100µA/60 seconds 
Control 129.06 47.85 59.6 228.9 
0.342 
Diabetes 110.50 66.23 38.8 281.9 
100µA/60 seconds 
Control 128.14 49.16 62 237.1 
0.413 
Diabetes 110.34 77.66 38.3 318.7 
100µA/60 seconds 
Control 130.24 51.97 49.6 238.8 
0.308 
Diabetes 107.41 78.45 27.5 312.4 
100µA/60 seconds 
Control 132.43 54.08 35.9 242.1 
0.261 
Diabetes 107.33 75.96 23.4 294.1 
Peak of Max 
response 
Control 142.99 39.56 74.5 233.47 
0.931 
Diabetes 141.10 85.93 40.1 369.01 
Change in 
response % 
Control 756.05 467.04 238.36 1905.94 
0.037* 
Diabetes 450.48 319.52 104.75 1113.00 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 37 Comparison between control group and diabetes group median of flux (PU) on the dorsum 
of the foot with no pressure applied during the iontophoresis of SNP using: Independent Sample t-
test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 24.64 12.18 11 59 
0.811 
Diabetes 23.67 11.36 11.6 49.2 
100µA/60 seconds 
Control 28.63 13.96 12.6 68.2 
0.186 
Diabetes 22.95 9.62 12 50.6 
100µA/60 seconds 
Control 44.27 26.18 18.1 94.1 
0.297 
Diabetes 36.07 16.59 12.7 69.4 
100µA/60 seconds 
Control 59.95 34.65 15.8 121 
0.807 
Diabetes 63.04 39.50 16.4 173.3 
100µA/60 seconds 
Control 73.97 43.86 14.9 167.2 
0.428 
Diabetes 89.81 72.49 14.9 252.9 
100µA/60 seconds 
Control 86.76 46.12 18 170.4 
0.300 
Diabetes 113.62 101.29 22.2 384.5 
100µA/60 seconds 
Control 96.52 49.37 23 186 
0.314 
Diabetes 123.03 101.49 39.4 372.2 
100µA/60 seconds 
Control 103.14 46.97 34.7 194.6 
0.304 
Diabetes 129.67 100.12 41.6 363.4 
100µA/60 seconds 
Control 111.09 47.18 41.3 196.7 
0.458 
Diabetes 128.03 85.26 43.2 364.6 
100µA/60 seconds 
Control 116.28 48.95 44.3 212.5 
0.421 
Diabetes 134.79 84.67 41.9 362 
100µA/60 seconds 
Control 119.73 47.11 44.7 196.6 
0.421 
Diabetes 137.69 82.57 47.9 366.5 
100µA/60 seconds 
Control 124.47 51.82 39.2 210.9 
0.556 
Diabetes 138.11 83.54 46.5 362.4 
100µA/60 seconds 
Control 119.07 43.26 49.1 185.5 
0.403 
Diabetes 137.27 82.40 47.1 366.2 
100µA/60 seconds 
Control 123.62 43.66 49.8 181.4 
0.572 
Diabetes 135.26 76.21 51.3 351.1 
100µA/60 seconds 
Control 123.51 45.73 43.7 191.7 
0.632 
Diabetes 133.67 77.87 52.2 363.9 
Peak of Max 
response 
Control 141.32 56.41 56.26 242.25 
0.376 
Diabetes 164.80 97.46 67.04 413.13 
Change in 
response % 
Control 517.86 247.75 153.91 1087.50 
0.214 
Diabetes 673.14 469.64 214.20 1607.15 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
 
  
297 
 
 
Table 38 Comparison between control group and diabetes group median of flux (PU) on the dorsum 
of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh using: 
Independent Sample t-test. 
Iontophoresis Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 6.40 2.83 4.1 17.2 
0.034* 
Diabetes 8.73 3.37 3.3 16.7 
100µA/60 seconds 
Control 6.72 2.76 4.3 17.1 
0.035* 
Diabetes 8.76 3.25 3.4 15.7 
100µA/60 seconds 
Control 7.22 2.99 4.4 18.2 
0.081 
Diabetes 9.05 2.97 3.3 13.3 
100µA/60 seconds 
Control 7.57 3.45 4.1 20.2 
0.127 
Diabetes 9.32 3.04 3.5 14.4 
100µA/60 seconds 
Control 7.74 3.70 4.3 20.2 
0.103 
Diabetes 9.79 3.42 3.8 16.5 
100µA/60 seconds 
Control 8.29 4.61 4.2 24.5 
0.307 
Diabetes 9.77 3.56 3.9 16.5 
100µA/60 seconds 
Control 8.49 5.26 4.3 27.8 
0.251 
Diabetes 10.41 4.10 4.2 17.7 
100µA/60 seconds 
Control 8.85 5.50 5.1 29.3 
0.267 
Diabetes 10.81 4.52 4.4 19.2 
100µA/60 seconds 
Control 9.13 6.26 4.6 33.5 
0.374 
Diabetes 10.83 4.33 4.6 17.9 
100µA/60 seconds 
Control 9.32 6.17 5.1 32.8 
0.359 
Diabetes 11.05 4.35 4.7 19.9 
100µA/60 seconds 
Control 10.11 6.38 5 32.2 
0.278 
Diabetes 12.34 5.29 4.9 25.9 
100µA/60 seconds 
Control 10.65 6.89 5.2 34.3 
0.609 
Diabetes 11.76 5.43 4.7 26.7 
100µA/60 seconds 
Control 10.41 6.54 4.9 31.5 
0.643 
Diabetes 11.30 3.87 4.7 17.9 
100µA/60 seconds 
Control 10.20 6.45 5.2 32.1 
0.404 
Diabetes 11.89 4.88 4.6 22.1 
100µA/60 seconds 
Control 11.14 8.43 4.8 42.8 
0.774 
Diabetes 11.84 4.81 4.5 21.8 
Peak of Max 
response 
Control 18.27 8.19 11.18 48.47 
0.447 
Diabetes 20.40 8.03 8.39 37.53 
Change in 
response % 
Control 192.00 80.08 113.73 458.38 
0.089 
Diabetes 144.70 77.64 40.97 307.95 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 39 Comparison between control group and diabetes group median of flux (PU) on the dorsum 
of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 7.37 4.41 2 19.2 
0.914 
Diabetes 7.51 2.81 2.7 12.9 
100µA/60 seconds 
Control 7.86 4.54 2.2 19.8 
0.779 
Diabetes 8.29 4.25 2.7 20.4 
100µA/60 seconds 
Control 11.67 18.53 2.2 88.5 
0.499 
Diabetes 8.32 4.25 2.7 21 
100µA/60 seconds 
Control 12.71 21.98 2.4 104.5 
0.507 
Diabetes 8.83 4.34 2.7 20.5 
100µA/60 seconds 
Control 12.10 16.70 2.4 80.2 
0.512 
Diabetes 9.15 4.32 2.9 19.7 
100µA/60 seconds 
Control 13.52 22.75 2.8 108.3 
0.485 
Diabetes 9.31 4.20 2.8 18.1 
100µA/60 seconds 
Control 15.41 29.93 2.8 141 
0.432 
Diabetes 9.19 4.46 2.8 19.5 
100µA/60 seconds 
Control 13.95 22.85 3.3 109 
0.437 
Diabetes 9.21 4.77 2.8 21.7 
100µA/60 seconds 
Control 12.49 16.40 2.9 78.8 
0.441 
Diabetes 9.09 4.53 2.9 21 
100µA/60 seconds 
Control 12.56 15.53 3.1 75.7 
0.400 
Diabetes 8.99 5.04 3.3 23.3 
100µA/60 seconds 
Control 12.06 13.06 3.1 63.9 
0.456 
Diabetes 9.35 5.27 2.9 24.9 
100µA/60 seconds 
Control 12.98 16.86 3.7 81.7 
0.464 
Diabetes 9.61 5.53 3.1 25.6 
100µA/60 seconds 
Control 13.47 18.23 3.9 88.1 
0.470 
Diabetes 9.89 5.87 2.9 26.8 
100µA/60 seconds 
Control 14.69 23.67 3.6 113.6 
0.489 
Diabetes 10.29 6.23 3 28.6 
100µA/60 seconds 
Control 15.48 26.16 3.7 124.7 
0.485 
Diabetes 10.59 6.55 3 30.3 
Peak of Max 
response 
Control 23.91 27.79 6.64 137.13 
0.481 
Diabetes 18.56 9.48 6.64 46.66 
Change in 
response % 
Control 199.67 124.29 45.29 633.29 
0.125 
Diabetes 145.36 55.33 74.17 261.72 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 40 Comparison between control group and diabetes group median of flux (PU) on the dorsum 
of the foot with pressure in Own shoes applied during the iontophoresis of ACh using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 6.25 1.67 3.2 8.6 
0.932 
Diabetes 6.19 1.90 3.5 10.7 
100µA/60 seconds 
Control 6.31 1.67 3.6 9 
0.576 
Diabetes 6.67 2.12 4.1 12.2 
100µA/60 seconds 
Control 6.50 1.76 3.3 9.7 
0.831 
Diabetes 6.35 2.29 4.2 11.9 
100µA/60 seconds 
Control 6.75 1.86 3.7 10 
0.981 
Diabetes 6.73 2.33 4.2 11.6 
100µA/60 seconds 
Control 6.73 2.16 3.8 11.1 
0.780 
Diabetes 6.94 2.33 4.4 11.8 
100µA/60 seconds 
Control 6.87 2.30 3.7 11.6 
0.998 
Diabetes 6.87 2.30 4.3 12.3 
100µA/60 seconds 
Control 7.02 2.29 4.1 12.7 
0.949 
Diabetes 7.07 2.64 4.3 12.8 
100µA/60 seconds 
Control 7.14 2.28 3.8 13.2 
0.936 
Diabetes 7.07 2.60 4.3 12.7 
100µA/60 seconds 
Control 7.45 2.27 4.2 13.8 
0.940 
Diabetes 7.39 2.67 4.2 12.9 
100µA/60 seconds 
Control 7.68 2.48 3.8 13.1 
0.887 
Diabetes 7.55 3.02 4.2 13.6 
100µA/60 seconds 
Control 7.53 2.50 4 13.5 
0.997 
Diabetes 7.53 3.06 3.8 14.1 
100µA/60 seconds 
Control 7.92 2.71 3.8 14.3 
0.532 
Diabetes 7.32 2.81 4.3 13.2 
100µA/60 seconds 
Control 7.82 2.75 3.8 14.5 
0.809 
Diabetes 7.57 3.09 3.9 13.5 
100µA/60 seconds 
Control 7.92 2.71 4.2 14.4 
0.890 
Diabetes 7.79 2.95 4.2 13.9 
100µA/60 seconds 
Control 8.40 3.02 3.9 15.8 
0.584 
Diabetes 7.83 2.98 4.2 13.9 
Peak of Max 
response 
Control 14.90 3.64 8.94 23.5 
0.803 
Diabetes 14.52 5.34 8.07 27.51 
Change in 
response % 
Control 149.65 66.86 29.87 274.80 
0.525 
Diabetes 136.01 55.09 65.77 293.04 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 41 Comparison between control group and diabetes group median of flux (PU) on the dorsum 
of the foot with pressure in Own shoes applied during the iontophoresis of SNP using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 6.21 2.39 3 11.3 
0.271 
Diabetes 7.29 3.37 3.3 13.9 
100µA/60 seconds 
Control 6.43 2.42 3.5 12 
0.341 
Diabetes 7.37 3.32 4 14.6 
100µA/60 seconds 
Control 6.64 2.54 3.9 11.9 
0.445 
Diabetes 7.37 3.10 4.2 13.8 
100µA/60 seconds 
Control 6.57 2.56 3.7 11.7 
0.177 
Diabetes 7.98 3.51 4.4 14.6 
100µA/60 seconds 
Control 6.52 2.42 3.5 10.3 
0.110 
Diabetes 8.35 4.13 4.2 17.1 
100µA/60 seconds 
Control 6.65 2.37 3.5 11.8 
0.090 
Diabetes 8.76 4.70 4.2 18.2 
100µA/60 seconds 
Control 6.57 2.41 3.5 12.3 
0.063 
Diabetes 9.03 5.03 3.9 19.4 
100µA/60 seconds 
Control 6.87 2.85 3.3 14.2 
0.108 
Diabetes 9.15 5.24 4.3 19.1 
100µA/60 seconds 
Control 6.83 2.73 3.3 15.2 
0.099 
Diabetes 8.99 4.79 4.5 17.4 
100µA/60 seconds 
Control 7.30 2.99 3.4 16.1 
0.260 
Diabetes 8.71 4.34 4.4 17.5 
100µA/60 seconds 
Control 7.39 3.20 3.4 17.1 
0.252 
Diabetes 8.82 4.06 4.4 17.8 
100µA/60 seconds 
Control 7.45 3.13 3.7 16.9 
0.172 
Diabetes 9.23 4.43 4.1 18.8 
100µA/60 seconds 
Control 7.22 2.93 3.8 16.7 
0.087 
Diabetes 9.55 4.88 4.2 21.8 
100µA/60 seconds 
Control 7.54 3.36 3.6 18.5 
0.230 
Diabetes 9.12 4.32 4.4 19.6 
100µA/60 seconds 
Control 7.45 3.53 3.7 18.8 
0.236 
Diabetes 9.00 4.07 3.9 18 
Peak of Max 
response 
Control 14.66 5.84 6.64 24.99 
0.098 
Diabetes 18.63 7.96 9.37 36.44 
Change in 
response % 
Control 139.22 51.86 36.83 252.02 
0.174 
Diabetes 171.43 84.82 84.80 340.80 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 42 Comparison between control group and diabetes group mean of flux (PU) on the dorsum of 
the foot with no pressure applied during the iontophoresis of ACh using: Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 21.67 13.98 9.93 71.03 
0.126 
Diabetes 29.94 17.17 11.64 63.03 
100µA/60 seconds 
Control 29.31 18.89 12.78 84.1 
0.167 
Diabetes 39.73 24.75 11.53 86.85 
100µA/60 seconds 
Control 41.99 21.43 15.57 96.34 
0.098 
Diabetes 59.58 39.07 13.89 158.8 
100µA/60 seconds 
Control 53.93 21.97 12.51 94.53 
0.208 
Diabetes 68.04 42.22 13.53 167.35 
100µA/60 seconds 
Control 67.18 28.24 25.34 143.13 
0.323 
Diabetes 80.00 47.10 16.46 173.83 
100µA/60 seconds 
Control 77.18 34.39 25.87 167.33 
0.401 
Diabetes 89.33 50.18 20.62 173.75 
100µA/60 seconds 
Control 85.52 37.75 31.93 187.96 
0.455 
Diabetes 97.13 53.29 22.66 180.32 
100µA/60 seconds 
Control 100.07 43.25 48.93 201.46 
0.890 
Diabetes 102.41 56.19 22.07 186.86 
100µA/60 seconds 
Control 116.98 44.96 54.94 225.13 
0.604 
Diabetes 108.02 56.37 26.11 187.88 
100µA/60 seconds 
Control 125.59 50.01 57.15 224.26 
0.248 
Diabetes 105.26 51.32 27.82 184.31 
100µA/60 seconds 
Control 130.94 46.43 56.81 226.84 
0.290 
Diabetes 111.96 58.03 30.9 204.09 
100µA/60 seconds 
Control 130.67 47.55 60.37 228.93 
0.351 
Diabetes 112.27 67.68 38.25 287.61 
100µA/60 seconds 
Control 129.83 48.93 63.49 236.78 
0.443 
Diabetes 112.81 80.23 38.22 330.17 
100µA/60 seconds 
Control 131.99 51.59 52.64 237.67 
0.322 
Diabetes 109.59 80.03 28.22 321.12 
100µA/60 seconds 
Control 133.99 53.84 36.69 242.13 
0.262 
Diabetes 108.66 77.55 23.97 302.41 
Peak of Max 
response 
Control 142.99 39.56 74.5 233.47 
0.931 
Diabetes 141.10 85.93 40.1 369.01 
Change in 
response % 
Control 711.29 431.85 228.69 1771.97 
0.042* 
Diabetes 433.65 308.32 102.61 1065.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 43 Comparison between control group and diabetes group mean of flux (PU) on the dorsum of 
the foot with no pressure applied during the iontophoresis of SNP using: Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 25.30 12.54 11.56 61.54 
0.835 
Diabetes 24.44 11.41 11.84 50.46 
100µA/60 seconds 
Control 29.56 14.31 13.17 70.54 
0.192 
Diabetes 23.86 9.61 12.4 50.77 
100µA/60 seconds 
Control 45.66 27.78 18.13 97.05 
0.332 
Diabetes 37.58 17.74 13.03 76.62 
100µA/60 seconds 
Control 61.62 35.86 16.26 128.79 
0.806 
Diabetes 64.83 40.74 16.52 178.42 
100µA/60 seconds 
Control 75.58 44.35 15.61 169.21 
0.412 
Diabetes 92.24 73.75 15.13 259.41 
100µA/60 seconds 
Control 88.54 46.62 19.83 173.31 
0.302 
Diabetes 115.11 100.12 22.91 372.21 
100µA/60 seconds 
Control 98.11 49.84 24.36 185.23 
0.310 
Diabetes 125.05 102.17 40.05 369.64 
100µA/60 seconds 
Control 104.67 47.73 33.77 194.16 
0.295 
Diabetes 131.76 100.13 42.89 373.05 
100µA/60 seconds 
Control 112.80 48.05 41.6 196.75 
0.434 
Diabetes 131.05 87.20 45.18 372.15 
100µA/60 seconds 
Control 117.98 49.24 45.84 210.15 
0.405 
Diabetes 137.56 87.12 42.26 372.67 
100µA/60 seconds 
Control 121.38 47.80 46.88 199.2 
0.406 
Diabetes 140.41 84.96 48.22 376.16 
100µA/60 seconds 
Control 125.73 51.96 40.36 213.03 
0.518 
Diabetes 141.00 85.89 47.82 371.93 
100µA/60 seconds 
Control 121.68 44.66 48.69 184.07 
0.425 
Diabetes 139.51 84.40 47.8 375.59 
100µA/60 seconds 
Control 125.07 44.94 50.29 185.84 
0.555 
Diabetes 137.54 78.24 52.35 359.86 
100µA/60 seconds 
Control 125.04 46.76 43.28 192.66 
0.607 
Diabetes 136.17 79.59 53.37 371.39 
Peak of Max 
response 
Control 141.32 56.41 56.26 242.25 
0.376 
Diabetes 164.80 97.46 67.04 413.13 
Change in 
response % 
Control 502.76 244.33 157.04 1065.78 
0.241 
Diabetes 643.82 448.18 212.22 1572.60 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 44 Comparison between control group and diabetes group mean of flux (PU) on the dorsum of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 6.83 2.93 4.19 17.96 
0.045* 
Diabetes 9.02 3.29 3.41 16.65 
100µA/60 seconds 
Control 7.19 2.96 4.51 18.33 
0.076 
Diabetes 9.14 3.30 3.56 16.1 
100µA/60 seconds 
Control 7.71 3.22 5 19.57 
0.127 
Diabetes 9.40 3.09 3.45 14.45 
100µA/60 seconds 
Control 8.06 3.65 4.67 21.36 
0.181 
Diabetes 9.68 3.21 3.6 15.16 
100µA/60 seconds 
Control 8.20 3.81 5 21.03 
0.132 
Diabetes 10.17 3.60 4 16.74 
100µA/60 seconds 
Control 8.75 4.79 4.41 25.61 
0.354 
Diabetes 10.15 3.71 4.11 16.73 
100µA/60 seconds 
Control 8.94 5.47 4.77 29.01 
0.299 
Diabetes 10.74 4.27 4.26 18.72 
100µA/60 seconds 
Control 9.30 5.65 5.71 30.38 
0.289 
Diabetes 11.25 4.78 4.59 20.97 
100µA/60 seconds 
Control 9.59 6.36 5.23 34.22 
0.395 
Diabetes 11.26 4.50 4.82 18.7 
100µA/60 seconds 
Control 9.75 6.28 5.45 33.64 
0.386 
Diabetes 11.43 4.47 4.91 20.43 
100µA/60 seconds 
Control 10.53 6.47 5.51 33.1 
0.306 
Diabetes 12.68 5.46 5.13 26.74 
100µA/60 seconds 
Control 11.03 6.95 5.66 34.76 
0.620 
Diabetes 12.12 5.51 4.91 27.38 
100µA/60 seconds 
Control 10.79 6.65 5.31 32.3 
0.655 
Diabetes 11.67 4.03 4.93 19.06 
100µA/60 seconds 
Control 10.62 6.62 5.45 33.39 
0.439 
Diabetes 12.23 5.03 4.76 23.13 
100µA/60 seconds 
Control 11.34 8.14 5.04 41.42 
0.725 
Diabetes 12.18 4.96 4.59 22.99 
Peak of Max 
response 
Control 18.27 8.19 11.18 48.47 
0.447 
Diabetes 20.40 8.03 8.39 37.53 
Change in 
response % 
Control 172.88 75.75 104.14 446.39 
0.126 
Diabetes 133.73 69.18 40.83 295.90 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 45 Comparison between control group and diabetes group mean of flux (PU) on the dorsum of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 7.96 4.49 2.17 19.9 
0.942 
Diabetes 8.05 3.09 2.86 15.16 
100µA/60 seconds 
Control 8.42 4.68 2.45 20.54 
0.856 
Diabetes 8.71 4.35 2.85 21.14 
100µA/60 seconds 
Control 12.01 17.55 2.33 84.4 
0.490 
Diabetes 8.76 4.41 2.76 22.04 
100µA/60 seconds 
Control 13.08 21.45 2.45 102.37 
0.506 
Diabetes 9.28 4.62 2.84 22.21 
100µA/60 seconds 
Control 12.54 16.60 2.56 80.11 
0.529 
Diabetes 9.73 4.66 2.96 21.86 
100µA/60 seconds 
Control 14.05 22.93 2.98 109.5 
0.489 
Diabetes 9.84 4.48 2.88 19.92 
100µA/60 seconds 
Control 15.71 29.33 3.03 138.65 
0.437 
Diabetes 9.67 4.79 2.94 21.64 
100µA/60 seconds 
Control 14.44 22.99 3.51 109.99 
0.438 
Diabetes 9.68 5.09 2.84 23.41 
100µA/60 seconds 
Control 13.02 16.52 3.11 79.75 
0.445 
Diabetes 9.61 4.90 3.03 23.02 
100µA/60 seconds 
Control 13.12 15.97 3.22 78.02 
0.411 
Diabetes 9.52 5.46 3.51 25.5 
100µA/60 seconds 
Control 12.45 13.02 3.2 63.86 
0.473 
Diabetes 9.84 5.59 2.98 26.72 
100µA/60 seconds 
Control 13.51 17.47 3.77 84.78 
0.466 
Diabetes 10.04 5.88 3.24 27.47 
100µA/60 seconds 
Control 13.93 18.48 4.08 89.62 
0.477 
Diabetes 10.34 6.23 3.01 28.93 
100µA/60 seconds 
Control 15.28 24.23 3.88 116.5 
0.481 
Diabetes 10.68 6.56 3.16 30.58 
100µA/60 seconds 
Control 15.95 26.15 3.9 125.04 
0.476 
Diabetes 10.95 6.83 3.18 32 
Peak of Max 
response 
Control 23.91 27.79 6.64 137.13 
0.481 
Diabetes 18.56 9.48 6.64 46.66 
Change in 
response % 
Control 174.99 119.05 38.69 616.06 
0.155 
Diabetes 127.73 45.14 74.17 216.61 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 46 Comparison between control group and diabetes group mean of flux (PU) on the dorsum of 
the foot with pressure in Own shoes applied during the iontophoresis of ACh using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 6.56 1.67 3.3 9.09 
0.861 
Diabetes 6.45 1.94 3.49 11.15 
100µA/60 seconds 
Control 6.68 1.71 3.89 9.51 
0.696 
Diabetes 6.94 2.21 4.33 12.91 
100µA/60 seconds 
Control 6.97 1.88 3.49 10.31 
0.752 
Diabetes 6.74 2.34 4.59 12.52 
100µA/60 seconds 
Control 7.21 1.99 3.91 10.86 
0.950 
Diabetes 7.16 2.55 4.36 12.56 
100µA/60 seconds 
Control 7.17 2.31 4 11.64 
0.830 
Diabetes 7.35 2.62 4.54 13.51 
100µA/60 seconds 
Control 7.32 2.39 4.05 12.06 
0.967 
Diabetes 7.29 2.61 4.4 12.98 
100µA/60 seconds 
Control 7.43 2.32 4.45 12.73 
0.913 
Diabetes 7.53 2.93 4.42 14.25 
100µA/60 seconds 
Control 7.54 2.37 4.12 13.55 
0.965 
Diabetes 7.50 2.92 4.51 14.2 
100µA/60 seconds 
Control 7.86 2.25 4.45 13.78 
0.988 
Diabetes 7.85 3.02 4.29 14.78 
100µA/60 seconds 
Control 8.06 2.55 3.91 13.82 
0.925 
Diabetes 7.96 3.32 4.57 15.69 
100µA/60 seconds 
Control 7.97 2.54 4.11 14.19 
0.996 
Diabetes 7.98 3.42 4.06 16.35 
100µA/60 seconds 
Control 8.32 2.71 3.93 14.46 
0.573 
Diabetes 7.76 3.08 4.39 14.06 
100µA/60 seconds 
Control 8.20 2.79 3.99 14.92 
0.847 
Diabetes 7.99 3.48 4.05 15.97 
100µA/60 seconds 
Control 8.35 2.82 4.31 15.27 
0.916 
Diabetes 8.24 3.26 4.26 15.38 
100µA/60 seconds 
Control 8.73 3.02 4.06 15.59 
0.661 
Diabetes 8.25 3.26 4.32 14.85 
Peak of Max 
response 
Control 14.90 3.64 8.94 23.5 
0.803 
Diabetes 14.52 5.34 8.07 27.51 
Change in 
response % 
Control 136.28 61.02 30.63 263.45 
0.581 
Diabetes 125.65 47.70 64.24 255.00 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 47 Comparison between control group and diabetes group mean of flux (PU) on the dorsum of 
the foot with pressure in Own shoes applied during the iontophoresis of SNP using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 6.57 2.50 3.14 11.98 
0.279 
Diabetes 7.71 3.60 3.55 14.46 
100µA/60 seconds 
Control 6.85 2.53 3.57 12.73 
0.353 
Diabetes 7.81 3.52 4.5 15.24 
100µA/60 seconds 
Control 7.03 2.65 4.15 12.71 
0.365 
Diabetes 7.96 3.34 4.32 14.51 
100µA/60 seconds 
Control 6.93 2.71 4 11.62 
0.178 
Diabetes 8.43 3.73 4.64 15.15 
100µA/60 seconds 
Control 6.96 2.57 3.66 11.25 
0.119 
Diabetes 8.81 4.25 4.35 17.48 
100µA/60 seconds 
Control 7.07 2.55 3.65 12.59 
0.098 
Diabetes 9.19 4.74 4.71 18.38 
100µA/60 seconds 
Control 7.02 2.63 3.64 13.19 
0.066 
Diabetes 9.51 5.03 4.01 19.24 
100µA/60 seconds 
Control 7.30 3.05 3.51 15.01 
0.115 
Diabetes 9.63 5.40 4.6 19.4 
100µA/60 seconds 
Control 7.31 2.93 3.51 16.16 
0.132 
Diabetes 9.35 4.84 4.87 17.36 
100µA/60 seconds 
Control 7.72 3.23 3.57 16.95 
0.259 
Diabetes 9.23 4.55 5.02 18.5 
100µA/60 seconds 
Control 7.81 3.37 3.58 17.83 
0.236 
Diabetes 9.36 4.20 4.61 17.86 
100µA/60 seconds 
Control 7.85 3.32 3.77 17.91 
0.170 
Diabetes 9.73 4.59 4.28 19 
100µA/60 seconds 
Control 7.67 3.17 3.91 17.69 
0.097 
Diabetes 10.02 5.00 4.37 21.84 
100µA/60 seconds 
Control 7.93 3.51 3.88 19.16 
0.185 
Diabetes 9.76 4.50 4.76 19.99 
100µA/60 seconds 
Control 7.85 3.67 3.9 19.33 
0.209 
Diabetes 9.59 4.33 4.04 18.74 
Peak of Max 
response 
Control 14.66 5.84 6.64 24.99 
0.098 
Diabetes 18.63 7.96 9.37 36.44 
Change in 
response % 
Control 124.89 43.93 37.44 215.18 
0.137 
Diabetes 156.10 76.46 77.65 291.82 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 48 Comparison between control group and diabetes group median of flux (PU) on the Plantar 
of the foot with no pressure applied during the iontophoresis of ACh using: Independent Sample t-
test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 45.22 32.22 11.8 122.3 
0.046* 
Diabetes 71.80 43.65 10.9 150.3 
100µA/60 seconds 
Control 44.78 31.79 8 120 
0.006* 
Diabetes 84.01 47.37 12.3 166.8 
100µA/60 seconds 
Control 59.97 39.06 11.8 130.4 
0.003* 
Diabetes 117.98 68.15 11.6 218.6 
100µA/60 seconds 
Control 87.74 74.46 14 280.4 
0.012* 
Diabetes 165.60 99.90 16.5 324.2 
100µA/60 seconds 
Control 105.96 104.81 14.9 421.3 
0.033* 
Diabetes 188.11 113.00 23.5 369.7 
100µA/60 seconds 
Control 130.41 129.36 9.2 515 
0.104 
Diabetes 203.95 128.43 23.8 412.2 
100µA/60 seconds 
Control 143.90 134.62 11.9 556 
0.126 
Diabetes 215.81 133.14 29.7 463.5 
100µA/60 seconds 
Control 153.66 137.10 18.9 571.6 
0.146 
Diabetes 222.55 133.47 31.6 478.6 
100µA/60 seconds 
Control 164.49 138.38 15.6 582.7 
0.130 
Diabetes 238.69 142.22 37.5 541 
100µA/60 seconds 
Control 183.41 138.92 11 583.5 
0.208 
Diabetes 246.98 152.56 35.7 620.5 
100µA/60 seconds 
Control 193.87 144.86 10.2 579.8 
0.256 
Diabetes 253.88 161.37 38.8 663.9 
100µA/60 seconds 
Control 202.97 149.53 9.5 577.8 
0.399 
Diabetes 248.19 161.78 46 675.2 
100µA/60 seconds 
Control 212.48 150.96 17.2 572.6 
0.396 
Diabetes 258.02 160.39 51.7 681.2 
100µA/60 seconds 
Control 219.14 164.21 10.6 576.8 
0.452 
Diabetes 260.47 151.49 58.8 673.3 
100µA/60 seconds 
Control 218.60 168.44 10.6 590.7 
0.459 
Diabetes 260.48 156.91 46.2 692 
Peak of Max 
response 
Control 223.44 140.95 33.39 588.58 
0.089 
Diabetes 314.91 167.14 47.67 662.91 
Change in 
response % 
Control 491.46 355.82 46.74 1272.23 
0.746 
Diabetes 543.54 585.51 58.05 2298.87 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 49 Comparison between control group and diabetes group median of flux (PU) on the Plantar 
of the foot with no pressure applied during the iontophoresis of SNP using: Independent Sample t-
test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 50.13 61.57 6.7 267.9 
0.365 
Diabetes 67.52 45.70 22.8 184.5 
100µA/60 seconds 
Control 48.54 60.26 8 270.6 
0.167 
Diabetes 76.53 54.62 24.8 219 
100µA/60 seconds 
Control 61.47 78.54 7.4 356.9 
0.255 
Diabetes 90.69 66.88 23.6 230 
100µA/60 seconds 
Control 84.66 83.00 7.9 376.3 
0.194 
Diabetes 121.96 81.69 33 256.2 
100µA/60 seconds 
Control 115.46 88.61 6.8 324.6 
0.197 
Diabetes 157.38 98.94 34.5 366.1 
100µA/60 seconds 
Control 143.24 121.10 11.1 363.5 
0.378 
Diabetes 177.60 99.63 35 424.6 
100µA/60 seconds 
Control 156.12 127.75 18.3 418.5 
0.365 
Diabetes 193.88 109.66 40.5 464.4 
100µA/60 seconds 
Control 163.81 134.38 12.6 496.7 
0.499 
Diabetes 192.97 110.96 56.9 488.2 
100µA/60 seconds 
Control 161.89 136.93 25.2 527.9 
0.436 
Diabetes 196.31 113.92 53.3 495.7 
100µA/60 seconds 
Control 163.39 135.21 13.4 551.5 
0.543 
Diabetes 190.29 117.53 44.8 488 
100µA/60 seconds 
Control 162.08 131.46 16.4 537.4 
0.528 
Diabetes 189.45 117.53 52.9 471.4 
100µA/60 seconds 
Control 162.21 129.28 12.3 518.6 
0.567 
Diabetes 186.15 109.22 59.5 461 
100µA/60 seconds 
Control 166.83 125.40 9.9 481.5 
0.650 
Diabetes 184.92 101.43 79.3 452.8 
100µA/60 seconds 
Control 155.81 119.80 11.3 469.4 
0.392 
Diabetes 187.89 90.25 73 431.3 
100µA/60 seconds 
Control 161.27 120.01 18.4 494.5 
0.583 
Diabetes 181.20 81.34 68.7 384.4 
Peak of Max 
response 
Control 203.12 138.22 32.07 502.48 
0.315 
Diabetes 247.69 112.18 110.78 485.71 
Change in 
response % 
Control 645.00 722.90 16.21 2484.31 
0.110 
Diabetes 332.47 146.04 66.77 611.09 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 50 Comparison between control group and diabetes group median of flux (PU) on the Plantar 
of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.66 1.54 2.1 8.9 
0.014* 
Diabetes 5.14 1.84 2.4 8.8 
100µA/60 seconds 
Control 3.91 1.84 2.1 9.9 
0.025* 
Diabetes 5.49 2.13 2.5 9 
100µA/60 seconds 
Control 4.04 1.98 2.2 10.3 
0.049* 
Diabetes 5.49 2.23 2.3 10 
100µA/60 seconds 
Control 4.11 2.06 2.1 10.7 
0.048* 
Diabetes 5.52 2.04 2.3 9.2 
100µA/60 seconds 
Control 4.05 2.00 2.2 10 
0.044* 
Diabetes 5.56 2.26 2.4 10.4 
100µA/60 seconds 
Control 4.01 2.00 2.1 9.7 
0.035* 
Diabetes 5.67 2.48 2.4 11.3 
100µA/60 seconds 
Control 4.06 1.96 2 9.9 
0.036* 
Diabetes 5.67 2.42 2.4 11.4 
100µA/60 seconds 
Control 4.24 2.06 2 9.7 
0.025* 
Diabetes 6.01 2.40 2.5 10.4 
100µA/60 seconds 
Control 4.42 2.10 1.9 11.1 
0.039* 
Diabetes 5.79 2.34 2.5 10.1 
100µA/60 seconds 
Control 4.44 2.74 1.9 14.5 
0.104 
Diabetes 6.03 2.86 2.5 12 
100µA/60 seconds 
Control 4.52 2.88 1.9 15.2 
0.155 
Diabetes 5.96 2.94 2.7 13.3 
100µA/60 seconds 
Control 4.51 2.82 2 14.6 
0.184 
Diabetes 5.85 3.03 2.6 13.9 
100µA/60 seconds 
Control 4.63 2.83 2 13.6 
0.211 
Diabetes 5.89 2.98 2.6 13.6 
100µA/60 seconds 
Control 4.58 2.71 2.1 12 
0.172 
Diabetes 5.91 2.87 2.8 12.6 
100µA/60 seconds 
Control 4.40 2.29 2 11.2 
0.126 
Diabetes 5.75 2.81 2.7 12.5 
Peak of Max 
response 
Control 8.98 4.19 4.22 21.98 
0.100 
Diabetes 11.48 4.50 4.38 20.16 
Change in 
response % 
Control 146.20 63.87 78.91 322.58 
0.284 
Diabetes 124.02 53.23 54.33 257.34 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 51 Comparison between control group and diabetes group median of flux (PU) on the Plantar 
of the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.59 1.33 1.8 6.4 
0.060 
Diabetes 5.45 4.00 2.4 18.5 
100µA/60 seconds 
Control 3.62 1.32 1.9 6.1 
0.047* 
Diabetes 5.80 4.50 2.5 20.9 
100µA/60 seconds 
Control 3.89 1.79 2 9.2 
0.134 
Diabetes 5.95 5.67 2.3 25.8 
100µA/60 seconds 
Control 4.05 1.90 2 8.8 
0.194 
Diabetes 5.41 4.08 2.3 19 
100µA/60 seconds 
Control 4.09 1.85 2.2 8.3 
0.157 
Diabetes 5.99 5.52 2.4 25 
100µA/60 seconds 
Control 4.01 1.74 2.1 8 
0.131 
Diabetes 5.65 4.30 2.4 19.7 
100µA/60 seconds 
Control 4.16 1.97 2.1 8.6 
0.187 
Diabetes 5.97 5.60 2.4 25.3 
100µA/60 seconds 
Control 4.43 2.34 2 10.7 
0.240 
Diabetes 7.23 10.15 2.5 43.4 
100µA/60 seconds 
Control 4.36 2.12 2.2 9.5 
0.237 
Diabetes 7.39 11.03 2.5 46.5 
100µA/60 seconds 
Control 4.15 1.89 2.1 9.3 
0.190 
Diabetes 7.73 11.82 2.5 49.7 
100µA/60 seconds 
Control 4.25 2.18 2.3 10.6 
0.237 
Diabetes 6.81 9.22 2.7 39.6 
100µA/60 seconds 
Control 4.20 1.84 2 9.1 
0.222 
Diabetes 6.91 9.54 2.6 40.9 
100µA/60 seconds 
Control 4.19 1.74 2 8.4 
0.261 
Diabetes 6.58 9.17 2.6 39.2 
100µA/60 seconds 
Control 4.22 1.72 2 8.7 
0.184 
Diabetes 6.70 7.99 2.8 35 
100µA/60 seconds 
Control 4.22 1.81 2.1 9.3 
0.210 
Diabetes 7.17 10.18 2.7 43.4 
Peak of Max 
response 
Control 8.00 3.59 3.71 17.02 
0.137 
Diabetes 14.86 19.78 4.38 84.87 
Change in 
response % 
Control 128.37 86.96 65.78 401.81 
0.654 
Diabetes 141.91 88.61 11.24 358.75 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 52 Comparison between control group and diabetes group median of flux (PU) on the Plantar 
of the foot with pressure in Own shoes applied during the iontophoresis of ACh using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.59 1.01 2.1 5.9 
0.003* 
Diabetes 5.19 1.95 1.7 8.8 
100µA/60 seconds 
Control 3.69 1.21 2.1 6.8 
0.003* 
Diabetes 5.47 2.07 1.8 9 
100µA/60 seconds 
Control 3.63 1.23 2.2 6.8 
0.002* 
Diabetes 5.63 2.23 2.1 9.7 
100µA/60 seconds 
Control 3.67 1.39 2.1 6.5 
0.003* 
Diabetes 5.67 2.32 2.1 9.5 
100µA/60 seconds 
Control 3.59 1.23 2.2 6.8 
<0.001** 
Diabetes 5.72 2.32 2.2 10 
100µA/60 seconds 
Control 3.67 1.48 2.1 7.6 
0.004* 
Diabetes 5.54 2.07 2.3 8.6 
100µA/60 seconds 
Control 3.96 2.12 2 9.6 
0.024* 
Diabetes 5.77 2.38 2.2 11.1 
100µA/60 seconds 
Control 3.68 1.74 2 8.3 
0.007* 
Diabetes 5.55 2.12 2.1 8.1 
100µA/60 seconds 
Control 3.87 2.12 1.9 11 
0.018* 
Diabetes 5.78 2.39 2.3 9.3 
100µA/60 seconds 
Control 3.84 2.02 1.9 9.7 
0.015* 
Diabetes 5.75 2.37 2.2 10.2 
100µA/60 seconds 
Control 3.80 2.15 1.9 9.7 
0.010* 
Diabetes 5.98 2.59 2.3 11.3 
100µA/60 seconds 
Control 3.94 2.37 1.9 10.9 
0.018* 
Diabetes 6.09 2.72 2.4 11.8 
100µA/60 seconds 
Control 3.97 2.33 2 10.4 
0.020* 
Diabetes 6.01 2.60 2.4 12.2 
100µA/60 seconds 
Control 3.99 2.47 1.9 11.1 
0.035* 
Diabetes 5.85 2.51 2.3 10.6 
100µA/60 seconds 
Control 3.89 2.29 1.9 10.2 
0.027* 
Diabetes 5.73 2.39 2.3 9.1 
Peak of Max 
response 
Control 8.13 3.48 3.8 16.92 
0.013* 
Diabetes 11.54 4.20 4.34 16.9 
Change in 
response % 
Control 125.83 70.15 13.14 284.52 
0.845 
Diabetes 130.29 60.42 50.67 257.34 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 53 Comparison between control group and diabetes group median of flux (PU) on the Plantar 
of the foot with pressure in Own shoes applied during the iontophoresis of SNP using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.50 0.81 2.4 5.7 
0.022* 
Diabetes 4.65 1.93 2.1 9.4 
100µA/60 seconds 
Control 3.46 0.95 2.2 6.5 
0.012* 
Diabetes 4.74 1.87 1.7 8.5 
100µA/60 seconds 
Control 3.63 1.19 2.2 7.7 
0.037* 
Diabetes 4.67 1.85 1.7 7.9 
100µA/60 seconds 
Control 3.54 1.01 2.1 6.8 
0.035* 
Diabetes 4.80 2.29 1.8 10.1 
100µA/60 seconds 
Control 3.56 0.99 2.4 6.9 
0.018* 
Diabetes 4.87 2.07 2.1 8.5 
100µA/60 seconds 
Control 3.63 1.05 2.5 7 
0.039* 
Diabetes 4.69 1.85 1.6 7.3 
100µA/60 seconds 
Control 3.59 0.89 2.7 6.8 
0.044* 
Diabetes 4.41 1.57 2 7.6 
100µA/60 seconds 
Control 3.74 1.14 2.6 6.6 
0.164 
Diabetes 4.41 1.69 1.5 7.8 
100µA/60 seconds 
Control 3.68 1.01 2.3 6.7 
0.261 
Diabetes 4.20 1.70 1.5 7.8 
100µA/60 seconds 
Control 3.68 0.90 2.3 6.6 
0.113 
Diabetes 4.50 2.02 1.4 8.2 
100µA/60 seconds 
Control 3.62 0.93 2.6 6.9 
0.124 
Diabetes 4.39 1.90 1.5 8.9 
100µA/60 seconds 
Control 3.51 0.78 2.5 5.9 
0.071 
Diabetes 4.37 1.86 1.4 8.4 
100µA/60 seconds 
Control 3.88 1.52 2.5 8.5 
0.360 
Diabetes 4.43 2.00 1.4 8.2 
100µA/60 seconds 
Control 3.93 1.66 2.1 9.6 
0.288 
Diabetes 4.63 2.19 1.3 9.8 
100µA/60 seconds 
Control 4.10 1.99 2.2 11.6 
0.662 
Diabetes 4.39 1.77 1.4 7.7 
Peak of Max 
response 
Control 7.84 3.97 4.78 22.03 
0.202 
Diabetes 9.55 3.68 4.45 17.42 
Change in 
response % 
Control 118.30 59.06 61.21 286.51 
0.708 
Diabetes 111.26 47.50 11.24 190.31 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
  
313 
 
 
Table 54 Comparison between control group and diabetes group mean of flux (PU) on the Plantar of 
the foot with no pressure applied during the iontophoresis of ACh using: Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 47.27 33.03 12.41 120.7 
0.046* 
Diabetes 74.37 44.50 11.33 150 
100µA/60 seconds 
Control 46.89 32.85 10.09 120.82 
0.006* 
Diabetes 86.94 47.26 12.53 167.84 
100µA/60 seconds 
Control 61.91 39.58 12.5 136.06 
0.003* 
Diabetes 119.68 67.90 12.29 210.06 
100µA/60 seconds 
Control 90.50 75.48 14.53 285.09 
0.012* 
Diabetes 169.98 102.49 17.1 334.55 
100µA/60 seconds 
Control 107.88 102.87 14.66 408.37 
0.029* 
Diabetes 192.55 115.84 23.98 382.12 
100µA/60 seconds 
Control 132.11 129.60 9.78 518.31 
0.049* 
Diabetes 208.65 131.41 24.1 423.73 
100µA/60 seconds 
Control 145.65 135.60 13.9 559.91 
0.117 
Diabetes 220.53 136.63 29.59 475.79 
100µA/60 seconds 
Control 156.41 138.34 21.17 576.73 
0.142 
Diabetes 227.05 136.34 32.19 485.69 
100µA/60 seconds 
Control 170.08 137.31 16.02 584.81 
0.143 
Diabetes 242.06 144.28 37.8 552.29 
100µA/60 seconds 
Control 186.34 139.27 13.32 585.41 
0.204 
Diabetes 251.27 155.84 35.82 632.6 
100µA/60 seconds 
Control 196.50 145.32 10.6 581.59 
0.248 
Diabetes 257.97 163.25 39.11 669.41 
100µA/60 seconds 
Control 204.87 149.94 11.03 579.29 
0.380 
Diabetes 252.36 164.45 45.86 681.33 
100µA/60 seconds 
Control 213.75 151.28 17.49 576.58 
0.372 
Diabetes 262.03 162.67 51.48 687.87 
100µA/60 seconds 
Control 219.48 163.68 11.21 573.45 
0.417 
Diabetes 264.38 154.87 58.46 680.92 
100µA/60 seconds 
Control 218.87 167.36 11.01 587.19 
0.419 
Diabetes 264.65 159.12 46.77 696.15 
Peak of Max 
response 
Control 223.44 140.95 33.39 588.58 
0.089 
Diabetes 314.91 167.14 47.67 662.91 
Change in 
response % 
Control 460.66 344.35 51.80 1240.94 
0.721 
Diabetes 516.13 563.94 58.37 2213.42 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 55 Comparison between control group and diabetes group mean of flux (PU) on the Plantar of 
the foot with no pressure applied during the iontophoresis of SNP using: Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 51.45 62.29 6.87 272.72 
0.330 
Diabetes 70.39 46.32 23.63 188.99 
100µA/60 seconds 
Control 49.90 60.77 8.3 273.25 
0.164 
Diabetes 78.38 55.31 25.6 220.3 
100µA/60 seconds 
Control 62.61 77.32 8.06 351.63 
0.221 
Diabetes 94.01 68.55 24.61 231.43 
100µA/60 seconds 
Control 85.68 80.51 8.62 366.07 
0.174 
Diabetes 124.09 81.68 34.26 263.13 
100µA/60 seconds 
Control 116.59 88.32 7.62 322.51 
0.189 
Diabetes 159.19 98.88 36.2 368.02 
100µA/60 seconds 
Control 144.77 120.54 11.85 366.85 
0.359 
Diabetes 180.58 101.00 36.07 430.63 
100µA/60 seconds 
Control 157.35 127.90 18.35 418.3 
0.366 
Diabetes 195.09 109.55 41.84 465.78 
100µA/60 seconds 
Control 163.84 135.86 14.37 501.32 
0.465 
Diabetes 195.65 111.51 58.7 492.63 
100µA/60 seconds 
Control 163.93 138.32 25.19 533.74 
0.430 
Diabetes 199.05 114.48 55.05 500.66 
100µA/60 seconds 
Control 165.48 135.62 14.71 552.75 
0.526 
Diabetes 193.60 118.05 46.26 491.93 
100µA/60 seconds 
Control 164.05 132.88 17.02 543.06 
0.517 
Diabetes 192.41 117.58 54.92 475.89 
100µA/60 seconds 
Control 163.78 130.22 12.94 523.15 
0.534 
Diabetes 189.99 110.35 61.35 466.51 
100µA/60 seconds 
Control 167.77 126.48 10.58 486.85 
0.601 
Diabetes 188.82 102.20 80.65 456.65 
100µA/60 seconds 
Control 157.93 120.67 12.22 474.81 
0.395 
Diabetes 190.06 91.38 73.63 436.15 
100µA/60 seconds 
Control 162.24 121.12 18.99 499.26 
0.563 
Diabetes 183.48 82.20 69.13 387.65 
Peak of Max 
response 
Control 203.12 138.22 32.07 502.48 
0.315 
Diabetes 247.69 112.18 110.78 485.71 
Change in 
response % 
Control 604.93 685.26 17.48 2348.29 
0.112 
Diabetes 310.31 139.64 62.81 585.86 
 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 56 Comparison between control group and diabetes group mean of flux (PU) on the Plantar of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of ACh using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.91 1.78 2.24 10.26 
0.023* 
Diabetes 5.39 1.90 2.48 9.17 
100µA/60 seconds 
Control 4.16 1.97 2.15 10.69 
0.029* 
Diabetes 5.74 2.14 2.54 9.39 
100µA/60 seconds 
Control 4.29 2.17 2.23 11.51 
0.060 
Diabetes 5.75 2.22 2.39 9.57 
100µA/60 seconds 
Control 4.44 2.31 2.19 12.1 
0.069 
Diabetes 5.85 2.06 2.36 9.05 
100µA/60 seconds 
Control 4.40 2.36 2.3 11.94 
0.076 
Diabetes 5.86 2.29 2.44 10.51 
100µA/60 seconds 
Control 4.28 2.27 2.13 11.5 
0.042* 
Diabetes 5.99 2.50 2.4 11.6 
100µA/60 seconds 
Control 4.38 2.23 2.09 11.54 
0.046* 
Diabetes 5.97 2.42 2.42 11.6 
100µA/60 seconds 
Control 4.62 2.39 2.09 11.3 
0.039* 
Diabetes 6.42 2.55 2.54 10.64 
100µA/60 seconds 
Control 4.70 2.31 1.96 12 
0.086 
Diabetes 6.14 2.46 2.54 9.94 
100µA/60 seconds 
Control 4.75 2.91 2 15.27 
0.136 
Diabetes 6.25 2.86 2.61 12.35 
100µA/60 seconds 
Control 4.78 3.02 1.94 16.03 
0.162 
Diabetes 6.25 2.97 2.75 13.39 
100µA/60 seconds 
Control 4.78 2.96 2.04 15.49 
0.208 
Diabetes 6.08 2.98 2.63 13.92 
100µA/60 seconds 
Control 4.90 2.93 2.07 14.55 
0.213 
Diabetes 6.17 2.94 2.64 13.72 
100µA/60 seconds 
Control 4.84 2.83 2.25 13.42 
0.179 
Diabetes 6.17 2.86 2.84 12.76 
100µA/60 seconds 
Control 4.69 2.50 2.01 12.7 
0.135 
Diabetes 6.07 2.84 2.76 12.6 
Peak of Max 
response 
Control 8.98 4.19 4.22 21.98 
0.100 
Diabetes 11.48 4.50 4.38 20.16 
Change in 
response % 
Control 130.92 53.81 77.08 255.98 
0.268 
Diabetes 112.01 42.00 48.11 198.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 57 Comparison between control group and diabetes group mean of flux (PU) on the Plantar of 
the foot with pressure in Orthopaedic shoes applied during the iontophoresis of SNP using: 
Independent Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.77 1.40 1.86 6.63 
0.037* 
Diabetes 5.93 4.98 2.48 22.88 
100µA/60 seconds 
Control 3.83 1.41 2.06 6.42 
0.043* 
Diabetes 6.45 5.73 2.54 26.1 
100µA/60 seconds 
Control 4.10 1.88 2.16 9.67 
0.126 
Diabetes 6.64 6.95 2.39 31.15 
100µA/60 seconds 
Control 4.24 1.95 2.19 9.07 
0.163 
Diabetes 6.09 5.36 2.36 24.38 
100µA/60 seconds 
Control 4.32 1.98 2.19 8.57 
0.160 
Diabetes 6.62 6.82 2.44 30.31 
100µA/60 seconds 
Control 4.26 1.85 2.08 8.37 
0.145 
Diabetes 6.26 5.60 2.4 25.16 
100µA/60 seconds 
Control 4.41 2.04 2.19 8.98 
0.179 
Diabetes 6.62 6.84 2.42 30.47 
100µA/60 seconds 
Control 4.63 2.35 2.06 10.73 
0.225 
Diabetes 7.63 10.55 2.54 45.15 
100µA/60 seconds 
Control 4.58 2.19 2.25 9.86 
0.222 
Diabetes 7.80 11.34 2.54 47.8 
100µA/60 seconds 
Control 4.41 2.00 2.14 9.51 
0.189 
Diabetes 8.03 11.92 2.61 50.18 
100µA/60 seconds 
Control 4.49 2.27 2.32 10.43 
0.230 
Diabetes 7.38 10.26 2.75 43.87 
100µA/60 seconds 
Control 4.44 1.98 2.02 9.31 
0.200 
Diabetes 7.48 10.20 2.63 43.73 
100µA/60 seconds 
Control 4.42 1.86 2.05 8.71 
0.248 
Diabetes 7.13 10.14 2.64 43.19 
100µA/60 seconds 
Control 4.44 1.86 2.07 9.01 
0.180 
Diabetes 7.30 9.12 2.84 39.63 
100µA/60 seconds 
Control 4.46 1.92 2.18 9.54 
0.207 
Diabetes 7.59 10.72 2.76 45.66 
Peak of Max 
response 
Control 8.00 3.59 3.71 17.02 
0.137 
Diabetes 14.86 19.78 4.38 84.87 
Change in 
response % 
Control 117.79 82.24 59.46 372.83 
0.797 
Diabetes 124.58 67.91 12.92 270.93 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 58 Comparison between control group and diabetes group mean of flux (PU) on the Plantar of 
the foot with pressure in Own shoes applied during the iontophoresis of ACh using: Independent 
Sample t-test. 
Iontophoresis  Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.73 1.06 2.24 6.06 
0.002* 
Diabetes 5.49 2.05 1.76 9.17 
100µA/60 seconds 
Control 3.81 1.28 2.15 7.13 
0.003* 
Diabetes 5.73 2.19 1.84 9.39 
100µA/60 seconds 
Control 3.85 1.35 2.23 7.01 
0.002* 
Diabetes 5.94 2.31 2.26 9.76 
100µA/60 seconds 
Control 3.92 1.60 2.19 7.81 
0.005* 
Diabetes 5.98 2.44 2.16 9.67 
100µA/60 seconds 
Control 3.79 1.33 2.2 6.94 
<0.001** 
Diabetes 5.99 2.38 2.28 9.89 
100µA/60 seconds 
Control 3.95 1.65 2.13 8.3 
0.006* 
Diabetes 5.85 2.18 2.39 8.81 
100µA/60 seconds 
Control 4.19 2.21 2.09 10.15 
0.026* 
Diabetes 6.04 2.49 2.24 10.97 
100µA/60 seconds 
Control 3.91 1.86 2.09 8.98 
0.008* 
Diabetes 5.93 2.41 2.14 9.15 
100µA/60 seconds 
Control 4.14 2.18 1.96 11.29 
0.020* 
Diabetes 6.08 2.52 2.38 9.41 
100µA/60 seconds 
Control 4.05 2.05 2 10.03 
0.014* 
Diabetes 6.07 2.52 2.29 10.35 
100µA/60 seconds 
Control 4.05 2.19 1.94 10.04 
0.007* 
Diabetes 6.42 2.72 2.39 11.38 
100µA/60 seconds 
Control 4.17 2.41 1.95 11.11 
0.014* 
Diabetes 6.43 2.74 2.48 11.57 
100µA/60 seconds 
Control 4.20 2.35 2.05 10.65 
0.017* 
Diabetes 6.34 2.65 2.46 12 
100µA/60 seconds 
Control 4.19 2.50 1.92 11.35 
0.026* 
Diabetes 6.24 2.68 2.37 10.77 
100µA/60 seconds 
Control 4.12 2.32 1.94 10.55 
0.025* 
Diabetes 6.09 2.63 2.35 9.73 
Peak of Max 
response 
Control 8.13 3.48 3.8 16.92 
0.013* 
Diabetes 11.54 4.20 4.34 16.9 
Change in 
response % 
Control 116.36 64.56 14.61 267.80 
0.988 
Diabetes 116.65 49.22 48.11 198.32 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 59 Comparison between control group and diabetes group mean of flux (PU) on the Plantar of 
the foot with pressure in Own shoes applied during the iontophoresis of SNP using: Independent 
Sample t-test. 
Iontophoresis Group Mean SD Min. Max. p 
0µA/60 seconds 
Control 3.76 1.20 2.51 8.04 
0.035* 
Diabetes 4.92 1.91 2.35 9.26 
100µA/60 seconds 
Control 3.73 1.36 2.22 8.72 
0.028* 
Diabetes 5.03 1.98 1.78 8.66 
100µA/60 seconds 
Control 3.91 1.55 2.29 9.68 
0.072 
Diabetes 5.01 1.94 1.84 8.08 
100µA/60 seconds 
Control 3.82 1.42 2.18 9.14 
0.060 
Diabetes 5.02 2.25 1.88 9.54 
100µA/60 seconds 
Control 3.82 1.39 2.57 9.13 
0.027* 
Diabetes 5.22 2.19 2.28 8.99 
100µA/60 seconds 
Control 3.93 1.41 2.57 9.05 
0.066 
Diabetes 5.01 1.97 1.69 7.89 
100µA/60 seconds 
Control 3.90 1.28 2.86 8.94 
0.079 
Diabetes 4.81 1.68 2.12 8.18 
100µA/60 seconds 
Control 4.03 1.49 2.66 8.77 
0.205 
Diabetes 4.76 1.86 1.56 8.32 
100µA/60 seconds 
Control 3.96 1.38 2.4 8.83 
0.325 
Diabetes 4.51 1.93 1.54 8.49 
100µA/60 seconds 
Control 3.97 1.34 2.4 8.95 
0.173 
Diabetes 4.79 2.13 1.43 8.68 
100µA/60 seconds 
Control 3.92 1.33 2.74 9.02 
0.185 
Diabetes 4.69 2.03 1.59 9.34 
100µA/60 seconds 
Control 3.81 1.24 2.73 8.5 
0.102 
Diabetes 4.72 1.97 1.45 8.81 
100µA/60 seconds 
Control 4.14 1.77 2.75 9.38 
0.395 
Diabetes 4.72 2.17 1.43 8.66 
100µA/60 seconds 
Control 4.18 1.86 2.21 9.62 
0.336 
Diabetes 4.85 2.19 1.42 8.97 
100µA/60 seconds 
Control 4.39 2.08 2.23 11.41 
0.687 
Diabetes 4.67 1.92 1.6 8.2 
Peak of Max 
response 
Control 7.84 3.97 4.78 22.03 
0.202 
Diabetes 9.55 3.68 4.45 17.42 
Change in 
response % 
Control 103.58 42.32 57.96 215.52 
0.637 
Diabetes 96.93 38.99 12.92 161.54 
p >0.05 NS; *p <0.05 S; **p <0.001 HS 
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Table 60 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the dorsal surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.465* 0.039* 
Baseline Label 1/0µA/60 seconds (Mean) -0.495* 0.026* 
Peak of Max response -0.390 0.089 
Change in response % (Using Median) 0.240 0.309 
Change in response % (Using Mean) 0.306 0.189 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 61 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the dorsal surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.242 0.304 
Baseline Label 1/0µA/60 seconds (Mean) -0.216 0.361 
Peak of Max response -0.370 0.108 
Change in response % (Using Median) -0.157 0.508 
Change in response % (Using Mean) -0.221 0.349 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 62 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the plantar surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.227 0.337 
Baseline Label 1/0µA/60 seconds (Mean) -0.254 0.280 
Peak of Max response -0.332 0.152 
Change in response % (Using Median) -0.207 0.381 
Change in response % (Using Mean) -0.189 0.425 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 63 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the plantar surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.221 0.348 
Baseline Label 1/0µA/60 seconds (Mean) -0.209 0.377 
Peak of Max response -0.073 0.759 
Change in response % (Using Median) 0.126 0.597 
Change in response % (Using Mean) 0.122 0.608 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 64 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the dorsal surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.257 0.274 
Baseline Label 1/0µA/60 seconds (Mean) -0.270 0.250 
Peak of Max response -0.392 0.087 
Change in response % (Using Median) -0.124 0.602 
Change in response % (Using Mean) -0.144 0.544 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 65 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the dorsal surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.211 0.372 
Baseline Label 1/0µA/60 seconds (Mean) -0.242 0.305 
Peak of Max response -0.199 0.401 
Change in response % (Using Median) -0.103 0.664 
Change in response % (Using Mean) -0.040 0.868 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 66 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the plantar surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.179 0.450 
Baseline Label 1/0µA/60 seconds (Mean) -0.195 0.411 
Peak of Max response -0.032 0.895 
Change in response % (Using Median) 0.061 0.799 
Change in response % (Using Mean) 0.075 0.752 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 67 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the plantar surface in control group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) 0.175 0.461 
Baseline Label 1/0µA/60 seconds (Mean) 0.195 0.410 
Peak of Max response 0.313 0.178 
Change in response % (Using Median) 0.337 0.146 
Change in response % (Using Mean) 0.352 0.128 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 68 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the dorsal surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.004 0.990 
Baseline Label 1/0µA/60 seconds (Mean) -0.031 0.913 
Peak of Max response -0.191 0.495 
Change in response % (Using Median) -0.212 0.447 
Change in response % (Using Mean) -0.186 0.507 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 69 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the dorsal surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.339 0.216 
Baseline Label 1/0µA/60 seconds (Mean) -0.400 0.139 
Peak of Max response -0.545* 0.036* 
Change in response % (Using Median) -0.396 0.144 
Change in response % (Using Mean) -0.359 0.189 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 70 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the plantar surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.323 0.240 
Baseline Label 1/0µA/60 seconds (Mean) -0.357 0.191 
Peak of Max response -0.220 0.431 
Change in response % (Using Median) -0.041 0.885 
Change in response % (Using Mean) 0.056 0.844 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 71 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the plantar surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.419 0.120 
Baseline Label 1/0µA/60 seconds (Mean) -0.390 0.151 
Peak of Max response -0.323 0.240 
Change in response % (Using Median) -0.210 0.453 
Change in response % (Using Mean) -0.183 0.513 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 72 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the dorsal surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) 0.040 0.887 
Baseline Label 1/0µA/60 seconds (Mean) -0.009 0.974 
Peak of Max response -0.228 0.414 
Change in response % (Using Median) -0.290 0.294 
Change in response % (Using Mean) -0.232 0.405 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 73 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the dorsal surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.191 0.495 
Baseline Label 1/0µA/60 seconds (Mean) -0.227 0.416 
Peak of Max response -0.227 0.415 
Change in response % (Using Median) -0.221 0.429 
Change in response % (Using Mean) -0.161 0.568 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 74 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the plantar surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.074 0.794 
Baseline Label 1/0µA/60 seconds (Mean) -0.110 0.696 
Peak of Max response -0.316 0.251 
Change in response % (Using Median) -0.309 0.263 
Change in response % (Using Mean) -0.276 0.319 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 75 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the plantar surface in diabetes group using Pearson correlation coefficient. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.116 0.680 
Baseline Label 1/0µA/60 seconds (Mean) -0.134 0.634 
Peak of Max response -0.177 0.527 
Change in response % (Using Median) -0.047 0.867 
Change in response % (Using Mean) -0.060 0.833 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 76 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the dorsal surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.290 0.215 
Baseline Label 1/0µA/60 seconds (Mean) -0.373 0.105 
Peak of Max response -0.244 0.301 
Change in response % (Using Median) -0.002 0.995 
Change in response % (Using Mean) -0.096 0.686 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 77 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the dorsal surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.267 0.255 
Baseline Label 1/0µA/60 seconds (Mean) -0.205 0.387 
Peak of Max response -0.200 0.398 
Change in response % (Using Median) 0.075 0.753 
Change in response % (Using Mean) 0.027 0.910 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 78 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the plantar surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) 0.041 0.865 
Baseline Label 1/0µA/60 seconds (Mean) 0.030 0.900 
Peak of Max response -0.155 0.514 
Change in response % (Using Median) -0.280 0.232 
Change in response % (Using Mean) -0.221 0.349 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 79 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the plantar surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.102 0.668 
Baseline Label 1/0µA/60 seconds (Mean) -0.089 0.710 
Peak of Max response 0.066 0.782 
Change in response % (Using Median) 0.050 0.835 
Change in response % (Using Mean) 0.011 0.965 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 80 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the dorsal surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.230 0.329 
Baseline Label 1/0µA/60 seconds (Mean) -0.298 0.202 
Peak of Max response -0.343 0.139 
Change in response % (Using Median) -0.132 0.578 
Change in response % (Using Mean) -0.143 0.548 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 81 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the dorsal surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.178 0.452 
Baseline Label 1/0µA/60 seconds (Mean) -0.235 0.319 
Peak of Max response -0.251 0.286 
Change in response % (Using Median) -0.135 0.569 
Change in response % (Using Mean) -0.023 0.925 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 82 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the plantar surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.179 0.450 
Baseline Label 1/0µA/60 seconds (Mean) -0.197 0.405 
Peak of Max response -0.117 0.622 
Change in response % (Using Median) 0.006 0.980 
Change in response % (Using Mean) 0.003 0.990 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 83 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the plantar surface in control group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) 0.102 0.667 
Baseline Label 1/0µA/60 seconds (Mean) 0.104 0.663 
Peak of Max response 0.164 0.490 
Change in response % (Using Median) 0.265 0.259 
Change in response % (Using Mean) 0.292 0.212 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 84 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the dorsal surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.041 0.884 
Baseline Label 1/0µA/60 seconds (Mean) -0.018 0.950 
Peak of Max response -0.282 0.308 
Change in response % (Using Median) -0.204 0.467 
Change in response % (Using Mean) -0.257 0.355 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 85 Correlation between Orthopaedic shoes Dorsal PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the dorsal surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.239 0.390 
Baseline Label 1/0µA/60 seconds (Mean) -0.275 0.321 
Peak of Max response -0.321 0.243 
Change in response % (Using Median) -0.318 0.248 
Change in response % (Using Mean) -0.257 0.355 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 86 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of ACh on the plantar surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.312 0.257 
Baseline Label 1/0µA/60 seconds (Mean) -0.400 0.140 
Peak of Max response -0.271 0.328 
Change in response % (Using Median) 0.036 0.899 
Change in response % (Using Mean) 0.086 0.761 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 87 Correlation between Orthopaedic shoes Plantar PP (KPa) and Flux (PU) during the 
iontophoresis of SNP on the plantar surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.508 0.053 
Baseline Label 1/0µA/60 seconds (Mean) -0.579 0.024* 
Peak of Max response -0.489 0.064 
Change in response % (Using Median) -0.075 0.791 
Change in response % (Using Mean) -0.046 0.869 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
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Table 88 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the dorsal surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) 0.020 0.945 
Baseline Label 1/0µA/60 seconds (Mean) 0.043 0.879 
Peak of Max response -0.175 0.533 
Change in response % (Using Median) -0.275 0.321 
Change in response % (Using Mean) -0.264 0.341 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 89 Correlation between Own shoes Dorsal PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the dorsal surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.093 0.742 
Baseline Label 1/0µA/60 seconds (Mean) -0.121 0.666 
Peak of Max response -0.311 0.260 
Change in response % (Using Median) -0.254 0.362 
Change in response % (Using Mean) -0.189 0.499 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 90 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of ACh on the plantar surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) -0.005 0.985 
Baseline Label 1/0µA/60 seconds (Mean) -0.054 0.850 
Peak of Max response -0.325 0.237 
Change in response % (Using Median) -0.293 0.289 
Change in response % (Using Mean) -0.261 0.348 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
Table 91 Correlation between Own shoes Plantar PP (KPa) and Flux (PU) during the iontophoresis 
of SNP on the plantar surface in diabetes group using Spearman correlation test. 
Flux (PU) 
PP (KPa) 
r p 
Baseline Label 1/0µA/60 seconds (Median) 0.007 0.980 
Baseline Label 1/0µA/60 seconds (Mean) -0.018 0.950 
Peak of Max response -0.104 0.713 
Change in response % (Using Median) -0.161 0.567 
Change in response % (Using Mean) -0.232 0.405 
Correlation is highly significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed). * 
 
 
